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Abstract
Interleukin 18 (IL-18) was originally identified as an interferon y inducing factor in the 
livers of mice treated with LPS and Propionibacterium acnes. Initial studies focused on 
IL-18 as a Thl driving cytokine. Subsequently, myriad effects of XL-18 have emerged, 
indicating a broader role to include effects on innate immunity, via activation of 
macrophages and NK cells. This thesis sought to further investigate the role of IL-18 in 
innate immune responses. IL-18 neutralisation prior to LPS challenge reduces tissue 
myeloperoxidase levels, implicating IL-18 at some stage in neutrophil activation. This 
study defines direct biological effects of IL-18 on neutrophils. IL-18 promoted in vivo 
migration of neutrophils, concuiTently, IL-18 enhanced neutrophil adhesion molecule 
expression in vitro. Furthermore, IL-18 induced neutrophil cytokine and chemokine 
release, including IL-8, which could further promote neutrophil accumulation. 
Additionally, IL-18 provoked neutrophil degranulation, and primed neutrophils for 
enhanced respiratory burst in response to fMLP. Finally, IL-18 stimulated leukotriene 
synthesis by neutrophils.
IL-18 promotes protective immune responses in parasitic, viral, fungal and bacterial 
infections. Aberrant immune responses are similarly associated with over expression of 
IL-18. Accordingly, elevated IL-18 is reported in rheumatoid arthritis (RA), 
inflammatory bowel disease (IBD), sarcoidosis, and sepsis. RA synovial fluid 
neutrophils are primed and activated in vivo., a process to which IL-18 may contribute. 
Neutrophils derived from the synovial fluid o f  patients with RA, exhibited enhanced 
cytokine release in  response to IL-18, which included r elease o f  TNFa. Thus, IL-18 
may promote joint damage via neutrophil activation. Neutralisation of IL-18 in a model
of acute inflammation significantly reduced swelling and neutrophil accumulation. 
Given its proinflammatory effects on T cells and macrophages, targeting IL-18 is 
suggested as an attractive therapeutic strategy. These data suggest that effects mediated 
by neutrophils may be reduced.
Effective neutrophil responses are paramount to clearance of gi'am-positive infections. 
IL-18-deficient mice exhibit enhanced arthritis but reduced systemic sepsis following 
infection with Staphylococcus aureus. Both features of this altered response may, in 
part, be explained by reduced neutrophil function. IL-18 promoted in vitro bactericidal 
activity of human neutrophils; cells derived horn IL-18-deficient mice exhibited 
reduced killing ability in vitro. However, administration of IL-18 prior to infection with 
S. aureus resulted in significant mortality compared to controls, thereby suggesting that 
IL-18 promoted host toxicity rather than an early protective response. Further analysis 
revealed rapid, early IFNy production, elevated Toll-like receptor expression and 
changes in ex vivo immune responses. In contrast, post-infection administration of IL-18 
substantially reduced artliritis, although no direct evidence of enhanced neutrophil 
bacterial killing was observed. Supplementary IL-18 promotes vaccine efficacy and 
may therapeutically address Th2 diseases such as asthma. These data caution addition of 
exogenous IL-18, Additionally, this model highlights the complex evolution of immune 
responses, and demonstrates discrepant consequences of intervention at different time 
points.
IL-18 is involved in innate and adaptive responses. Although traditionally described as 
simple phagocytes, neutrophils have subsequently been shown to mediate adaptive 
responses, for example by release of cytokines and expression of MHC peptide
complexes. A novel system of investigating neutrophil -  T cell interactions was 
established. Preliminary studies to investigate neutrophil antigen presentation were 
strongly suggestive that neutrophils could drive Class II restricted T cell responses. The 
role of soluble mediators in this interaction was investigated, however preliminary 
experiments elucidated no role for IL-18.
Data described here support a role of IL-18 in pathological inflammation, which can be 
perpetuated through neutrophil activation. Patients with elevated IL-18 a priori exhibit 
poor prognosis following giam-positive infection, similar to mice treated with IL-18 
prior to S. aureus infection. Neutralising IL-18 in animal models of arthritis and 
inflammatory bowel disease has yielded promising results. Clearly, such manipulation 
of the immune system may leave the host vulnerable to infection. Therefore, the 
delineation of IL-18 mediated effects on neutrophils and S. aureus infection described 
herein requires close consideration in the context of therapeutic inteiwention.
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Chapter 1 General Introduction
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1.1 Cytokines
1.1.1 Cytokines and the inflammatory response
Communication between cells is obligatory for the orchestration of an inflammatory 
response. Cells may interact either via direct cell contact or the release of soluble 
factors. The term cytokine is applied to a rapidly growing number of small, non- 
stmctural proteins or glycoproteins that serve as protein messengers conveying 
information between and within cells through specific receptor molecules. In addition to 
their involvement in such processes as cell growth, differentiation, tissue repair, 
remodelling and development, cytokines play a central role in inflammatory and 
immune responses. Cytokines are instrumental in regulating the magnitude, nature and 
duration of the immune response, and as such are attractive therapeutic targets for 
modulating inflammatory diseases. The field of cytokine biology is rapidly expanding, 
promoted further by the near completion of the genome projects, which have allowed 
identification of new members of existing cytokine families and of novel cytokines.
1.1.2 Nomenclature and history
The generic term Tymphokine’ was introduced in 1969 to describe the origin and 
function o f soluble 1 ymphocyte derived factors (1). An increasing number o f  soluble 
factors were identified from cells of both lymphoid and non-lymphoid origin. 
Historically, individual soluble factors were identified on the basis of their biological 
function. However, it became apparent that proteins could share similar biological 
functions, and that many proteins had more than one function, therefore this
20
nomenclature became cumbersome. A consensus group fonned in 1979 and coined the 
teim ‘interleukin’. As this project commenced, interleukin 18 (IL-18) was amongst the 
most recently characterised cytokines. At present, IL-27 is defined (2) and the number 
of cytokine entities purified is greater than 150 and increasing (3).
1,1.3 Cytokine action
The discovery of numerous cytokines with diverse functions makes generalising the 
mechanism of cytokine action difficult. Cytokines were originally thought to function 
like hoiTnones. Indeed, IL-6 for example, operates like an endocrine factor, travelling 
via the circulation to reach a distant target, the hypothalamic-pituitary-adrenal axis, 
where it induces an acute phase response. Conversely, other cytokines act in a paracrine 
manner on adjacent cells. Some cytokines, which are associated with cell membranes, 
mediate effects via a cell contact dependent juxtacrine signalling. Cytokines may also 
function in an autocrine fashion, feeding back to the cell of origin. The mechanisms of 
cytokine actions are probably best described as a local intercellular communication 
network, providing a rapid and flexible modulation of immune responses. Cytokines 
also allow communication between immune cells and host tissues.
1.1.4 Cytokine receptors
Cytokines mediate effects by binding to their specific high affinity cell surface 
receptors. A relatively low concentration of cell surface receptors, approximately 100- 
1000 per cell, is required for biological effects (4) Depending on receptor affinity, 
usually between 10"^  ^and 10"^  M, the receptor requirement may be even lower; IL-l can
21
induce effects in the presence of fewer than 10 receptors per cell. Cytokines can be 
divided into at least 6 different families depending on the receptors they bind. These 
include: interferon receptor family (IFNyR, IL-l OR), TNF family (Fas, TNFa), 
haematopoietic family (IL-3R, GM-CSFR), immunoglobulin family (IL-IR, IL-18R), 
type II -  TGF(3R, and the 7 transmembrane chemokine receptors. The extracellular 
domain of many receptors may be enzymatically cleaved and released, retaining ligand 
binding activity and thus acting as an inhibitor. Binding of cytokines to their specific 
receptors activates various signalling pathways, including MAP kinases, JAKS and 
STATS, INKS, and NFkB.
1.1.5 Cytokines activate the innate immune system
The innate immune system evolved in multicellular organisms to reduce the 
consequences of microbial invasion. This arm of the immune system functions 
regardless of the microbe’s antigen specificity, serving not only as a first line of defence 
but potentially defining the nature of subsequent adaptive response, primarily through 
the release of cytokines. Activation of the innate immune system may be mediated by 
microbial components (e.g. cell wall polysaccharides) or endogenous signals of cellular 
damage (e.g. heat shock proteins). Cytokines are the primary means of communication 
for the activated imiate immune system. TNFa, IL-l and IL-6 are among the cytokines 
with key roles in innate immunity. Activation of the innate immune system leads to a 
hepatic acute phase response (release of acute phase proteins), a central neiTous system 
response (fever, myalgia), a somatic tissue response (breakdown of muscle and fat), and 
an immunological response (release of neutrophils from the bone marrow, macrophage 
and neutrophil activation). If inappropriately activated, this ‘hard-wired’ response may
22
be lethal. Uncontrolled activation of the innate immune system can result in potentially 
fatal exaggerated IL-l and TNFa release, as is evident in sepsis. Furthermore, there is 
evidence that persistent activation of the innate immune system occurs in chronic 
inflammatory conditions such as rheumatoid arthritis, where the effects of uncontrolled 
imiate immunity manifest as metabolic abnormalities, tissue destruction and 
remodelling.
1.1.6 Cytokines influence adaptive immunity
Protective immunity to pathogens is the result of a complex interplay between the innate 
and adaptive immune systems. The innate immune system detects pathogens via a 
restricted range of pattern recognition receptors, providing a rapid response and 
mobilising the adaptive immune system. The adaptive response is almost infinitely 
flexible, capable of generating a broad immunological repertoire allowing specific 
recognition of pathogens. Cytokines play a key role in providing fine control required 
for evolution of the adaptive response; other regulators include co-stimulatory 
mediators vital to T cell -  dendritic cell interactions. The dominant response to specific 
antigen may be cell mediated (Thl) or humoral (Th2) depending on factors driving the 
differentiation o f  n aïve CD4 T cells. Most immune responses are 1 ikely to involve a 
balance of both Thl and Th2 phenotypes. T cells initially stimulated in the presence of 
IL-l2 and IFNy develop into Thl cells, whereas activation in the presence of IL-4 
promotes Th2 development. The ability of IL-l2 and IL-4 to drive Thl and Th2 
differentiation respectively is enhanced by their inliibitory effects on the opposing 
pathway (5, 6). In this context, IL-l2 and IL-4 are prototype T cell driving factors,
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however as more cytokines are identified, the cytokine networks influencing T cell 
differentiation become increasingly more complex.
1.2 Interleukin-18 (IL-18)
IL-18 was originally identified as an interferon y inducing factor ( IGIF), in  sera and 
liver extracts of mice treated sequentially with Propionibacterium acnes and LPS (7). 
Sera fi*om these mice induced copious IFNy from anti-CD3 stimulated T cells. This 
IFNy production was greater than that elicited by addition of excess IL-12 alone, 
indicating the presence of an additional IFNy stimulating factor. Analysis of the amino 
acid sequence demonstrated that IL-18 was a new member of the IL-1 family (8).
1.2.1 Regulation of gene expression
IL-18 inRNA is constitutively and stably expressed in many tissues. The hIL-18 gene 
localises to chromosome 11 and mIL-18 maps to chromosome 9, linked to Iddm2 locus. 
The gene order, ATM-IL-18-DRD2-THY1, is the same in mouse and human (9). The 
mIL-18 gene is composed of 7 exons, of which 1 and 2 are non-coding. Two TATA-less 
IL-18 promoters have been identified. Promoter activity upstream of exon 2 acts 
constitutively, whereas an area upstream of exon 1 can be LPS activated (10). The 
transcription factors, IFN consensus sequence binding protein (ICSBP) and PU.l are 
critical for the activation of the IL-18 promoter upstream of exons 1 and 2, respectively 
(11). NFkB recognition sequences have also been identified in the promoter region of 
IL-18. Unusually for a cytokine gene, the 3’ untranslated region of human IL-18 mRNA 
lacks AUUUA destabilisation sequences, which may explain the constitutive expression
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of IL-18 mRNA in freshly isolated human peripheral blood mononuclear cells, murine 
splenic macrophages and non-immune cell (12).
Three single nucleotide polymorphisms were detected in the IL-18 promoter. There 
were no significant differences in promoter activity between alleles without stimulation, 
but after stimulation with PMA/ionomicin one allele had distinctly lower activity than 
the other. Comparison of allele frequency in populations of multiple sclerosis patients 
and healthy controls demonstrated no significant differences (13). Whether IL-18, like 
IL-1, contains polymorphisms with strong disease associations remains to be elucidated.
1.2.2 IL-18 production and processing
IL-18 is transcribed as a 24 kD pro-molecule with no measurable biological activity. 
There is no signal peptide, which would be required for secretion, thus alternative 
processing occurs. Processing of pro to active forms may be mediated by several 
enzymes. Studies in caspase 1 (IL-ip converting enzyme, ICE) deficient mice indicate 
that this is probably the principal IL-18 processing pathway (14). Caspase 1 cleaves IL- 
18 at Asp^  ^ residue, and although also a cleavage site for caspase 4, the processing 
predominantly occurs via caspase 1. Caspase 3 cleaves between Asp^  ^ and Ile^ ® 
resulting in accumulation of inactive products, implying a role for caspase 3 as a 
scavenger for mature IL-18 (15). Proteinase-3, found in the azulophilic granules of 
neutrophils, also generates biologically active cleavage products ofIL-18 (16). Nitric 
oxide, a destmctive molecule in inflammatory reactions, inactivates caspase 1, thus 
regulating IL-18 processing (17). Other caspase regulatory factors remain largely 
unknown. Interestingly, both IL-18 and caspase 1 promotors contain consensus
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sequences for IRFl (interferon regulatory factor) and ICSBP, implicating interferons in 
the regulation of both IL-18 transcription and IL-18 processing.
In addition to pro and active forms, fuither species of IL-18 have been identified. 
Macrophages produce an inactive 48 kD dimer, which is recognised by pro-IL-18 
specific antibodies (18). Another inactive fonn of IL-18 is found complexed with IgM 
in the serum. Termed ‘Type IF IL-18, this is present in the serum, at relatively high 
concentrations, in approximately 30% of the normal population studied (19). The 
functional implications of these species of IL-18 are as yet unknown. Further regulation 
of IL-18 is presumed to occur at the level of release from the cell; however, like IL-1, 
the precise mechanisms are ill defined. Studies employing ATP to promote release of 
IL-18 demonstrated that caspase processing of IL-18 is not required for pro-IL-18 
release; however, proteins recmited by caspase-1 are speculated to be involved in 
mature IL-18 release (20). IL-ip release in response to ATP occurs tlirough shedding of 
cytokine containing mircovesicles; whether a similar mechanism mediates IL-18 release 
remains to be elucidated (21). Given the constitutive, widespread expression of IL-18 
mRNA, extensive post-transcriptional regulation seems likely.
1.2.3 IL-18 receptors
The IL-18Ra was originally identified on the Hodgkin's disease cell line, L428, on the 
basis of IL-18 binding assays. The receptor was subsequently identified as the 
previously orphan receptor IL-lRrpl (IL-18Ra/IL-lR5). Human IL-18Ra maps to 
2ql2-21 near IL-1 a, IL-IRA and IL-lRl and IL-R2 (22). A novel member of the IL-IR 
family, AcPL (IL-18R(3/IL-1R7), was identified as a second receptor subunit. The IL-
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18Ra alone binds with relatively low affinity (Kd of 20 -  50 nM) (23). IL-18R(3 does 
not itself bind IL-18, but the IL-18Ra(3 heterodimer exhibits increased affinity for IL-18 
(Æd o f  0.2 nM), and i s necessary for receptor s ignalling ( 24). C o-transfection s tiidies 
demonstrate that the IL-18R complex is responsive to IL-18 in  a highly specific (no 
response to other IL-1 ligands) and unique mamier (no functional pairing with other IL- 
1 receptor family members, including IL-lRl, IL-IRII, IL-lRAcp, T1/ST2, IL-lRrp2, 
SIGIRR and IL-IAPL) (25). Extracellularly, the IL-18 receptors consist of three 
immunoglobulin domains, and intracellularly, both chains contain a TIR (Toll/IL-1 
Receptor) domain, a motif that is conserved through evolution fiom Drosophila. 
Computer modelling and mutational analysis reveal that Glu"^  ^ and Lys^  ^ are critical 
amino acid residues for binding of IL-18 to cell surface receptors (26). Crystal 
structures of either IL-18 or the receptor complex have not yet been resolved.
There is no evidence of soluble forms of the IL-18 receptor, which is in contrast to the 
closely related cytokine homologue, IL-IR. Type II IL-IR acts as a non-signalling 
decoy receptor, which may be cleaved from the cell membrane to generate a soluble 
inhibitory receptor. Moreover, recombinant soluble IL-18 receptor a  or p chains, 
generated by cloning the extracellular domains, do not bind IL-18 with sufficient 
affinity to mediate biological effects. A combination of both a  and p chains mediate 
some inhibitory effects but only at large molar excesses (27). In vivo inhibition of IL-18 
is mediated by the IL-18 Binding Proteins (IL-18BP, Section 1.2.5).
IL-18Ra mRNA is widely distributed and in addition to being detected in lymphoid and 
myeloid cells, was identified in thymus, spleen, liver, lung, intestine, colon, placenta, 
prostate, heart, testis, ovary, and brain (22). Expression of IL-18Ra does not confer
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responsiveness to IL-18, as there is an absolute requirement for both chains (24). IL-12 
enhances IL-18Ra and p chain expression on T, B and NK cells, enhancing IL-18 
responsiveness (28). This provides a Thl response amplification loop, as IL-12RP is 
upregulated on T cells in response to IL-18. Conversely, IL-4 reduces IL-18R 
expression on T cells (29). EFNa also upregulates IL-18R expression on T cells (30), 
The receptor regulation on other cell types is ill defined.
1.2.4 Signalling via the IL-18R
The signalling pathways proposed to operate downstream of IL-18 are illustrated in Fig. 
1.1. Binding of IL-18 to the IL-18R complex induces signalling pathways shared with 
other IL-IR family members. These involve recruitment of myeloid differentiation 
factor 88 (MyD88) and IL-1 receptor associated kinase (IRAK) (31). Activated, 
phosphorylated IRAK interacts with the adaptor protein, TNF receptor associated factor 
(TRAF6), which results in translocation of NFkB to the nucleus (32). Dominant 
negative transfectants of IkBu inhibit IL-18 dependent NFkB activation and IFNy 
expression by KG-1 cells (33). IL-18 may also activate the stress kinase pathways, and 
is documented to activate extracellular signal related kinases (ERK) and p38 (34). 
Furthermore, GADD45a is induced by IL-18 in Thl cells, which in turn binds MEKK4, 
amplifying the MAP kinase associated effects of IL-18 (35). IFNy production in 
response to IL-18 is reduced in the absence of (y/c2, a JAK family non-receptor tyrosine 
kinase (36). This raises the possibility of cross talk between JAK-STAT and MAP 
kinase pathways in cytokine signalling. Whether significant differences exist between 
IL-18 induced signalling pathways in different cell populations is not elucidated.
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Figure 1.1 Signalling pathways activated by IL-18
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1.2.5 IL-18 antagonists
IL-18 Binding Proteins (IL-18BP), like IL-18R, are Ig superfamily members. 
Notwithstanding the presence of a single Ig domain, IL-18BPs bear little homology to 
either chain of the IL-18R. The IL-18BP lacks a transmembrane domain, and is thus 
only found in soluble form. Four human and two mouse isoforms of IL-18BP exist, 
arising from alternative splicing. These binding proteins are widely expressed, and have 
been identified in various cDNA libraries (37). HIL-18BPa exhibits highest affinity for 
hIL-18, which is similar to that of the IL-18Rap heterodimeric receptor. HIL-18BPc 
also neutralises hIL-18, but differs from the ‘a’ isoform at its C terminus, resulting in 
lower affinity interaction. HIL-18BPb and d lack complete Ig domains and do not bind 
hIL-18. Both murine IL-18BP isofoims (b and d) bind and neutralise mIL-18, mlL- 
18BPd also cross reacts with hIL-18. The binding proteins effectively neutralise IL-18 
at relatively low concentrations, neutralising approximately 95% of IL-18 activity at a 
molar excess of 2 (38). The function of the non-binding isoforms of the IL-18BP 
remains elusive. AIthough experimental evidence i s awaited, preferential s ecretion o f 
binding and non-binding isoforms seems likely to modulate IL-18 mediated responses.
Expression of IL-18BP is enhanced in vitro by proinflammatory cytokines including 
IFNy, IL-12, IL-15, and IL-2, suggesting negative feedback regulation of IL-18 (39, 40). 
Similarly, in disease states associated with exaggerated IL-18 expression, such as sepsis 
and GvHD, IL-18BP levels are elevated (41, 42). Interestingly, IFNa, which exerts 
inhibitory effects on IL-1, TNF a  and IL-18 release, also enhances IL-18BP expression 
(43), In healthy humans, the mean concentration of IL-18BP in the circulation is 2.15 
ng/ml (range 0.5-7 ng/ml). The mean molar equivalent is 100 pM. Mean molar
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concentration of IL-18 at 64 pg/ml is 2-3 pM, therefore, with a Kd of 400 pM, 85% of 
circulating IL-18 is free. In septic patients, IL-18PB concentrations increase 
approximately 10 fold, but IL-18 concentrations increase 20 fold (41). As such, relative 
levels o f  IL-18 a nd b inding p roteins a re 1 ikely to d etermine o verall IL-18 a ctivity i n 
vivo.
A  recent addition to the IL-1 family, IL-1H4 (IL-lF7b), binds IL-18Ra, but does not 
induce signalling. Wlien expressed in mammalian cells, IL-IH is secreted as 2 
polypeptides. IL-IH i s cleaved b y caspase 1 and exhibits some amino acid sequence 
homology with IL-lra. Both pro- and mature IL-IH bind IL-18Ra, although mature IL- 
IH binds with greater affinity (44, 45). Evidence for in vivo IL-18 inhibitory effects of 
IL-IH is awaited.
IL-18 antagonists are synthesised by viruses. Several poxvirus genes encode proteins 
with sequence similarity to IL-18BP. These viral IL-18BPs (vIL-18BP) are secreted 
from cells infected with vaccinia., ectromelia and cowpox, and inliibit NFKB activation 
and IFNy induction in response to either human or murine IL-18 (46). Mollusicum 
contagiosum gene MC54L encodes a larger vIL-18BP, which exhibits functional 
similarity to other IL-18PBs. The extent to which these proteins contribute to vims 
vimlence awaits deletion studies.
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1.2.6 Functional effects of IL-18
IL-18 was originally defined as an IFNy inducing factor that promoted the development 
of Thl cells, however, since its discovery, the known effecter roles of IL-18 have 
rapidly expanded.
IL-18 influences lymphocyte differentiation and function
IL-18 and IL-12 synergistic ally induce IFNy production by T cells via reciprocal 
upregulation of cytokine receptors. Additionally, the IFNy promotor includes consensus 
binding sites for AP-1 and NFkB and STAT-4 (47, 48). Thus, in the presence of sub- 
optimal levels of IL-12, IL-18 induces significant IFNy production by CD4 and CDS T 
cells without TCR ligation (49, 50), although for cell commitment to Th/cl lineage, 
TCR engagement is required (51). The requirement for both IL-12 and IL-18 for 
optimal IFNy secretion is apparent in vivo; IL-18-deficient mice have normal IL-12 
levels but produce limited IFNy (52); similarly, administration of IL-12 to ICE-deficient 
mice resulted in reduced IFNy production compared to wild type controls. IL-12 and IL- 
1 also induce IFNy in human T cells, suggesting that IFNy induction may be a feature of 
other IL-1 family members (53). IL-18Ra has been proposed as a Thl cell marker (54). 
IL-18 acts on differentiated Thl cells to enhance FAS mediated c ytotoxicity and co- 
stimulate IL-2, GM-CSF, and IL-2Ra production and proliferation. Conversely, IL-18 
has no effect on differentiated Th2 clones (55,56).
hi addition to promoting IFNy production and Thl development, IL-18 may influence 
the opposing Th2 arm of the immune response. Together with IL-2, IL-18 co-induces 
IL-13 in murine T and NK cells and, in the presence of TCR activation, induces T cell
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IL-4, IL-10, IL-13 and IFN-y production (57, 58). IL-18, in combination with IL-2, anti- 
CD3 and anti-CD28, markedly enhances IL-4 production by CD4 T cells. Naïve T cells 
express low levels of IL-18Ra and respond to IL-18 by producing IL-13 and GM-CSF 
(59). When cultured alone or in combination with IL-4, IL-18 is known to induce 
murine T cell Th2 differentiation, although IL-18 responsiveness is lost in differentiated 
Th2 cells. These effects are dependent upon genetic influences, as spleen cells from 
BALB/c and C56BL/6 strains of mice stimulated with anti-CD3 and IL-18 exhibit 
enhanced Th2 and Thl responses, respectively (60).
IL-18 synergises with IL-12 to induce IFNy preductionby B cells (61); however, in 
isolation IL-18 induces high IgE expression by B cells (59). Daily administration of IL- 
18 augmented serum IgE, which was dependent of IL-4 but not IL-13 (58). Similarly, 
mice over-expressing caspase 1 in the skin, which results in enlianced expression of 
mature IL-18, exhibit elevated serum IgE and develop dermatitis. This dermatitis is 
partially abrogated by crossing these mice onto an IL-18-deficient background. 
Intriguingly, the skin pathology associated with IL-18 persists even in the absence of 
IgE in serum, demonstrated by crossing the animals which over-express caspase 1 onto 
a STAT-6-deficient background (59, 62). In a model of helminth infection, 
administration of IL-18 completely inhibited IgE production, which was dependent on 
IFNy (61). Thus IL-18 can promote Thl or Th2 lineage maturation dependent upon 
underlying genetic influences and the ambient cytokine milieu.
In addition to its effects on T cell cytokine production, IL-18 exerts effects on CDS and 
NK T cell mediated cytotoxicity (63). IL-18 upregulates perforin and FAS dependent
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cytotoxicity (55, 64), but has no effect on TRAIL (TNF related ap opto sis inducing 
ligand) (65). These effects of IL-18 operate independently of IL-12.
In addition to modulating cytokine production, effects of IL-18 on lipid mediators have 
been investigated. Unlike IL-1, IL-18 does not induce cyclooxygenase (COX) or 
prostaglandin Ei (PGE2) expression in human PBMC. Furthemiore, inhibition of 
endogenous IL-18 resulted in upregulation of spontaneous PGE2 release (66). These 
effects may be cell type specific as IL-18 induces COX expression in chondrocytes (67).
IL-18 exerts effects on non T cell populations
Extensive effects of IL-18 have been documented on myeloid and tissue cell 
populations. In conjunction with IL-3, IL-18 induces IL-4 and IL-13 production by bone 
marrow derived basophils (68). IL-18 stimulates eosinophils to release IL-8 (69) and 
basophils and mast cells to release histamine. Histamine is reported to stimulate IL-18 
and IFNy production by PBMC and, as such, induction of this Thl like response may be 
evidence of a negative feedback loop (70). Overexpression of IL-18 in the skin resulted 
in accumulation of neutrophils in the spleen (71). Morover, repeated injection of IL-18 
into mice resulted in eosinophilia and significant neutrophilia, suggesting that IL-18 has 
haematopoietic effects (72), although further studies in IL-18-deficient animals are 
awaited.
Direct effects of IL-18 on macrophages and dendritic cells (DC) have been obseived. 
Stimulation of bone marrow derived macrophages or splenic DC with IL-12 and IL-18 
can induce IFNy production (73, 74). Langerhans cells (LC) also produce IL-18 (75), 
and IL-18-deficient animals exhibit defects in LC migration (76). IL-18 stimulation of
34
peritoneal macrophages induces IL-6 production, independent of the intermediate 
induction of endogenous cytokines such as TNFa or IL-ip (77). Macrophages derived 
from rheumatoid arthritis (RA) synovial membrane (but not peripheral blood 
monocytes) respond directly to IL-18 with TNFa production (78).
Numerous cells not directly associated with the immune system respond to IL-18. IL-18 
exerts effects on chondrocytes, promoting cartilage matrix degradation (67). Endothelial 
cells and synovial fibroblasts upregulate intracellular adhesion molecule-1 (ICAM-1) 
and VCAM-1 expression in response to IL-18 (79). In addition, IL-18 promotes 
migration and angiogensis of endothelial cells both in vitro and in vivo. IL-18 has 
further been shown to inhibit osteoclast formation via T cell GM-CSF production (80). 
Kératinocytes, originally believed to produce but not process IL-18 (81), have been 
shown to secrete biologically active IL-18 when treated with dinitrochlorbenzene and 
proinflammatory mediators such as LPS (82).
Clearly IL-18 exerts extensive effects of IL-18 on numerous cell populations. Whilst 
some contradictory effects await resolution, IL-18 undoubtedly operates as part of an 
extensive cytokine network, thus its effects are critically dependent on ambient cytokine 
milieu and genetic background. Unsurprisingly, IL-18 modulation exerts significant 
effects not only in host protection against pathogens but also host autotoxicity.
The biological effects of IL-18 are summarised in Figure 1.2.
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Figure 1.2 Biological effects of IL-18 adapted from Mclnnes et al (83)
1.2.7 Host defence
IL-18 possesses broad and potent immunomodulatory properties, thus IL-18 modulation 
dramatically alters the pathogenesis of a broad array of infectious diseases. The major 
effects of some such studies are summarised in Table 1.1. Interpreting the importance of 
endogenous IL-18, and establishing the potential benefits of supplementing with 
exogenous IL-18, is essential given the clinical potential of cytokine targeting therapies.
Table 1.1 IL-18 and infectious disease (adapted from (84))
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Microorganism rIL-18 IL-18 IL-18
administration neutralisation Knock Out
Yersinia improved exacerbated *
enterocolitica
Staphylococcus * * variable
aureus
Mycobacterium * * exacerbated
tuberculosis
Salmonella improved exacerbated
typhimurium
Legionella * not exacerbated *
pneumophila
Streptococcus * exacerbated exacerbated
pneumoniae
Cryptococcus improved exacerbated exacerbated
neoformans
Candida albicans * exacerbated exacerbated
Protozoa
Leishmania * * exacerbated
major * * not exacerbated
Improved (with * exacerbated
IL-12)
Toxoplasma Improved not exacerbated *
gondii
Plamodium Improved (with exacerbated
berghei IL-12)
Herpes Simplex improved * *
Murine * * not exacerbated
cytomegalovirus
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Intracellular Bacterial infections
Intracellular bacteria require cell mediated immune responses for their eradication. The 
role of IL-12 in such protective Thl type responses is well defined. The intracellular 
pathogen Mycobacterium avium has been widely studied using a variety of murine 
strains, including IL-18 and IL-18Ra-deficient mice, demonstrating a critical role for 
IL-18 in expulsion of the pathogen (52, 85, 86), Healthy PPD responsive control donors 
display a greater ability to produce IL-18 and IFNy in response to antigen, compared to 
patients with M. tuberculosis infection (87). However, patients with active disease 
exhibit raised plasma IL-18 levels (88) and in vitro stimulation of PBMC leads to 
increased IL-18 production (89). In leprosy the Thl/Th2 balance is key to disease 
outcome, but currently the role of IL-18 is conflicting. In resistant tuberculoid leprosy 
(TL), protective IFNy production is associated with increased IL-18 mRNA expression 
within lesions. Following in vitro challenge with bacterial antigen, monocytes from TL 
patients show increased IL-18 mRNA expression and IFNy production compared to 
cells from patients with susceptible lepromatous leprosy (LL) (90). However, one LL 
cohort studied exhibited elevated semm IL-18 levels (59), suggesting that IL-18 may 
promote the development of Th2 response, characteristic of LL. Further in vivo studies 
have shown the importance of IL-18 in the protective immune response to Salmonella 
typhimurium (91) and, although IL-18 expression is elevated in Legionella pneumophila 
infection, neutralisation of IL-18Ra was of no consequence to the outcome of the 
infection (92). Treatment with anti-IL-18 receptor (3 chain antibody in a murine model 
of Listeria monocytogenes infection demonstrated the protective effects of IL-18 
through modulation of early innate immune responses, Thl development and memory 
responses (93).
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Extracellular Bacterial Infections
Host responses to extracellular bacteria are at least partly mediated by neutrophil 
dependent killing mechanisms. IL-18 induces monocyte IL-8 production, which is 
chemotactic to neutrophils, and other effects of IL-18 on neutrophils are addressed 
throughout this study. Neutralisation of IL-18 in a murine model of Yersinia 
eterocolitica reduced resistance to infection, in an IFNy independent manner (94). IL- 
18-deficient mice fail to clear Streptococcus pneumoniae as effectively as wild type 
controls (95). Staphylococcus aureus infection in IL-18-deficient mice results in 
reduced sepsis but enhanced arthritis, possibly indicative of a dual role for IL-18 in 
protective bactericidal responses, but a detrimental role in promoting sepsis (96).
Role of IL-18 in sepsis
Sepsis may be defined as a potentially fatal condition, which can occur as a sequel to 
severe illness or trauma and is caused by LPS fiom gram-negative bacteria; but similar 
symptoms may result from overwhelming gram-positive infection. The role of IL-18 in 
endotoxic shock is critically dependent on initiating factors. Administration of 
neutralising antibodies to IL-18 results in 100% survival following LPS administration 
that would otherwise be fatal (97). Propionibacterium acnes primed IL-18-deficient 
mice show a defect in negative regulation of TNFa, resulting in increased mortality 
following challenge with endotoxin (98). Septic patients have elevated levels of both 
IL-18 and its natural antagonist IL-18BP (41, 99). Interestingly, septic patients with 
gram-positive infections have significantly higher IL-18 plasma levels than patients 
with gram-negative infection (100).
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Fungal infections
Stimulation of peritoneal exudate cells with IL-18 and IL-12 enhances the suppressive 
effects on growth of Cryptococcus neoformans. Similarly, protective effects of IL-18 
administration on in vivo infection with C neoformans were the result of increased 
IFNy release from NK cells, downregulation of IL-4 production and enhanced NO 
generation by macrophages (101, 102). Furtheimore, IL-18 appears effective even in the 
absence of IL-12 (103). In a chronic fungal asthma model, IL-18 promotes innate 
responses preventing the development of severe fungus-induced asthmatic disease 
(104). In caspase-1-deficient mice, exogenous IL-18 restores defective Thl responses 
during Candida albicans infection (105).
Viral infections
Immunity to viral infection is mediated via early production of IFNa and IFN(3, 
followed by NK cell activation and antigen specific CDS cell responses. IFNy 
production by CDS and NK cells is crucial for controlling viral infections. The 
administration of IL-18 to animals prior to infection with Herpes simplex virus (HSV) 
results in upregulated IFN-y dependent NO production, leading to improved survival; 
this effect was evident in the absence of T cells, implying IL-18 also augments innate 
immunity to viruses (106). In an in vivo model of Vaccinia infection, IL-18 
administration reduces pock formation (107). Pirating of IL-18 binding proteins by 
poxviruses may contribute to their immunosuppressive abilities (Section 1.2.5), and is 
consistent with a critical role for IL-18 in defense against the virus. In vitro, IL-18 
increased HIV-1 production in a clironically infected monocyte cell line (108). 
However, including IL-18 as an adjuvant enhanced the efficacy of a DNA vaccine 
against FIV and in models of HIV, apparently by promoting Thl responses (109).
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Protozoan Infections
The activation of macrophages by IFNy is a critical component of the immune response 
against intracellular protozoan infection. In animal models, cutaneous inoculation of 
Leishmania major induces either self-limiting, localised lesions or fatal visceral lesions, 
depending on genetic background. Resistance is associated with CD4 cell IFNy 
production. IL-18 deficiency renders mice susceptible to Leishmania infection (96, 
110). Infection of IL-18-deficient mice on a resistant background results in severe local 
lesions, which eventually resolve, indicating a protective effect of IL-18, but also that 
immunity is not exclusively due to IL-18 (111). Studies of animal models of malaria 
indicate protective effects of IL-18. Treatment of mice with miIL-18 conferred 
protection to both Plasmodium yeolii and P. berghei, which was associated with 
elevated serum IFNy. Similarly, IL-18-deficient mice or mice treated with neutralising 
anti-IL-18 antibodies were more susceptible to P. berghei than controls (112). Patients 
with uncomplicated P. falciparum malaria, who mount an effective Thl response, 
exhibit elevated serum IL-18 (113).
Anti tumour activity
Anti tumour activity of IL-18 has been explored in the context of a wide range of 
tumours, including sarcoma (114), neuroblastoma (115), melanoma (116), glioma (117), 
colon carcinoma (118), and bladder carcinoma (119). Various mechanisms are proposed 
for the observed anti-tumour effects of IL-18, including activation of NK cells, CD4 and 
CD8 T cells as well as induction of FasL and augmentation of production of reactive 
oxygen species ( 120, 121). Early studies demonstrated inhibitory efleets o f  IL-18 on 
tumour angiogensis (122), although controversy arose following studies by Koch et al 
demonstrating pro-angiogenic properties of IL-18 (123).
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1.2.8 Autoimmunity
Molecules involved in protection against pathogens are invariably involved in 
inflammatory reactions resulting in tissue injury. As such, multiple pathological roles of 
IL-18 in immune disturbances have been described.
Inflammatory arthritis
IL-18, in both pro and mature forms, is present in the synovial membrane of patients 
with RA (78, 124, 125) and with psoriatic arthritis (PsA; unpublished observations). 
Elevated expression of IL-18 is detected in the semm of patients with Adult Onset Stills 
disease (126). In the synovial membrane, IL-18 expression localises to CD 14  ^ and 
CD68  ^macrophages and in fibroblast-like synoviocytes (FLS) in situ. IL-18R (a and P) 
chains are detected ex vivo on up to 40% of synovial CD3 lymphocytes and on 20% of 
synovial CD 14+ macrophages and in vitro on FLS (127). IL-18 may pei-petuate 
inflammation by promoting cytokine release, particularly TNFa, GMCSF and IFNy, 
from both lymphocyte and macrophage populations. Marked synergy with IL-12 and 
IL-15 is observed in this respect (78). In turn, IL-18 expression is upregulated in FLS by 
IL-ip and TNF-a, suggesting the existence of positive feedback loops. This feedback 
loop provides a link between monokine predominance in RA with innate cytokine 
production and Th/c 1 cell activation in synovial immune responses. IL-18 induces NO 
release by RA SM in vitro that, since NO inhibits caspase-1 activity, provides a further 
potential regulatory loop. IL-18 reduces chondrocyte proliferation, upregulates iNOS, 
stromelysin and cycloxygenase 2 expression, and increases glycosaminoglycan (GAG) 
release in vitro, thus potentially promoting cartilage degradation (67). However, IL-18 
may 1 imittissuedestmction viainhibitionofosteoclastmaturationthiough GM-CSF
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production by T cells (80). Fui-thermore, IFN-y production suppresses COX expression 
with consequent effects upon prostanoid mediated local inflammation.
The predominantly proinflammatory function of IL-18 has been demonstrated by 
targeting IL-18 in several arthritis models in vivo. Upon challenge with type II collagen 
(CII) in CFA, IL-18-deficient mice on a DBA/1 background exhibit reduced incidence 
and severity of arthritis. Ex vivo analysis determined that both cellular and humoral 
responses to CII were suppressed (128). Moreover, administration of recombinant IL-18 
abrogates erosive arthritis in DBA/1 immunised with CII in IF A (129). Neutralisation of 
IL-18 in vivo, using specific antibodies or IL-18BP, effectively reduces developing and 
established rodent arthritis in both streptococcal cell wall (130) and CIA models (131). 
These observations strongly suggest that the net effect of IL-18 expression is 
proinflammatory, at least in the context of antigen-driven articular inflammation. 
Clinical studies to test this hypothesis in RA are awaited.
Gastrointestinal inflammation
Elevated IL-18 mRNA and protein expression are reported in gut tissue from patients 
with Crohn’s disease (CD) and ulcerative colitis (UC) (132, 133). Elevated IL-18 is 
present in serum of CD but not UC patients (134). IL-18BP isoforms are upregulated in 
CD mucosa in epithelial cells and macrophages. Conespondingly, IL-18/IL-18BP 
complexes are detected in tissues together with free mature IL-18 (135). vivo model 
systems further implicate IL-18 in the pathology of IBD. IL-18 mRNA levels increase 
early in the colon during dextran sulphate sodium induced (DSS) colitis. Studies 
utilising several gene targeted murine strains suggest that IL-18 mediated effects on 
colonic inflammation are IFNy dependent, but independent of NO, Fas-L and TNFa
43
(136). ICE-deficient mice exhibit reduced severity of DSS colitis associated with 
reduced IL-18 expression (137). Moreover, DSS colitis is ameliorated either by anti-IL- 
18 antibody or by IL-18BP;Fc protein (138). IL-18BP:Fc treatment attenuated mRNA 
upregulation of multiple proinflammatory cytokine genes, chemokine genes, and matrix 
metalloprotease genes in the large intestine, which are commonly elevated during IBD. 
IL-12p40-deficient mice develop increased severity of TNBS induced colitis associated 
with enhanced IL-18 expression, suggesting interactions between IL-12 and IL-18 in 
colonic mucosa (139). Together these data strongly implicate IL-18 as an important 
mediator of gastrointestinal inflammation.
Insulin dependent diabetes mellitus
The NOD mouse is an accepted model of IDDM, and various studies in this model 
indicate a role for IL-18 in pathogenesis. Elevated IL-18 mRNA expression is detected 
in pancreata prior to onset of diabetes in the NOD mouse (140). However, addition of 
exogenous IL-18 appeared to bias islet infiltrating T cells to a Th2 phenotype, thus 
reducing disease severity (141). Thus, elevated IL-18 expression may be a preclinical 
feature of IDDM. Studies of diabetic patients demonstrated no significant elevation of 
serum IL-18 compared to noimal controls; however, patients’ first-degree relatives who 
fulfilled high risk of disease development criteria had significantly elevated serum IL- 
18 (142). IL-12-deficient NOD mice developed similar insulitis and IDDM compared to 
normal controls; the development of IL-18-deficient NOD mice is awaited (143).
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Pulmonary disease
Investigations into the role of IL-18 in pulmonary inflammation have yielded 
conflicting results. Antigen sensitised mice are nasally challenged with the same 
antigen, which induces lung eosinophilia and airway hyper-responsiveness (AHR), 
providing a murine model of asthma. In this model, adenoviral delivery of IL-18 in 
established AHR reduces AHR, IL-4 production, mucus expression and eosinophilia 
(144). Accordingly, IL-18-deficient mice, or mice treated with neutralising antibody 
against IL-18, exhibit marked eosinophilia together with exaggerated lung damage, 
compared with controls (145). However, administration of exogenous IL-18, 
intratracheally, at time of nasal challenge, enhanced eosinophilic infiltration. This 
transpired to be secondary to eotaxin production by bronchial epithelial cells in 
response to IL-18 (146).
In human studies, IL-18 has been implicated in allergic inflammation. Elevated serum 
IL-18 is detected in patients with acute astlima. Compared with normal control donors, 
the bronchoalveolar lavage (BAL) fluids obtained from asthmatics, have lower levels of 
IL-18 (147). These data suggest that the precise effect of IL-18 may depend upon the 
kinetics and nature of specific pulmonary antigen responses. Patients with sarcoidosis, 
exhibit elevated IL-18 in serum, epithelial lining fluid, BAL and BAL fluid cells 
compared to healthy controls (148). Whether neutralising IL-18 would successfully 
target the harmful effects of gi anuloma formation or simply permit the emergence of the 
underlying pathogen remains to be elucidated.
IL-18 exerts extensive biological effects, and over expression of this proinflammatory 
cytokine is associated with an array of diseases. The aims of this study included
45
exploration of the effects of IL-18 on neutrophils, therefore neutrophil biology is 
considered below.
1.3 Neutrophils
1.3.8 Background
Over 100 years ago, Ehrlich described the ‘polynuclear’ cell, which could spread 
secretory products to the environment as needed. Subsequently, myriad functions have 
been subscribed to neutrophils. The neutrophil is a terminally differentiated cell of 9-10 
pm diameter. In humans, there are approximately 4 x 10^/ml in the circulation, 
constituting up to 75% of total circulating leukocytes. 5% of circulating neutrophils are 
immature ‘band cells’ (Fig. 1.3). Neutrophils are derived from myeloblast stem cells in 
the bone marrow, which progressively lose cytoplasmic organelles and develop 
cytoplasmic granules, whilst simultaneously undergoing condensation and lobulation of 
the nucleus. The process of neutrophil maturation is outlined in Fig. 1.3. Progression 
from myeloblast to mature neutrophil takes about 2 weeks. The majority of neutrophils, 
rather than entering the blood, reside in the bone manow for a period before being 
phagocytosed by bone maiTow macrophages. The bone marrow contains up to 30 times 
more neutrophils than the blood, providing a buffer against neutrophil depletion and 
allowing a rapid outpouring of neutrophils in response to stimuli such as infection.
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1,3.2 Role of neutrophils in the immune response
Neutrophils are the cellular hallmark of acute inflammation. On receiving signals from 
sites of infection and trauma, large numbers of neutrophils exit the blood stream, and 
migrate into tissue. As the first cells to arrive at the source of the insult, the neutrophils’ 
principal role is believed to be ingestion and destruction of bacteria via the generation of 
reactive oxygen species and the release of lytic enzymes stored in granules. Neutrophils 
display a paucity of ribosomes and endoplasmic reticulum, yet retain some ability to 
synthesise proteins. Thus in addition to dealing directly with the offending stimulus, 
neutrophils may generate soluble mediators, allowing them to communicate with other 
cells. Furthermore, neutrophils display a dynamic and curious array of cell surface 
molecules, providing a further dimension to this communication network. Each of these 
aspects of neutrophil function is considered below.
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Figure 1.3 Neutrophil maturation in the bone marrow
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1.3.3 Neutrophil migration
Neutrophils exit the blood, entering tissues, guided along gradients of molecules 
perceived by the cell. In the blood, approximately 50% of neutrophils flow with the 
circulating erythrocytes, while the remainders are ‘marginated’ and loosely adherent to 
the vascular endothelium. Neutrophil transmigration is illustrated in Fig. 1.4.
Neutrophils employ a multiplicity of mechanisms for locomotion as they encounter 
different substances on their mai'ch from blood to tissues. Selectins (L-, E- and P- 
selectin) exhibit rapid binding characteristics, sustaining dynamic interactions between 
neutrophils and endothelium. Neutrophils pause for milliseconds between each rolling 
step, and just 2 adhesive bonds may maintain this process (149, 150). Moreover, L- 
selectin binding can signal fimctional responses, such as upregulation of CDllb/CDlS
(151). Arrest of the neutrophil is dependent on p2 integi'ins, (CD 1 lb/CD 18 or 
CD 11 a/CD 18 complexes). CD 1 la-deficient mice show reduced numbers of neutrophils 
at sites of inflammation, although this is less pronounced in CD 1 lb-deficient animals
(152). In vitro, cytokine activated endothelial cells induce shape change of neutrophils 
within 1-2 minutes of contact. Trans-endothelial migration follows and is complete 
within 1-2 minutes (153). Following shape change, L-selectin is shed and CD43 and 
CD44 are also partially shed. Other receptors traffic around the cell, for example, 
formyl peptide receptors and CR4 are sent to the forward regions (154-156). An anti­
adhesive role is proposed for CD43, which would facilitate migration; CD43-deficient 
mice show reduced trans-endothelial migration even in the presence of increased 
adhesion (157). Once trans-endothelial migration is complete, neutrophils encounter 
extracellular matrix where |3i integrins facilitate travel. Following transendothelial
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migration, neutrophils now show increased a 4Pi dependent adhesion (158). agpi, which 
binds VCAM and extracellular matrix, is expressed by neutrophils. Additionally, agp, 
contributes to neutrophil migration through fibroblast layers in vitro (159).
Neutrophil recruitment also influences subsequent cellular responses. In rodent models, 
depletion of neutrophils by specific monoclonal antibody (RB6-8C5 in mouse; RP-3 in 
rats) reduces both recruitment of macrophages and lymphocytes in autoimmune 
diseases, and immunity to tumours (160, 161). IL-8-induced CD4 T cell recruitment 
into subcutaneous tissues of rats is inhibited by RP-3 treatment (162). Furthermore, 
neutrophil infiltration of hapten challenge sites during contact hypersensitivity 
responses is essential for the subsequent recruitment of CD8 T cells (163). Accordingly, 
neutrophil migration into the tissues may affect the later accumulation of macrophages 
or T lymphocytes.
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Figure 1.4 Neutrophil migration
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1.3.4 Neutrophil anti-microbial defences
Patients with Chronic Granulomatous disease, who exhibit a deficiency of the NADPH 
oxidase system, are highly susceptible to bacterial and fungal infections, exemplifying 
the importance of the neutrophil respiratory burst. The oxidative burst depends on 
activation and assembly of the NADPH oxidase, a membrane associated electron 
transport chain. The primary products, superoxide anion and hydrogen peroxide, are 
relatively harmless, but give rise to potent anti-microbial compounds (Fig. 1.5). These 
reactive oxygen intermediates (ROI) also function as regulators of other immune cells 
and apoptosis. Toxic products of nitric oxide, such as peroxyntitrite (ONOO‘), may be 
generated by murine but not human neutrophils.
Neutrophil granules store myeloperoxidase, which catalyses numerous reactions of the 
respiratory burst, integral to neutrophil bactericidal activity. Details of proteins localised 
to gi'anules, along with an overview of neutrophil granule accumulation through 
maturation is illustrated in Fig. 1.3. In addition to physically destroying the target, 
granule constituents may modify the ongoing immune response. For example, cathepsin 
G is chemotactic to mononuclear cells (164). Cathepsin G-deficient mice exhibit 
exaggerated neutrophil influx to wounds. The subsequent defects in wound repair are 
presumed to reflect the absence of macrophages, which promote wound healing and 
phagocytose neutrophils ( 165). D efensins are a large family o f cysteine rich c ationic 
proteins. Found in neutrophil granules and other cells (macrophages, kératinocytes), 
defensins display potent, non-specific anti-microbial activity. However, individual 
defensins exert other discrete effects such as degranulating mast cells (166), stimulating 
IL-8 production from epithelial cells (167), and acting as chemoattractants for distinct T 
cell subsets (168, 169). Patients with Chediak-Higashi syndrome have giant azurophil
51
granules, which do not secrete enzymes normally, and accordingly suffer from severe 
infections and an atypical lymphoproliferative syndrome (170). Neutrophils exert potent 
antibacterial effects through generation of reactive oxygen species and release of 
granule proteins, and these armaments may also be instructive to the ongoing immune 
response.
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Figure 1.5 Possible sites for neutrophil oxidase assembly and reactions
1.3.5 Production of cytokines by neutrophils
Mature neutrophils are terminally differentiated cells containing meagre protein 
synthesis machinery. However, studies of highly purified (>99.5%) neutrophil 
populations, using molecular biology techniques and immunohistochemistry, 
convincingly demonstrate that neutrophils are capable of synthesising a variety of 
cytokines (Table 1.1).
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Neutrophil cytokine release may contribute to orchestrating inflammatory responses, as 
indicated by depletion studies described previously (Section 1.3.3). Furthennore, 
neutrophil depletion, in mice otherwise susceptible to Leishmanial liberates sufficient 
pre-stored IL-12 to initiate a protective Thl response (171). Mononuclear cells 
generally generate more cytokine than neutrophils on a per cell basis (Table 1.2). 
However, as neutrophils constitute the majority of infiltrating leukocytes in 
inflammation, their cytokine release is likely to provide a substantial contribution to the 
overall inflammatory response.
Cytokine release may be paracrine or autocrine in function. Many cytokines released by 
neutrophils exert an array of autocrine effects, and may prime and initiate respiratory 
burst and degranulation, delay apoptosis, and promote migration. As such, the cytokine 
network provides a potent amplification loop for neutrophil led responses. Conversely, 
cytokines may restrain neutrophils; IL-10 can suppress IL-8 production in response to 
LPS (172). A wide range of stimuli may induce cytokine production by PMN (Table 
1.3). The magnitude, kinetics and nature of cytokines released vary substantially 
depending on the stimulus; for example, opsonised Saccharomyces cerevisiae (Y-IgG) 
induces only proinflammatoiy cytokines, while LPS induces both pro (e.g. IL-1) and 
anti inflammatory (e.g. IL-lra) (173).
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Table 1.2 Cytokines expressed by neutrophils (adapted from (173))
in vitro in vivo
IL-1 a  and (3 IL-1 a  and P
IL-lra IL-lra
IL-8 IL-6
IL-12 IL-8
TNFa IL-10
IFNa IL-12
GROa,GROp KC, GROa
CINC-l,2a,3 CINC
IP-10 M IP-la/lp
MIG TNFa
M IP-la/lp 
TGFa, TGFp 
IL-3, G-CSF, M-CSF
TGFp
Table 1.3 Examples of stimuli for neutrophil IL-8, IL-1 and TNFa 
production (adapted from (173))
IL-8 IL-1 TNFa
LPS + -H +
IMLP + - -
TNFa + + +
IL-lp + + +
Leukotriene B4 + - -
IFNy + +
Substance P + - -
C5a + - -
frbronectin + + +
Monosodium ureate crystals + + -
PMA + + +
Respiratory Syncitial Virus + -
Epstein Barr Vims + + -
Candida albicans + + +
Staphylococcus aureus + + +
Cryptococcus neoformans + + +
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Table 1.4 Relative cytokine production by neutrophils and monocytes 
(adapated from (174))
cytokine cell type stimulus cell 
no./ml
concentration 
ng/ml/24 h
IL-8 PMN LPS lO' 2.8
MNC 10? 200
TNFa PMN Y-IgG 5x10^ 0.2
MNC 5x10^ 3
IL-1 (3 PMN LPS lO'^ 3.7
MNC 10^ 0.4
1.3.6 Neutrophil antigen presentation
Quiescent circulating n eutrophils e xpress C lass I MHC ( MHC-I). E xogenous p eptide 
antigen can bind neutrophil cell surface MHC-I and stimulate memory CD8 cells. 
Furthermore, neutrophils may process exogenous antigen via an alternate vacuolar 
pathway for presentation on MHC-I, and these processed peptides may by released for 
presentation by other cells (175). Stimulation with GM-CSF and IFNy increases MHC-I 
expression and may induce Class II MHC (MHC-II) (176). Following treatment with 
GM-CSF, neutrophils respond to superantigen by producing IL-8. Moreover, mutant 
superantigens lacking MHC-II binding activity fail to induce IL-8 (177). MHC-II 
positive neutrophils mediate superantigen-induced T cell activation, but lack the ability 
to process antigen for Class II presentation (178). In addition to MHC-II, human PMN 
cultured with IFNy express co-stimulatory molecules, CD80 and CD86 (179). Synovial 
fluid derived neutrophils constitutively express intracellular MHC-II, which is found on 
the cell surface following ex vivo culture (180). This suggests that neutrophils within the 
joint, but not in the synovial fluid, may express MHC-II, with the potential to present 
and process cryptic antigens. The in vivo relevance of neutrophil antigen presentation
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awaits clarification, but provides another intriguing potential link between neutrophils 
and the adaptive response.
1.3.7 Role of ueiitrophils in sepsis and infection
Neutrophils are critical to the clearance of numerous microbes, a role best exemplified 
in gram-positive infections such as 5"taphylococcus aureus. However, in the e vent o f  
overwhelming, severe infection, a systemic inflammatory response may develop. 
Whether neutrophils are friend or foe in sepsis is unclear. Neutrophilia arises following 
an outpouring of neutrophils from the bone marrow, which increases the proportion of 
immature ‘band’ cells in the circulation. Neutrophils derived from septic patients 
exhibit a complex altered functional phenotype. Although LPS may prime and activate 
neutrophils, a phenomenon o f  neutrophil endotoxin tolerance describes the refractory 
response of neutrophils to re-stimulation following appropriate encounter with 
endotoxin. Thus neutrophils obtained from patients with sepsis show decreased capacity 
to generate IL-1 upon stimulation with various agonists (181). This ‘tolerance’ is not 
restricted to initiation by LPS and is observed in patients with gram-positive sepsis. 
Following severe trauma, leukotrienes release by neutrophils diminishes, which 
condates with the occurrence of immature neutrophils, mostly band cells, in the 
circulation. Similarly, expression of 5-lipoxygenase in neutrophil fractions consisting 
mainly of band cells is decreased (182). Neutrophils in sepsis display some features of 
activation including enhanced expression of GDI lb. The resulting proclivity to 
sequester in mircovessels in an activated state may perpetuate endothelial damage. 
Interestingly, immature neutrophils show greater tendency to accumulate in the 
microvasculature during gram-positive sepsis (183).
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Migratory defects are reported in neutrophils during sepsis implying a scenario whereby 
activated neutrophils may deliver toxic oxygen species and proteolytic enzymes directly 
to the endothelium, promoting injury within microvascular beds. Interventions that 
target neutrophils or their products may offer protection from tissue injury and death in 
endotoxaemia, suggesting that these cells may be worthy of further clinical attention.
1.3.8 Role of neutrophils in arthritis
Normally acellular joints become heavily infiltrated with leukocytes in rheumatoid 
aifhritis. A pannus of proliferating cells foims over the cartilage, consisting of synovial- 
like, fibroblast-like, macrophage-like cells, and lymphocytes. The cartilage-pannus 
junction (CPJ) is the site of actual cartilage destruction. This ‘solid phase’ is bathed in 
synovial fluid ( SF), which b ecomes heavily infiltrated, primarily with neutrophils. In 
active disease, neutrophils may accumulate within the synovial fluid at concentrations 
exceeding 10  ^neutrophils/ml.
SF derived neutrophils display evidence of in vivo priming and activation. SF 
neutrophils contain less myeloperoxidase (MPO) than PB neutrophils; in SF, MPO is 
present in a form that suggests it has been co-secreted with oxidants (184). Compared to 
PB neutrophils, SF neutrophils exhibit increased GDI lb, GD35 (GRl) (185) and 
reduced formly peptide receptor expression. Functionally, SF neutrophils are refractory 
to priming; IFNy stimulated PB, but not SF, neutrophils exhibit enhanced respiratory 
burst in response to IMLP (186).
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Given the phenotype of SF neutrophils, predictably, the SF contains numerous 
neutrophil derived factors (including IL-1, IL-8, TNFa, LTB4), which may exert 
autocrine priming and activation of neutrophils. Additionally, IgG containing immune 
complexes found within the joint are potent neutrophil agonists. Unlike PB neutrophils, 
SF neutrophils express FcRI; cell free SF induces FcRI expression by PB PMN (187). 
Whether FcRII and III expression is modulated on SF compared to PB neutrophil 
remains controversial (188).
Neutrophils are absent from synovial explant cultures, however these tissues are 
obtained at end stage disease and with culture methods that favour dividing or long- 
lived cells. However, histological examination of the cellular composition of the CPJ 
revealed the presence of neutrophils (189). An activated neutrophil adjacent to cartilage 
may release harmful concentrations of reactive oxygen and degradative enzymes, a 
process termed ‘frustrated phagocytosis.’ In the fluid phase, potential for neutrophil 
damage includes release of products that break down hyaluron (190), reducing its 
viscosity, and others which saturate the synovial fluid anti-proteinase and antioxidant 
activity (191).
Peripheral circulating neutrophils in RA patients exhibit characteristics predominantly 
equivalent to normal PB neutrophils. However, RA plasma levels of lactoferrin and 
elastase are gi'eater than normal controls, possibly indicative of peripheral degranulation 
(192). Nevertheless, no difference in CDllb, CD16, CD32, CD35 and formyl peptide 
receptor expression is reported between RA and normal PB neutrophils ( 193). Other 
studies report elevated CD 16 on RA PB neutrophils and such discrepancies may be 
attributable to drug effects (185). The majority of evidence indicates that, in rheumatoid
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arthritis, rather than systemic deregulation, neutrophils undergo major changes on 
entering the joint.
Animal models of arthritis indicate that neutrophil depletion may ameliorate 
inflammation and j oint damage. In the rat adjuvant arthritis model, administration o f 
anti neutrophil antibody (RP3) reduced circulating neutrophils and neutrophil 
accumulation within the joint, concomitant with ameliorated arthritis. Interestingly, no 
parallel effects on T cell numbers within the joint were observed. Conversely, CD4 
depletion, in the same model system, markedly reduced neutrophil accumulation within 
the joint (194). Circumstantial evidence indicates that targeting neutrophil activation in 
human d isease m ay b e b eneficial. In  v itro, 1 eflunamide i nhibits n eutrophil m igiation, 
and patients receiving leflunamide display reduced neutrophil numbers in joints (195). 
Neutralising TNFa may modulate neutrophil function at many levels, as TNFa 
promotes neutrophil migration, priming, release of granules and ROI all of which may 
contribute to joint damage (reviewed (196)).
The SF is clearly a source of patho-physiologically altered neutrophils, which likely 
contribute to the disease process. This heterogeneous population of resting, primed and 
activated neutrophils indicates a dynamic population, which varies with prevailing 
conditions within the joint.
1.4 Cytokines as clinical targets
Cytokines are critically involved in the pathogenesis of several diseases such as 
arthritis, Crolm’s disease and sepsis, providing a rational for therapeutic targeting.
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Cytokine targeting has been extensively investigated in arthritis. Targeting cells of the 
immune system, by depletion of CD3 cells, provides transient improvements but severe 
side effects. Other more common agents for the treatment of arthritis, such as 
corticosteroids, affect the transcription, release and activity of cytokines. Some patients 
do not respond to these non-specific agents and these drugs exert toxic side effects. 
Specific anticytokine targeting may be achieved with monoclonal antibodies (e.g. 
Infliximab), soluble receptors (e.g. Etanercept), recombinant natural antagonists (e.g. 
IL-lRa) and anti-inflammatory cytokines (e.g. IL-10). The effects of targeting TNFa 
are summarised in Table 1.5. Treatment of arthritis with monoclonal antibody against 
TNFa results in a dramatic reduction in circulating IL-1, IL-6, ESR and CRP with 
associated clinical improvement; however, disease returns upon cessation of therapy 
(reviewed (4)).
Although animal models of sepsis provided promising results, treatment with soluble 
TNFa receptors actually increased mortality in one sepsis trial (the soluble TNFaR 
employed was an Fc fusion protein, and these results are speculated to relate to Fc 
effects) (197). There was no overall effect of TNFa neutralisation in another sepsis trial 
(198). A small subgroup of patients however, enjoyed clear benefit from this therapy.
Targeting IL-1 in arthritis revealed the importance of reagent choice. Use of soluble IL- 
IRl was not effective in treating arthritis (199). Indeed in human trials of 
endotoxaemia, administration of soluble IL-lRl resulted in decreased circulating IL- 
IRa, and increased circulating TNFa and IL-8 (200). This recombinant soluble receptor 
binds the natural antagonist reducing its overall biological effectiveness. However,
..
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treatment of arthritis patients with recombinant human IL-lRa demonstrated clinical 
benefit, although arguably with less efficacy than TNFa targeting (201).
Table 1.5 Effect of targeting TNFa in experimental and human disease (adapted
animal models efficacy human clinical studies efficacy
bacteraemic / endotoxic shock + rheumatoid arthiitis +
cerebral malaria + inflammatory bowel disease +
experimentally induced arthritis + IL-2 toxicity -
EAE 4- septic shock -
inflammatory bowel disease + Jarisch-Herxheimer reaction +
acute lung injury + cerebral malaria -
acute pancreatitis + graft vs. host disease -
graft vs. host disease +
Further potential benefits of cytokine directed therapies lie in combination therapy. This 
strategy provides better disease control, allows reduction in dose, reduces the toxicity of 
non-specific agents such as DMARDS, and may ease the impairment of host defences 
caused by specific cytokine targeting therapies. Clinical trials combining methotrexate 
and TNFa inhibitors demonstrate the efficacy of this rationale (203). Other 
combinations o f  therapies under consideration include targeting IL-1 and TNFa, and 
combining IL-lRa with DMARDs.
Cytokine actions and interactions in the pathogenesis of disease continue to be explored. 
Promising results obtained so far indicate the potential of cytokine based therapies.
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Furthermore, as novel cytokines are defined and characterised, these provide new 
avenues to explore the pathogenesis of disease and refine treatment strategies.
1.5 Objectives
The foregoing introduction demonstrates the importance of IL-18 in protective and 
pathogenic immune responses. This study aimed to address the role of IL-18 in early 
immune responses and neutrophil activation, specifically:
1. In vitro activation of human neutrophils by IL-18
2. In vivo effects of IL-18 on neutrophil function
3. The role of IL-18 in the host response to gram-positive infection, in vitro
and in vivo
4. The role of cytokines and other factors that potentially allow neutrophils
to interact with cells on the adaptive immune system
A series of in vitro and in vivo systems were employed to answer these questions.
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Chapter 2 Material and Methods
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2.1 Samples and ethical considerations
Samples were obtained from patients attending the Centre for Rheumatic Diseases, 
Glasgow Royal hifiimary and Gartnavel General Hospital. RA patients satisfied the 
1987 American College of Rheumatology diagnostic criteria (204). Samples were 
collected in the presence of 10 U/ml sodium hepaiin (Leo Laboratories, Bucks, UK). 
Synovial fluid (SF) was surplus to clinical requirement following routine therapeutic or 
diagnostic procedures and would otherwise have been discarded. Blood and SF samples 
were collected only when clinically indicated and informed consent was obtained from 
patients prior to research use of samples. Peripheral blood was obtained from normal 
healthy donors with informed consent. This study (Dr. LB. Mclnnes, A comparative 
study of synovial immune dysregulation in inflammatory arthritis; Project no. 
00RH004) was reviewed and approved by the Glasgow Royal Infirmary Ethics 
Committee.
2.2 Reagents
The source of reagents (either purchased or donated) is given in the text and Tables 2.2- 
2.5. All chemicals were obtained from S igma, Poole, UK, and all culture media and 
supplements were obtained from Invitrogen, Paisley, UK unless otherwise indicated.
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2.3 Cell culture
Human cells were cultured in RPMI 1640 medium, supplemented with 2 mM L- 
Glutamine, 100 lU Penicillin, 100 pg/ml Streptomycin and 10% foetal calf serum 
(‘complete RPMP). Foetal calf serum (PCS, Harlan, Loughborough, UK) was certified 
mycoplasma free by the manufacturer and heat inactivated at 56°C for 30 minutes. 
Iscove’s Modified Dulbecco’s Medium (I-DMEM) was similarly supplemented and 
used for whole blood culture. Murine cell cultures were carried out in the presence of 
complete RPMI supplemented with 25mM HEPES. The DOl 1.10-GFP cell line, which 
contains a plasmid confening antibiotic resistance, was cultured in complete medium 
supplemented with 0.5 mg/ml geneticin (Sigma). Cells were washed in medium 
containing antibiotics and L-Glutamine but not FCS. Cultures were incubated at 2>TC in 
a humidified incubator with 5% CO2. Cells were counted with a Neubauer 
haemocytometer (Weber Scientific International Ltd, UK) by diluting in cell counting 
fluid (O.OIM acetic acid, 0.1% trypan blue in PBS), allowing viability to be assessed by 
trypan blue exclusion.
2.4 Human sample preparation
2.4.1 Peripheral blood neutrophil preparation
Venous blood collected in the presence of 10 U/ml sodium heparin was mixed with 1 
part of 6% dextran (dextran from Leuconstoc mesenteroides, molecular weight 
approximately 160 000, Sigma; in 0.9% saline) to 4 parts blood, and incubated for 30 
minutes at 37°C. The huffy coat was subsequently layered over 5 ml lymphoprep
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(Nycomed, Oslo, Norway) and centrifuged at 400 x g in a swing bucket rotor for 25 
minutes at room temperatuie. Mononuclear cells in the interface were removed, leaving 
neutrophils in the cell pellet. Remaining erythrocytes were lysed by 30 seconds 
exposure to sterile distilled water followed by the addition of an equal volume of 2 x 
PBS. Alternatively, neutrophils were obtained by layering 5 ml of blood over 5 ml of 
Polymorphoprep (Nycomed) and processed as for lymphoprep. The neutrophils, found 
in the lower interface, were of similar purity and viability to those obtained using 
lymphoprep. Neutrophils were washed 3 times in RPMI by centrifuging at 300 x g for 5 
minutes at room temperature. Where indicated, autologous human serum was collected 
into a clot activator Vacutainer™ (Ref 367837, Becton Dickenson (BD), Oxford, UK).
2.4.2 Synovial fluid neutrophil preparation
Synovial fluids were diluted with an equal volume of RPMI followed by density 
centrifugation over lymphoprep, then washing of the neutrophils as in section 2.4.1.
2.5 Murine sample preparation
2.5.1 Murine blood preparation
Murine whole blood was obtained by cardiac puncture under terminal anesthesia 
(Schedule 1 procedure according to Home Office guidelines). The heart was exposed 
and blood withdrawn with a 23 G needle (all needles: BD Microlance™, BD). 
Anaesthesia was inducedby intraperitoneal ( i.p.) injection o f  1 2.5 mg/animal avertin 
(2,2,2-tribromoethanol) in PBS, with a 25 G needle (stock anaesthetic was prepared by
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dissolving 1 g avertin per 1 ml amyl alcohol and was stored at 4°C). Blood was 
collected in the presence of 20 U/ml heparin and processed within 20 minutes of 
collection. Murine huffy coats were obtained by addition of an equal volume of 6% 
dextran (as Section 2.4.1). Murine serum was obtained by allowing blood to clot 
overnight in Eppendorfs’'^  at 4°C. Clotted samples were centrifuged at 450 x g for 10 
minutes and the serum removed and stored at -20°C. Murine peripheral blood 
leukocytes were obtained following cardiac puncture and erytluocyte lysis. One volume 
of blood was added to 4 volumes of freshly prepared, sterile filtered, red cell lysis buffer 
(155 mM KH4CI, 10 mM KHCO3, 0.1 niM EDTA, in dHgO) and incubated for 5 
minutes at 4°C. Remaining white cells were washed twice in RPMI at 400 x g for 5 
minutes then resuspended at 2 x lO'^  cells/ml.
2.5,2 Murine spleen and lymph node preparation
Single cell suspensions of spleens and lymph nodes were obtained by passing tissues 
tlirough 100 pm Nitex membrane (Cadisch & Sons, London, UK) using a 5 ml syringe 
plunger, in the presence of RPMI. To emich for lymphocytes in lymph node cell 
suspensions, cells were resuspended at 4 x 10^/ml in complete RPMI, and cultured in 
150 cm  ^polystyrene flasks (Iwaki, Japan), for 2 h after which non-adherent cells were 
removed. Cells were washed three times in RPMI and resuspended at the desired cell 
concentration in complete RPMI with 25mM HEPES.
67
2.5.3 Murine neutrophil preparation
Murine neutrophils were obtained from thioglycollate induced peritoneal exudate cells 
(PEC, Section 2.11.2). PEC obtained from 2 BALB/c mice were washed once then 
resuspended in 8 ml PBS, and layered over 3 ml Histopaque® 1083 (Sigma). The 
gradient was centrifuged at 700 x g for 30 minutes at 20°C. The enriched population of 
neutrophils contained within the cell pellet was washed twice in RPMI then 
resuspended at 2 x lOVml.
2.5.4 Murine macrophage preparation
Peritoneal exudate cells were washed in PBS then resuspended in complete medium and 
adhered to a polystyrene flask for 3 -  4 h after which remaining adherent cells were 
incubated with ice cold PBS (without calcium or magnesium) at 4°C for 10 minutes. 
Cells were harvested with a cell scraper, then washed in RPMI and resuspended at 2 x
loVml.
2.5.5 Murine dendritic ceil preparation
Mice were sacrificed by ceiwical dislocation prior to aseptic removal of tibias and tibias, 
which were transfeired to ice cold RPMI. Muscle was removed and epiphyses cut off 
and bone marrow flushed out with 2 ml RPMI using a 2 ml syringe and a 23 G needle. 
The marrow plugs were broken up through a Nitex m embrane and the resulting cell 
suspension washed twice in RPMI. Cells were resuspended at 2 x 10^/ml in complete 
RPMI supplemented with 10% GM-CSF (supernatant of x63 myeloma, kind gift of Dr.
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Jim Brewer, Dept, of Immunology, University of Glasgow) and cultured in 60 mm petri 
dishes (Bihby Sterlin, Stone, UK). On day 3, a further 10 ml of complete RPMI 
supplemented with 10% GM-CSF was added. At days 6 and 8, 10 ml of cell culture 
medium was removed and centrifuged at 400 x g for 5 minutes. The cell pellet was 
resupended in 10 ml fresh medium containing GM-CSF and returned to the petri dish. 
Dendritic cells were harvested for assay on day 10.
2.5.6 Stimulation of murine cell cultures
Tissue culture plates were coated with 5 pg/ml anti-CD3 (BD, Clone 145-2C11) in PBS 
for 4 h at 37°C. Plates were washed with sterile PBS prior to addition of cells. In other 
experiments, cells were cultured with either 2 pg/ml concanavalin A (Con A, Sigma), 
toxic shock syndrome toxin-1 (TSST-1, Sigma), or formalin fixed Staphylococcus 
aureus. Concentration of stimuli is indicated in the figure legends. Fixed S. aureus were 
prepared by addition of 4% formaldehyde to an equal volume of 10^  CFU/ml S. aureus 
in PBS (Section 2.9.8). Bacteria were incubated for 30 minutes at 4°C then washed 3 
times with PBS at 700 x g for 10 minutes. Cell contact dependency was investigated 
with tissue culture insert strips (Nunc, Rosklide, Denmark), consisting of a 0.2 pm 
anopore membrane, allowing separation of 2 cell populations within a 96 well format.
2.5.7 Proliferation assays
Proliferation assays were performed in triplicate in U bottom 96 well culture plates 
(Nunc) at 2 X 10^  cells per well in a final volume of 200 pi. 1 pCi [^H] thymidine 
(Amersham Life Science, Bucks, UK) in 25 pi complete medium was added during the
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final 6 or 18 h of culture (as indicated in results) before harvesting onto filter mats 
(Wallac, Milton Keynes, UK) using a 1295-004 Betaplate™ 96 well harvester (Wallac), 
[^H] thymidine incoiporation was measured using a 1205 Betaplate^"^ liquid scintillation 
counter (Wallac). In some experiments parallel cultures were performed in flat bottom 
96 well plates and supernatants were stored at -20°C until estimation of cytokine 
content by ELISA (Section 2.6).
2.6 Cytokine assays
Concentration of cytokines in supernatants and seinm samples were estimated by 
ELISA. Paired antibodies and ELISA kits were used in accordance with the 
manufacturer’s recommendations (Table 2.2). All assays were optimised and validated 
prior to use. Maxisorp 96 well plates (Nunc) were coated with capture antibody in 0.1 
M NaHCOs overnight at 4°C. All subsequent steps were carried out at room 
temperature with reagents diluted in blocking buffer (PBS, 10% FCS). Plates were 
blocked for 2 h; samples and standards added for 2 h, followed by biotinylated 
secondary antibody for 1 h, then ExtrAvidin peroxidase (Sigma) conjugate for 45 
minutes. Plates were washed 4-8 times between each step with wash buffer (PBS 0.05% 
Tween 20). For each wash, wells were filled with wash buffer and allowed to stand for 
at least 1 minute prior to removal of wash buffer. For the final wash, remaining wash 
buffer was removed by pounding the plate on paper towels. Plates were developed with 
TMB (3,3 %5,5 ’ -tetra-methylbenzidine, KPL, Gaithersburg, USA), colour allowed to 
develop, and then read at 630 run with a Dynex MRX II plate reader and analysed using 
Dynex Revelation 3,2 software (Dynex, Middlesex, UK).
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2.7 Flow cytometry
2.7.1 Cell surface antigen staining
Human or murine cells were resuspended in FACS buffer (PBS, 0.2% sodium azide, 2% 
FCS) at approximately 4 x 10^  cells/ml. 100 pi of cell suspension, or 200 pi 
anticoagulated whole blood were added for each test in a 12 x 75 mm polystyrene tube 
(‘FACS tubes’ Falcon 2052, BD). Antibody binding non-specifically to murine Fc 
receptors was reduced in murine samples by incubation at room temperature for 15 
minutes with 0.5 pg Fc block (anti-mouse CD 16/32, BD). Cells were stained with 
various antibodies or appropriate isotype controls (Table 2.3), for 30 minutes, at 4°C in 
the dark. Where secondary detection reagents were necessary, cells were washed in 
FACS buffer, centrifuging at 400 x g for 5 minutes, then resuspended in 100 pi of 
FACS buffer containing the appropriate secondary reagent and incubated at 4°C in the 
dark for 30 minutes. At this stage, whole bloods were lysed with 2 ml BD 
FACSlysing^'^ solution for 10 minutes at room temperature. Cells were washed twice in 
FACS buffer, then resuspended in 200 pi FACS Flow, passed thiough Nitex and 
analysed on a FACSCaliber using CellQuest Software (all BD).
2.7.2 Intracellular cytokine staining
For intracellular staining, cells were resuspended at approximately 2x10^ cells/ml and 
cell surface antigens were stained as above. Cells were fixed by addition of 2 ml of 2% 
formaldehyde in PBS for 30 minutes at 4°C, washed twice in ‘perm’ buffer (FACS 
buffer supplemented with 0.5% saponin) and then incubated with antibody in perm
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buffer in the dark for 30 minutes at 4°C. Finally, cells were washed twice in perm 
buffer, then in FACS buffer and analysed as above. Details of antibodies are contained 
in Table 2.3.
2.7.3 FACS acquisition and analysis
Cells were acquired and analysed on a Becton Dickinson FACSCalibur. The instrument 
was calibrated monthly with CaliBRITE™ beads (BD), which are designed for use with 
the FACSCalibur'^'^. The beads were used to adjust instrument settings, set fluorescence 
compensation, and check instrument sensitivity.
Prior to running labelled cells, FSC (fomard scatter) and SSC (side scatter) were 
adjusted so cells of interested could be g ated on the screen. Unstained s amples were 
used as auto-fluorescence controls allowing FLl (FITC) and FL2 (PE/PI) detector 
settings to be adjusted so that auto-fluorescence background was roughly within the first 
decade of the log scale of the fluorescence intensity histogram. Unstained samples were 
compared with isotype and positively stained controls to confirai the correct scale. 
Compensation settings were set such that on a FLl vs. FL2 dot plot, an FLl positive 
population is vertically aligned with negative population, and an FL2 positive 
population is horizontally aligned with the FL2 negative population. Results are 
expressed either as % positive cells or mean fluorescence intensity (MFÏ).
.AM
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2.8 Histology
2.8.1 Cytospîns and staining
Cells were resuspended at approximately 4 x 10^  cells/ml in PBS and 200-500 pi spun 
onto a SuperFrost Plus glass slide (Shandon, Pittsburgh, PA) at 300 rpm, for 3 minutes, 
using a Shandon cytospin system. Cytospins were stained with DiffQuick™ (TBS, 
Skelmersdale, UK). Cells were fixed onto slides by immersion in methanol for 5 
minutes, and then allowed to air dry. Slides were immersed in Solution B (Eosin Y in 
phosphate buffer) for 2-3 minutes then immediately transferred to Solution C 
(Methylene blue in phosphate buffer) for 2-3 minutes. Staining was checked for 
intensity before cells were allowed to air dry then mounted with DPX mountant (BDH, 
Poole, UK). DiffQuick™ stained nuclear chi'omatin and neutrophil granules 
blue/purple, and eosinophil granules red/pink.
2.8.2 Tissue histology
Murine hind limbs were removed above the knee and immediately fixed in 10% neutral 
buffered formalin for at least 1 week. Paws were decalcified by soaking in 5% H N O 3 
for a further 3 weeks, then 6 pm sections were cut using a bone microtome. Sections 
were stained with haematoxylin and eosin using the standard method of the Dept, of 
Pathology, Western Infirmary, University of Glasgow.
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2.8.3 Image recording
A photographie system consisting off a Leica DM RB microscope connected to a digital 
camera, allowed recording of images via ImageAccess Software. In figure legends, low 
power magnficiation refers to an original magnification x 100; magnification x 630 is 
defined as high power
2.8.4 Fluorescence microscopy
3x10^ cells per test were incubated for 15 minutes with 0.5 pg Fc block then incubated 
with biotin-conjugated antibody for 30 minutes at 4°C in the dark. Cells were washed 
with sterile PBS containing 2% PCS, prior to addition of streptavidin conjugate. To 
distinguish green fluorescence protein (GFP) from a second fluorescent label, biotin 
conjugated antibodies were detected with steptavidin Texas Red (Vector Laboratories 
Inc, CA, USA), which has a nanow emission spectrum, reducing overlap between ‘red’ 
and ‘green’ signals. Cells were washed then fixed by the addition of 1 ml 1% 
paraformaldehyde (PFA) in PBS for 1 minute. Cells were washed in PBS and remaining 
PFA quenched by 30 seconds exposure to 1 ml 0.06% Gly-Gly in PBS. Cells were 
washed in PBS then in phenol free RPMI, and finally resuspended in phenol free 
complete RPMI with 25 mM HEPES. Cultures and analysis were performed in 8- 
chambered coverglass (borosilicate) slides (Nunc). Up to 10  ^cells in 1 ml were added to 
each chamber. Fluorescence was assessed by with an Axiovert SI00 fluorescence 
microscope. Images were recorded via a digital camera, acquired and analysed with 
Openlab software (Improvision, Coventry, UK).
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2.9 Neutrophil function and phenotype assays
2.9.1 Neutrophil purity
Cytospins of neutrophil preparations were stained (Section 2.8.1) and cells were 
identified as neutrophils by the presence of a multilobed nucleus and granular 
cytoplasm. Sample purity was also assessed by flow cytometry, identifying neutrophils 
both by forward/side scatter (Fig. 3.1) and staining contaminating cells with either FITC 
conjugated anti~CD3, anti-CD 19, anti-CD 14, or anti-CD 15 (staining as Section 2.7, 
antibodies detailed Table 2.3).
2.9.2 Neutrophil cytokine production in response to IL-18
Neutrophils were added to 96 well flat bottom plates (Nunc), at 2 x 10  ^cells/ml in 100 
pi complete RPMI 1640. Cells were stimulated, in triplicate, with recombinant human 
IL-18 (kind gift of Dr. LA. Grade, Centre for Rheumatic Diseases, Glasgow Royal 
Infirmary) at 1, 10, or 100 ng/ml for 1-24 h at 37°C. To determine whether IL-18 
induces de novo protein synthesis, cyclohexamide or actinomycin D (both at 2 pg/ml) 
was added to cultures for 30 minutes prior to IL-18 stimulation. Dexamthasone and 
methotrexate (both at 1 pM) were used in further inhibition studies. IL-18 signalling 
through the MAP Kinase pathways was investigated with the p38 inhibitor, SB 203580 
(5 pM), and the ERK inhibitor, PD 98059 (20 pM, both Alexis Biochemicals, 
Nottingham, UK). Stocks of inhibitors were prepared at > 1000 fold working 
concentration in DMSO and diluted in complete RPMI. Inhibitors and DMSO control
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were included throughout the culture and toxicity assessed by MTT. Culture 
supernatants were stored at -20°C until cytokine levels were estimated by ELISA.
2.9.3 MTT assay
To assess cell viability in culture, 2 x 10^  neutrophils in 200 pi were plated in 96 well 
plates and incubated for up to 24 h. 100 pi of supernatant was removed and 10 pi of 5 
mg/ml MTT (3-[4,5-DimethyIthiazol -2-yl] -  2,-5 diphenyltetrazolium bromdide) in 
dHzO, was added for the final 4 h of culture. Cells were lysed with an equal volume of 
isopropanol and theeolouredproduct quantifiedusing a platereader to detect OD570 
run.
2.9.4 CDl lb expression
Whole blood was diluted in LDMEM and cultured for 1 h in the presence or absence of 
100 ng/ml rhIL-18. The cells were stained for CDl lb, erythrocytes lysed then samples 
analysed by flow cytometry (Section 2.7).
2.9.5 Apoptosis
Neutrophils were incubated in complete medium, in the presence or absence of IL-18 
for up to 24 h. Cells were washed twice with FACS buffer and resuspended in binding 
buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaClz). 5 pi of 
Annexin V FITC and 10 pi 50 pg/ml PI was added to approximately 2 x 10^  cells and
76
incubated in the dark, at room temperature for 15 minutes before adding 400 pi binding 
buffer to each tube. Samples were analysed by flow cytometry (Section 2.7).
2.9.6 Effect of IL-18 on neutrophil respiratory burst
Neutrophils were placed in 24 well flat bottom plates (Nunc) at 10^  cells/ml in complete 
medium and stimulated with 100 ng/ml rhIL-18 for 1 h at 37°C. Cells were transferred 
to triplicate wells of a luminometer microtitre plate, in the presence of 10 pM Luminol. 
1 pM N-formyl-methionyl-leucyl-phenylalanine (fMLP) was added and the plate read 
immediately in a MLX microtitre plate luminometer (Dynex, Middlesex, UK). 
Magnitude of respiratory burst was estimated by Revelation software. This program 
recorded a Vmax, which is the rate of increase in emitted light to the maximum level 
recorded (A/B, Fig. 2.1).
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Figure 2.1 Assessment of neutrophil respiratory burst
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2.9.7 Neutrophil myeloperoxidase assay
This was carried out as previously described (205). Neutrophil preparations or murine 
footpads were homogenised with a pellet pestle motor homogeniser (Anachem, Luton, 
UK) in 2 ml of 20 mM potassium phosphate (pH 7.4) then centrifliged in a J2~MC 
centrifuge (BD) at 35 000 x g for 30 minutes, at 4°C. The pellet was resuspended in 2 
ml of 50 mM potassium phosphate (pH 6), containing 0.5 g/dl cetrimonium bromide. 
Resuspended pellets were h'ozen at -70°C until assay. Samples were thawed and 
sonicated for 1 minute at 50% power, 50% pulse with a Branson sonifier 250, then 
incubated for 2 h in a 60°C water bath, and centrifuged for 10 minutes at 12 000 x g in a 
Jouan BR4 microfuge. 25 pi of the supernatant were added to 750 pi 50 mM potassium 
phosphate containing 0.167 mg/ml o-dianisidine and 5 x 10"^% H2O2. Absorbance at 
460 nm was recorded from 1-3 minutes following initiation of reaction.
MPO activity per gram of tissue was calculated by:
MPO (U/gwt) = ( A 46o ) (1 3 .5 )
Weight (g)
A460 is the change in absorbance of 460 nm light from 1-3 minutes after initiation of the 
reaction. 13.5 is an empirically derived coefficient such that 1 unit MPO activity is the 
amount of enzyme that will reduce 1 pM peroxide per minute.
2.9.8 In vitro bacterial killing
Murine buffy coat or human neutrophil preparations were resuspended at lOVnil, in 
Media 199 containing 10% autologous serum. The cells were stimulated with 100 ng/ml
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rmIL“18 (Peprotech, EC Ltd, UK) or rhIL-18 for 1 h. S. aureus Cowan strain (SAC, 
kind gift of Prof. Curtis Gemmell, Dept, of Bacteriology, Glasgow Royal Infirmary) 
were stored in Microbanks (Pro-Lab Diagnostics, Neston Wirrel, UK) at -70°C and 
were cultured on 5% blood agar (kind gift of Dept, of Bacteriology, Western Infirmary, 
Glasgow) for 18 h at 37°C, followed by overnight growth in Mueller Hinton Broth 
(Sigma). The broth culture was washed 3 times in sterile PBS by centrifuging at 600 x g 
for 10 minutes at room temperature. Bacteria were resuspended in sterile PBS and 
standardised spectrophotometrically to contain 10® CFU/ml. This suspension was 
diluted in Media 199 containing 10% autologous serum, to 10^  CFU/ml, and allowed to 
opsonise for 20 minutes, at 37°C with gentle shaking. Bacteria were washed and 
resuspended at 10^  per ml. Equal volumes of stimulated cells and bacteria were mixed 
and incubated with gentle shaking for 20 minutes at 37°C. After incubation, 3 volumes 
of cold water were added to lyse the neutrophils and release bacteria which had been 
phagocytosed but not killed. Finally, remaining live bacteria were counted by plating 
dilutions in triplicate. Percentage killing was estimated by calculating (Bacteria only -  
Test)/(Bacteria only) x 100. ‘Bacteria only’ is a control from which addition of cells 
were omitted.
2.10 Gene expression analysis
2.10.1 RNA extraction
Cell pellets of 10^  -  10^  PMN were resuspended in 0.2 ml RNAzol B (Biogenesis Ltd, 
Poole, U.K.) per 10  ^cells and stored at -70°C prior to processing. Samples were thawed 
on ice, 50 pi chloroform added and samples shaken for 15 seconds before incubation on
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ice for 5 minutes. The samples were centrifuged at 11,000 x g, at 4°C for 15 minutes. 
The upper aqueous phase was removed to a clean tube and an equal volume of 
isopropanol added, mixed and incubated for 45 minutes on ice before centrifuging as 
above. The RNA containing pellet was washed in 70% ethanol then resuspended in 
sterile distilled water (Injection grade, Steripak Ltd, Cheshire, UK).
RNA was extracted from 400 pi murine heparinised blood by RNAqueous™ Blood 
module and kit (Ambion, Cambridge, UK) according to the manufacturer’s instructions. 
Erythrocytes were lysed by 10 minutes incubation with 1.2 ml of the manufacturer’s 
buffer, at 4°C. Samples were centrifuged at 10,000 x g for 30 seconds in a microfuge 
and the supernatant removed. Remaining erythrocytes were lysed by mixing with a 
further 1 ml of lysis buffer and centrifuging as before. The leukocytes were disrupted in 
a high concentration guanidinium salt solution that simultaneously lysed the cells and 
inactivated endogenous RNAses (206). The lysate was diluted with ethanol allowing 
RNA to bind to a glass fibre filter, while most other cellular components flowed 
through. The filter was washed 3 times then the RNA eluted the manufacturer’s buffer 
(a very low ionic strength solution). Sections of murine spleen and footpads were stored 
in RNAlater' '^^ (Ambion) at 4°C until RNA extractions were performed with 10 mg of 
spleen, or total footpad, using Nucleospin® RNA II columns (Macherey-Nagel, Duren, 
Germany) according to the manufacturer’s protocol. Tissues, immersed in the 
manufacturer’s lysis buffer, were homogenised with a pellet pestle motor homogeniser 
(Anachem). This system worked on an identical principal to the RNAqueous Kif^ *^ . 
Concentration of RNA was determined by its optical density by the following formula 
(207):
[(62 X OD260) -  (36 X OD280)] X dilution of sample = ‘RNA’ pg/ml
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Contaminating genomic DNA was removed with DNA-free' '^^ (Ambion) according to 
the manufacturer’s instructions. Typically, 2-4 units of DNAse I was added to 20 pi of 
RNA in the presence of the manufacturer’s buffer and incubated at 37°C for 30 minutes. 
DNAse inactivation reagent was added for 2 minutes then removed by centrifugation 
leaving RNA in the supernatant.
2.10.2 Reverse transcription
RNA (1-5 pg) was incubated with 0.5 pg 01igo(dT)i2-i8 (Invitrogen) at 70°C for 10 
minutes, quick chilled, then reverse transcribed using 100 U Superscript II RT 
(Invitrogen) at 42°C for 50 minutes in the presence of the manufacturer’s buffer (50 
mM Tris.HCl (pH 8 .3), 75 mM KCl, 3 mM MgCh) with 0.01 M DTT and 0.5 mM 
dNTPs in a total volume of 20 pi. Finally, the Superscript was inactivated by heating to 
70°C for 10 minutes. Where appropriate ‘no RT’ controls were perfonned in the 
absence of Superscript.
2.10.3 Primer design
Oligonucleotide primers were designed to span regions of interest using Primer 0.5 
software (Whitehead Institute for Biomedical Research, Cambridge, MA). This program 
screens a given sequence for pairs of oligonucleotide primers that fit given parameters, 
including an optimal primer length of 20 bases, melting temperatures of between 50 and 
60°C, a GC content of between 40 and 65% and self complementarity of less than 3 bp 
overall. Selected primer pairs were tested using Amplify software (vl.2, University of 
Wisconsin, WI, USA) to predict the size of PCR product, and ensure the primers did not
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bind other regions of the sequence. Where possible, primers were designed to span two 
intron-exon boundaries, allowing discrimination between products resulting from 
amplification of cDNA and contaminating genomic DNA. A predicted annealing 
temperature for the PCR was obtained using HyperCard 2.2 software (Apple Computer 
Inc. CA). Primer specificity was checked by analysing the sequences using the basic 
local aligmnent search tool (BLASTn), within the National Center for Biotechnology 
Information's (NCBI) World Wide Web site.
2.10.4 Polymerase chain reaction
Amplification reactions were performed in a final volume of 25 pi (unless otherwise 
stated) in a 0.2 ml Thermo-Tube (ABgene, Surrey, UK). Reactions were carried out 
using Thermus aquaticus DNA Polymerase (Invitrogen) in the manufacturer’s buffer 
(Ix; 20 mM Tris.HCl (pH 8.4), 50 mM KCl). The standard conditions in each PCR 
were:
1 pi template cDNA (approx. 100 ng)
0.5 pi 100 pM each primer 
0.5 pi 10 mM dNTP mix 
0.25 units Taq DNA polymerase
0 .5 -1  pi 50 mM MgCh (independently optimised for each PCR)
Reaction conditions are shown in Table 2.1. Primers are listed in Table 2.4.
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Table 2.1 PCR reaction conditions
Temperature (‘^ C) Time
Denaturing 94 2 minutes
Amplification denature 94 30 seconds
(35 cycles) anneal 56 30 seconds
extend 72 30 seconds
Extend 72 10 minutes
The product of the hIL-18Ra PCR was confirmed by cloning into TA vector 
(Invitrogen), and sequencing with T7 DNAse polymerase kit (Amersham, 
Buckinghamshire, U.K.) according to the manufacturer’s protocol. PCR products were 
analysed on gels containing 1% agarose (w/v) (Molecular Biology Grade, Promega Inc.) 
in 1 X TBE buffer with 0.5 pg/ml ethidium bromide. The samples were loaded beside 
0.5 pg 1 Kb Ladder (Invitrogen) with 25% (v/v) loading buffer (10 mM Tris.HCl (pH 
8.0), 1 mM EDTA, 33% (w/v) glycerol and 600 pg/ml bromophenol blue) and the gel 
was run at a constant 5 V/cm in 1 x TBE until the bromophenol blue had migrated 
approximately 5 cm thiough the gel. The product was visualised under ultraviolet 
illumination (320 nm).
2.10.5 Real time PCR
Taqman real-time PCR (208) was performed using an ABI prism 7700 sequence 
detector according to the manufacturer’s instructions (PerkinElmer Applied Biosystems, 
Foster City, CA). The principal of the method is outlined below (Fig 2,2).
Primers and fluorescentprobes (Table 2.5) were designed using the PrimerExpress™ 
vl.O program and purchased from Biosource UK. The fluorescent probes contained a 
reporter dye (FAM or VIC) covalently attached at the 5’ end and a quencher dye
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(TAMRA) attached at the 3’ end. Probes and primers were HPLC purified. Extension
from the 3’ end of the probe was blocked by the attachment of a 3’ phosphate group.
Each reaction contained:
200 pM each dATP, dCTP, dGTP
400 pM dUTP
5 mM MgCla
0.625 U AmpliTaqGold
0.25 U AmpErase Uracil N~Glycosylase
50 mM KCl, 10 mM Tris.HCl (pH 8.3), 10 mM EDTA
The above were purchased as qPCR™ Core Kit, (Eurogentec, Belgium).
300 nM each primer 
200 nM detection probe 
1 pi cDNA template (approx. 100 ng) 
total volume -  25 pi.
Amplifications were preformed in triplicate using an initial cycle of 50°C for 2 minutes 
and 95°C for 10 minutes followed by 45 cycles of 95°C for 15 seconds and 50°C for 1 
minute. Data analysis was performed using Sequence Detector software (PerkinElmer 
Applied Biosystems), which calculates the thi'cshold cycle (Ct). This represents the PCR 
cycle at which an increase in fluorescence above a threshold can first be detected. The 
cDNA levels during the linear phase of amplification were normalised against 
hypoxanthine phosphorbosyltransferase (HPRT) controls, by subtracting the mean Ct 
value of HPRT from that of the gene of interest (ACt). To obtain a value for fold 
increase relative to HPRT the formula 2'^ *“^  was used. Multiplication of this value was 
used to estimate mRNA expression as % HPRT. The error is the standard deviation of 
the difference: s = V(S 1^ +82 )^ where Si and S2 are the standard deviations of the mean Ct
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of HPRT and the gene of interest respectively. Results are expressed as mean ± 
percentage error.
1. Polymerisation
Forward
Primer5’3’5’
2. Strand displacement
5’3’5’
Probe 3’
I s 3’
5’
3’5’Reverse
Primer
5’3’5’
3. Cleavage
5’3’5’
4. Polymerisation 
complete
3’
5’
3’
\  /
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5’3’5’
>  3’— 5’
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Figure 2.2 Schematic representation of real time PCR
A reporter dye, FAM or VIC was covalently attached to the 5’ end of the probe 
(F). A quencher (Q), TAMRA was attached to the 3’ end. PCR product 
amplification resulted in cleavage of the probe, thus removing the inhibitory 
action of the quencher from the reporter.
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2.11 Animal models
2.11.1 Animals
All animal experiments were performed according to UK Home Office regulations 
under Project Licence 60/2402, procedure 8, and 60/2217, procedures 1 and 7.
Outbred 6-8 week old male Swiss mice (original breeding stock NIH)were obtained 
from Harlan (Orlac, Bicester, UK). IL-18-deficient and wild type control mice were 
obtained as previously described (96). 6-8 week old BALB/c, C57B1/6 and C3H/HeJ 
mice were obtained from Harlan. TNFR p55 knock out mice (209) were a kind gift of 
Prof. Allan Mowat, Dept of Immunology, University of Glasgow. The DO 11.10 T cell 
receptor transgenic mice, on a BALB/c background, were a kind gift of Prof. Paul 
Garside, Dept of Immunology, University of Glasgow. Mice were fed standard mouse 
chow and water ad libitum under standard conditions of temperature and light in 
accordance with UK Home Office regulations.
2.11.2 Carrageenan induced acute inflammation
Carrageenan induced inflammation was initiated in 6-8 week old female BALB/c mice 
as previously described (210). Neutralising monoclonal anti-IL-18 Ab or isotype control 
Ab (both 25 pg in 50 pi PBS per animal, equivalent to 1.5 mg/kg, R&D Systems) was 
administered i.p. 30 min before and 24 h after sub cutaneous injection of 300 pg X 
carrageenan, in 50 pi PBS, into the right hind footpad; a 28 G needle was used for both 
injections. The change in footpad thickness between the right and left hind limbs was
86
measured with a dial caliper (Kroeplin, Munich, Germany). Differences are recorded as 
change in footpad thickness expressed in millimeters.
2.11.3 Cell recruitment to the peritoneal cavity
6-8 week old BALB/c, C3H/HeJ or C57B1/6 TNFR p55-deficient mice or wild type 
controls, received rmIL-18 in PBS with 0.05% BSA, or earner alone, i.p. 4-48 h 
following injection, mice were sacrificed by exposure to rising concentrations of carbon 
dioxide and the peritoneal cavity cells were harvested by making a ventral midline 
incision with scissors and retracting the abdominal skin, exposing the intact peritoneal 
wall. 5 ml PBS containing 10 U/ml sodium heparin (Leo Laboratories) was injected 
through the peritoneal wall with a 23 G needle. The abdomen was gently massaged then 
the fluid withdrawn. A similar volume of lavage was recovered from each animal. Total 
cell counts were performed in a cell counter (COULTER ACT; Coulter, Miami, FL) and 
differential cell counts enumerated on cytocentrifuge slides stained with DiffQuick™. 
Differential counts (200 cells) were perfonned under a light microscope and the results 
presented as number of neutrophils per cavity. Alternatively, cells were stained and 
analysed by flow cytometry. Cell recruitment into the peritoneal cavity was also 
induced with thioglycollate. Brewers thioglycollate medium (Difco, East Molesey, UK) 
was prepared according to the manufacturer’s instmctions; 40.5 g medium was 
dissolved by boiling in 1 liter of sterile de-ionised water, aliquoted, then autoclaved and 
stored in the dark. 1.5 ml was injected i.p. into BALB/c mice and 4 h later cells were 
harvested by peritoneal lavage.
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2.11.4 Induction and assessment of septic arthritis
This was performed as previously described (211). S, aureus LS-1, a TSST-1 producing 
strain, was originally isolated from a spontaneous outbreak of murine septic arthritis 
(kind gift of Dr. T. Bremell, University of Lund, Lund, Sweden). Bacteria were stored 
and prepared as for SAC (Section 2.9.8). Mice received 5 x 10^  CPU S. aureus LS-1 in 
150 [i\ PBS injected i.v. Mice were treated with 200 ng rmIL-18 or carrier alone (PBS 
with 0.05 % BSA) administered i.p either 2 h prior to, or 18 h post infection. LPS 
contamination of rmIL-18 was assessed by E-Toxate (Limulus Amebocyte Lysate, 
Sigma) according to manufacturer’s instructions and found to be <25 pg LPS per 1 pg 
IL-18. The maximum contaminating dose of LPS was administered in some control 
experiments. Mice were observed daily for up to 14 days. Mice were weighed and 
weight loss recorded as % starting weight. Incidences of artliritis and footpad diameter 
(calliper measurement) were measured. An artliritic index was derived by observation of 
each limb, scoring each footpad as below, giving a maximum score of 12 per animal.
1 erythema alone
2 swelling and erythema
3 erythema, swelling and loss of function (ability to grip cage)
The severity of septicaemia was judged clinically by characteristic changes, scoring 1 
per each of the following, maximum septic index score of 3 per mouse;
i) coat appearance (‘staring’ coat)
ii) posture (hunched posture)
iii) lack of spontaneous movement
Mclnnes et al (224) previously validated the above clinical indicators. Animals were 
scored by two observers, BPL and author. To assess in vivo bacterial distribution.
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animals were sacrificed by avertin-induced terminal anaesthesia (Section 2.5.1), and 
heparinised bloods, sections of spleens (weighed), kidneys and footpads were obtained. 
Tissues were homogenised, serially diluted in PBS and 10 pi of each dilution was plated 
in triplicate on 5% blood agar and cultured at 37°C for 18 h to determine the CPU 
present. Serum was collected and stored at -20°C until assay for cytokine concentration 
by ELISA. Heparinised blood and spleen were collected for RNA extraction (Section 
2.10.1), or for in vitro culture (Section 2.5.1 and 2).
2.11.5 Confirmation of A".
The presence of S. aureus LS-1 in the tissues of infected mice was confirmed by 
comparing the original stock of LS-1 with bacteria isolated fr om infected animals. The 
presence of S. aureus was confirmed by positive coagulase and staphylase tests, and the 
stock and test bacteria showed an identical antibiogram result. An ID 32 STAPH 
(bioMerieux, Lyon, France) system of standardised miniaturised biochemical tests, used 
in conjunction with a specific database, also confmned the presence of S. aureus and 
indicated the test and stock bacteria were highly likely to be of the same strain.
2.12 Statistical analysis
Data were obtained from observations and measurements made on individuals (mice, 
humans, cells etc). Statistical tests were applied to evaluate how far the observed 
evidence differed fr om what would be expected if the null hypothesis were true. From 
these statistics, p  values were calculated and if/? < 0.05 the null hypothesis was rejected 
and the difference considered significant. 2-sample (Student’s) t tests were applied to
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test whether 2 normally distributed populations had the same mean. When populations 
exhibited skewed distribution, a Mann Whitney U test was applied to test the difference 
between the means. Chi-squared tests were used with data sets in which individuals fell 
into mutually exclusive categories. Kaplan Meier analysis was applied to survival data 
allowing withdrawals from the study to be compensated for. Statistical analysis was 
performed using Minitab software (State College, PA).
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Table 2.2 ELISA reagents
ELISA Supplier Capture Detection Sensitivity range
pg/ml pg/ml pg/ml
Murine
IFNy Pharmingen 4 2 10-10 000
IL-6 Pharmingen 2 2 10-10 000
IL-5 Pharmingen 2 2 10-10 000
IL-4 Pharmingen 2 2 10-10 000
TNFa Phaimingen 8 2 20-20 000
IL-18 Pepreotech 2.5 0.3 40-40 000
human
IL -la Genzyme 2 1 10-10 000
IL-8 R&D 4 2 40-40 000
TNFa Pharmingen 1 1 10-10 000
IFNy Biosource* 4 0.4 10-10 000
IL-6 Biosouce* 1 0.4 10-10 000
LTB4 R&D Kit Kit 20-12 000
Murine ELISA antibodies were purified rat anti-mouse antibodies; human ELISA 
antibodies were mouse anti-human antibodies. Detection antibodies were biotin 
conjugated. Peroxidase conjugate was used at 1 pg/ml (ExtrAvidin®, Sigma).
* Biosource Cytosets (Fleurus, Belgium).
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Table 2.3 Antibodies for flow cytometry
Antigen Isotype Supplier (Clone) Label
Murine
CDS Rat IgG2b BD (17A2) PE
CD4 Rat IgG2a BD (RM4-5) PE
CD19 Rat IgG2a BD (1D3) FITC
Pan NK Rat IgM BD (DX5) FITC
OVA-TcR Mouse IgG2a (KJ1.26) Bio
GR-1 (Ly-6G) Rat IgG2b Caltag (RB6-8C5) FITC, PE and Bio
F4/80 (Ly-71) Rat IgG2b Caltag(Cl:A3-l) FITC and PE
Human
CD3 Mouse IgGl Sigma (UCHT-1) FITC
CD4 Mouse IgGl Sigma (H129.19) PE
CDl lb Mouse IgGl Sigma (44) FITC
CDl 4 Mouse IgG2a BD (M5E2) FITC
CDl 5 Mouse IgM Sigma (DU-HL60-3) FITC
CD19 Mouse IgGl Sigma (SJ25-C1) FITC
IL-18R Mouse IgGl R&D (70625) PE
IL-18 Mouse IgG2a R&D (MAB 318) none
Antibodies were used according to the suppliers’ recommendations. Biotin conjugated 
antibodies were detected with 0.2 pg test streptavidin-FITC (BD). Anti hIL-18 was 
detected with FITC-anti mouse conjugate (Serotec).
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Chapter 3 A role for IL-18 in neutrophil activation
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Introduction
IL-18 is a pleiotrophic cytokine which influences both adaptive and innate immune 
responses. In addition to driving Thl responses, a role for IL-18 in innate immunity is 
increasingly recognised. IL-18 enhances NK cell cytotoxicity and directly induces IFNy 
production (52) and directly induces monokine production by macrophages that 
constitutively express IL-18R (78). Furthermore, neutralisation of IL-18 before LPS 
challenge reduces tissue myeloperoxidase (MPO) levels, suggesting that IL-18 is 
implicated at some stage in neutrophil activation (97). Commensurate with a putative 
early role in immune responses, IL-18 mRNA is widely distributed, facilitating rapid 
generation of cytokine if required.
Neutrophils are the most abundant circulating leukocyte in humans, with up to 2 x 10^ ® 
cells in circulation. The neutrophil population undergoes rapid turnover, the bone 
marrow generating up to 10^  ^per day. Such cell turnover is presumably justified by the 
protective value of such cells, which react rapidly and destroy pathogens. The 
neutrophil armoury may promote not only host defense but also tissue damage. 
Neutrophil infiltration is a feature of many autoimmune lesions including psoriasis, 
inflammatory bowel disease, and RA, although their qualitative and quantitative 
contribution therein is unclear. In RA, neutrophils constitute up to 90% of synovial fluid 
(SF) cells and their presence has been documented at the cartilage-pannus junction 
(189). Activated neutrophils secrete many of the cytokines and extracellular matrix 
degrading enzymes implicated in RA pathogenesis (reviewed (188, 196)). IL-18 is 
involved in  the pathogenesis o f  several inflammatory disease states and is present at 
significant levels in the RA synovium (78), where it induces and sustains articular Thl
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cell responses and independently promotes TNFa production. In the present study, I 
have explored the hypothesis that the functional role of IL-18 in innate immune 
responses may extend to neutrophil activation, and that this property of IL-18 may be of 
importance in chronic inflammatory diseases. Effective neutrophil regulation is crucial 
to protective, controlled immune responses, thus understanding factors that influence 
neutrophil function reveals further details of the orchestration of the immune response. 
The present report documents for the first time direct biological effects of IL-18 upon 
neutrophils.
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Results
3.1 Assessment of neutrophil sample purity
Neutrophil sample purity was assessed by flow cytometry, allowing observation of size 
(forward scatter), granulaiity (side scatter) and expression of cell specific surface 
markers. Human peripheral blood leukocytes formed 3 populations when analysed by 
forward and side scatter (Fig. 3.1a). Following purification by polymorphoprep (Fig. 
3.1b) or lymphoprep (Fig. 3.1c), monocyte and lymphoyte populations were largely 
removed. Contaminating cells present in neutrophil samples were specifically identified 
by labelling with monoclonal antibodies, demonstrating that neutrophil preparations 
routinely contained <1% CD3 positive T cells (Fig. 3.2b), <1% CD 19 positive B cells 
(Fig. 3.2c), and importantly, <1% CD 14 positive monocytes (Fig. 3.2d). CD 15, a 
neutrophil marker was expressed by >96% cells in purified neutrophil samples (Fig. 
3.2e). Finally, to confirm these obseiwations, cytopreps of neutrophil preparations were 
stained with DiffQuick^^ and examined microscopically. Nuclear chromatin and 
neutrophil granules were stained purple, and eosinophilic granules stained pink. This 
allowed neutrophils to be identified by their characteristic multilobed nuclei, and 
granular cytoplasm. The majority of cells were easily identified as neutrophils, rare 
(<0.5%) eosinophils were also identified by this method (Fig. 3.3a and b).
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Figure 3.1 Assessment of neutrophil sample purity
Neutrophil sample purity was routinely assessed by flow cytometry. Cells were 
characterisied by cell size (forward scatter, FSC) and granularity (side scatter, 
SSC). (a) Human peripheral blood leukocytes prior to separation; G1 
containing neutrophils, G2 monocytes and G3 lymphocytes, (b) Cells 
following purification by polymorphoprep or (c) dextran sedimentation and 
lymphoprep. Cells shown were derived from a normal donor and representative 
of >10 similar experiments.
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Figure 3.2 Assessment of neutrophil sample purity (2)
FACS analysis of neutrophils purified from a normal donor and labelled with the 
antibodies indicated on the axes; representative of 3 similar experiments.
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Figure 3.3 Cytoprep of neutrophil samples
Cytopreps of neutrophils purified with lymphoprep were stained with 
DiffQuick^  ^ then examined microscopically, (a) Low power magnification, 
arrow highlights a contaminating eosinophil, which were found to be <0.5% of 
total cells, (b) high power magnification. Cells shown are derived from a 
normal donor and representative of 3 similar experiments.
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3.2 Neutrophil expression of IL-18 receptor
To investigate whether IL-18 may modulate neutrophil function, evidence o f  IL-18R 
expression was sought, initially at the mRNA level. Neutrophils derived from both 
normal donors and RA patients constitutively expressed IL-18Ra and IL-18RP chain 
mRNA (Fig. 3.4a). Surface expression of IL-18Ra protein was confirmed by FACS in 
PB samples from both normal donors and RA patients. No significant difference in the 
level of expression was observed in PB derived from RA or noimal donors (Fig. 3.4b). 
Similar data were obtained using a whole blood FACS method in which IL-18Ra 
expression was assessed by gating the neutrophil population on the basis of forward and 
side scatter (Fig. la) and assessing the fluorescence of cells within the gate. This 
suggests that IL-I8Ra expression on peripheral blood PMN was constitutive and 
unlikely to reflect partial activation during purification. To determine whether IL-18Ra 
expression is sustained after tissue entry, IL-18Ra levels on neutrophils derived from 
RA SF were examined. Significantly higher levels of IL-lSRa were observed (Fig. 
3.4b), indicating that IL-18 responsiveness could be maintained, or even enhanced, 
within a chronic inflammatory lesion. Detection of IL~18R(3 at the protein level awaits 
development of appropriate reagents at this time.
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Figure 3.4 Neutrophils express IL-18R mRNA and protein.
(a) RT-PCR was used to detect IL-18Ra chain and p chain mRNA expression. 
Lanes 1-4, IL-18Ra expression; lanes 5-8, IL-18Rp expression; L, ladder. 
Lanes 1 and 5 are representative of normal PB derived neutrophils, 2 and 6 of 
positive control (cDNA derived from driven human Thl cells, kind gift of 
Duncan Thomson), 3 and 7 of no RT control, and lanes 4 and 8 negative 
(water) control, (b) Cell surface expression of IL-18Ra on neutrophils was 
assessed by FACS analysis of normal PB neutrophils (n = 6), RA PB (n = 7), 
and RA SF (n = 12). To ensure sample processing did not affect IL-18Ra 
expression, analysis was performed on either gated whole blood (Fig. 3.1a) or 
purified neutrophils. Neutrophil purification did not alter IL-18Ra expression 
and data in (b) are pooled from both methods. Data are mean ± SEM of each 
group. *p < 0.05, vs. normal PB, by Student’s t test.
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3.3 IL-18 modulated neutrophil adhesion molecule expression
Constitutive expression o f  IL-18Ra indicated that IL-18 could exert early effects on 
neutrophil function. In the blood, approximately 50% of neutrophils flow with the 
circulating erythrocytes while the remainder are ‘marginated’ and loosely adherent to 
the vascular endothelium. Neutrophils roll along the endothelium by reversible 
interactions between E-selectin on the endothelium and the sialyl-Lewis’^ moiety of 
CD 15 on the neutrophil. Activation of the neutrophil induces expression of the integrin 
CD lib  (CR3) allowing high affinity binding to endothelial ICAM-1, facilitating 
diapedesis and allowing the neutrophil entry to the tissue. Since neutrophils 
constitutively expressed IL-18R, and IL-18 could be involved in early imiate responses, 
whether IL-18 mediated regulation of CD 11b on neutrophils was investigated. IL-18 
enhanced neutrophil C D llb expression; a representative histogram is illustrated in Fig. 
3.5. PB neutrophils from RA patients expressed significantly higher basal levels of 
CD llb than normal donors, indicating partial prior activation in vivo. Incubation of PB 
neutrophils from either normal donors or RA patients with rhIL-18 resulted in a 
significant increase in CD llb expression compared with control cells (Table 3.1). 
Maximal CD llb expression was similar in RA and normal donor groups. Regulation of 
CD llb on SF derived neutrophils was not assessed as these neutrophils are highly 
activated in vivo and express elevated CD llb (185). These observations suggest a 
possible central role for IL-18 in leukocyte migration. Commensurate with this, IL-18 
has been shown to be released from stressed endothelial cells (212) and induce ICAM-1 
expression on endothelial cells (213).
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Figure 3.5 Representative histogram of GDI lb expression by neutrophils
Whole blood was cultured with medium alone or rmIL-18 for 1 h then 
neutrophil were stained for GDI lb expression and analysed by flow cytometry. 
Solid histogram -  isotype control, solid line - medium control stained with 
GDI lb, dotted line - cells cultured with IL-18 then stained for GDI lb. Mean 
fluorescence intensity in MI was assessed (Table 3.1).
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Table3.1 IL-18 up-regulated CD llb expression in normal and RA PB
neutrophils
CD llb Expression (MFI)
PB Neutrophils Medium IL-18
Normal (n = 4) 38.7 ± 15.9 312.7 ±39.5**
RA(n = 8) 148 + 51.7* 300 ± 27**
Whole blood cultures were prepared either with medium alone or in the 
presence of rhIL-18 (100 ng/ml) for 1 hour, after which CDl lb expression was 
assessed by flow cytometry. Neutrophils were gated by forward/side scatter 
and the MFI of CD llb expression within the neutrophil gate was assessed. 
Data are expressed as mean fluorescence intensity ± SD. IL-18 induced CD 11b 
up regulation in both normal and RA derived PB neutrophils, although 
significant increase in CD llb was observed a priori in RA PB neutrophils 
when compared with neutrophils derived fiom normal donors. <0.05 vs. 
respective medium control. < 0.05 vs. normal PB, by Mann-Whitney U test.
3.4 IL-18 induced chemokine production by neutrophils
Neutrophils are abundant in inflammatory lesions, and their ability to produce both C-C 
and C-X-C chemokines is extensively documented. Neutrophils derived fiom normal, 
RA PB or RA SF produced high levels of IL-8 in a dose-dependant manner in response 
to IL-18. Of interest, neutrophils derived from different cohorts exhibited different 
responsiveness to IL-18. RA peripheral blood derived neutrophils were hyporesponsive
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to IL-18 compared to neutrophils obtained from normal donors (Fig. 3.6a, also 
addressed in Section 3.7). RA SF neutrophils exhibited significantly enhanced 
responses to IL-18 compared to blood derived neutrophils. This is likely to be a 
reflection of events mediated within the joint, rather than patient variation; when 
neutrophils obtained from different compartments within the same RA patient were 
compared, the SF derived neutrophils exhibited a clearly enhanced response to IL-18 
compared to PB derived neutrophils (Fig. 3.6b). Chemokine release in response to IL-18 
was rapid; IL-8 was detectable 4 h following exposure to IL-18, although this response 
was maximal after 24 h (Fig. 3.7). These data provide a further mechanism whereby IL- 
18 may promote neutrophil recruitment into inflammatory lesions.
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Figure 3.6 IL-18 induced chemokine release by neutrophils.
(a) IL-18 induced IL-8 production by PB neutrophils from normal donors (11 
of 11 tested), RA donors (12 of 12 tested) and from RA SF (14 of 14 tested). 
Data are mean ± SEM of cytokine production for all donors in each cohort, (b) 
lL-8 production from matched PB and SF neutrophils obtained from individual 
patients and stimulated with 100 ng/ml IL-18. */? < 0.05 vs. medium alone, by 
Student’s t test.
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Figure 3.7 Time course of IL-18 stimulated IL-8 release
Normal PB neutrophils were stimulated with 100 ng/ml IL-18 and supernatants 
harvested at the times indicated. IL-8 release was assessed by ELISA. Data are 
mean ± SEM of 3 normal donors. *p < 0.05 vs. medium, by Student’s t test.
3.5 IL-18 induced cytokine production by neutrophils
In addition toreleasing chemokines, neutrophils produce a wide variety o f  cytokines 
including IL-1, 3, 10, 12, and TNFa. Neutrophils were therefore stimulated with rhlL- 
18 for 24 h and cytokine concentration in supernatants was assessed by ELISA. Only 
low levels of IL-1 a  production were consistently observed from PB neutrophils derived 
from normal donors (Fig. 3.8a). No IL-1 a  was produced by RA PB neutrophils. Neither 
patient nor normal PB donor neutrophils produced TNFa. In contrast, RA SF 
neutrophils released highlevels o f  IL-1 a  and TNFa in respouse to IL-18 in a dose- 
dependent manner (Fig. 3.8a and b). Thus, the potential for ex vivo cytokine and 
chemokine release appeared to be qualitatively and quantitatively altered by prior in 
vivo activation. As IL-18 is known to be a potent IFNy inducing factor, and neutrophils
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are reported to be capable of IFNy production, neutrophil culture supernatants were 
assayed for IFNy by ELISA. Neutrophils derived from normal donors did not release 
IFNy in response to any dose of IL-18.
3.6 IL-18 induced de novo cytokine and chemokine production
To determine whether de novo protein synthesis was required for the observed 
chemokine and cytokine production, neutrophils were cultured in the presence of 
protein synthesis inhibitors. Actinomycin D (AD) is an intercalating agent, which 
inhibits transcription, and cyclohexamide (CH) binds ribosomes, inliibiting translation. 
Addition of AD or CH led to highly significant suppression of all chemokine (Fig. 3.9) 
and cytokine (Fig. 3.10) production, in all donor cohorts. To exclude the possibility of 
cell death accounting for reduced chemokine production, inhibitor toxicity was 
estimated by MTT, demonstrating no effect on cell viability (Fig. 3.11). Accordingly, de 
novo cytokine synthesis, rather than granule release alone, most likely explains these 
observations.
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Figure 3.8 IL-18 induced cytokine release from human neutrophils
(a) IL-18 induced IL-1 a  release by PB neutrophils from 5 of 11 normal donors 
and 14 of 14 RA SF samples. Only 2 out of 12 RA-derived PB neutrophil 
samples produced low levels of IL-1 a  (data not shown), (b) IL-18 induced 
TNFa release in 14 of 14 RA SF neutrophil samples. No TNFa release was 
observed from either normal or RA-derived PB neutrophils. Data are mean ± 
SEM of cytokine production for all donors in each cohort. < 0.05 vs. 
medium control by Student’s t test.
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Figure 3.9 IL-18 induced de novo chemokine transcription and translation.
Neutrophils were incubated with either 2 pg/ml actinomycin D (AD) or 2 
pg/ml cyclohexamide (CH) for 30 min before activation with 100 ng/ml IL-18. 
IL-8 production by (a) normal PB neutrophils (n = 5), (b) PB neutrophils from 
RA patients (n = 5) and (c) SF neutrophils from RA patients (n = 2) is shown. 
Data are mean ± SEM of each group. *p < 0.05 vs. medium control, **p < 0.01 
vs. IL-18 by Student’s t test.
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Figure 3.10 IL-18 induced de novo cytokine transcription and translation.
Neutrophils from RA SF (n = 2) were cultured as described in Fig. 3.9. (a) IL- 
l a  and (b) TNFa production by RA SF neutrophils were measured by ELISA. 
Data are mean ± SEM of each group. < 0.05 vs. medium control, **p < 0.01 
vs. IL-18 by Student’s t test.
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Figure 3.11 Toxicity of Actinomycin D and Cyclohexamide
Neutrophils from normal donors (n = 3) were cultured as described in Fig. 3.9 
and cell viability after 18 h was assessed by MTT assay. Data are mean ± 
SEM.
3.7 Drug effects on IL-18 activation of neutrophils
The reduced IL-8 production in response to IL-18 in RA donors (Fig. 3.5) was of 
interest. To determine effects of concomitant drug therapy, neutrophils were 
preincubated with the synthetic coriticosteriod, dexamethasone (DEX), or an anti­
metabolite, methotrexate (MTX). The dose of drug used in vitro was determined by 
previous reports and a titration of 100 nM to 10 pM. The optimum dose of 1 pM 
reproducibly reduced IL-18 stimulated cytokine release. Dexamethasone exhibited more 
potent inhibitory effects although methotrexate also significantly reduced IL-8 release 
(Fig. 3.12). Several other factors are likely to influence neutrophil function including 
age, disease duration and current disease activity. Furthermore, in vitro culture with 
such drugs is at best a surrogate for prolonged in vivo exposure.
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3.8 IL-18 signalling through MAP kinase pathways in neutrophils
Dexamethasone is reported to exert effects via inhibition of MAP kinase pathways 
(214). Furthermore, emerging evidence suggests that IL-18 may activate MAP kinases, 
which are involved in neutrophil activation (215). Studies in which p38 MAP kinase 
and ERK were specifically inhibited indicated that IL-18 stimulated IL-8 release from 
neutrophils was primarily p38 dependent, and may also involve ERK (Fig. 3.13a). The 
dose of inhibitors used in these studies was previously determined (216). Toxicity of 
these inhibitors was assessed by MTT assay and found to be insignificant (Fig. 3.13b).
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IL-18 + MTX
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Figure 3.12 DMARDS inhibited IL-18 induced IL-8 release
Normal PB neutrophils (n = 5) were pretreated with 1 pM dexamethasone 
(DEX) o r 1 pM methotrexate (MTX) for 3 0 min before activation with 1 00 
ng/ml IL-18. Dexamethasone and methotrexate significantly reduced IL-18 
induced IL-8 release. Data are mean ± SEM. Up < 0.01 vs. medium, *p < 0.05 
and **p < 0.01 vs. IL-18, by Student’s t test.
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Figure 3.13 IL-18 activated neutrophils through MAP kinase dependent 
pathways
Normal human neutrophils were cultured in the presence of 5 pM SB203580 
(p38 inhibitor) or 20 pM PD98059 (ERK inhibitor) for 18 h with or without 
stimulation with 100 ng/ml IL-18. (a) IL-8 release was assessed by ELISA (n = 
5). (b) Toxicity of inhibitors was assessed by MTT (n = 3). Data are mean ± 
SEM. *p < 0.01 vs. IL-18, < 0.05 vs. medium, by Student's t test.
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3.9 Effects of IL-18 on neutrophil degranulation
Neutrophil granules store potent anti-bacterial proteins which contribute to degradation 
of ingested material, or may be released extracellulaiy in response to stimuli such as IL- 
8 or immune complexes binding FcyR. To determine whether IL-18 promoted 
neutrophil granule release, neutrophil culture supernatants were assayed for a secondary 
granule constituent, lactoferrin, which seiwes as a surrogate marker for neutrophil 
degranulation. Lactoferrin release increased dose dependently in response to IL-18 (Fig. 
3.14a). These data were extended using the maximum stimulating dose of IL-18 (100 
ng/ml). Lactoferrin release in response to IL-18 was significantly higher from SF 
neutrophils than from RA or normal PB neutrophils, commensurate with in situ 
activation in the synovial compartment (Fig. 3.14b). This further confirmed that 
neutrophils maintained an IL-18 responsive state in an inflamed compartment.
3.10 Effects of IL-18 on respiratory burst
The key role of the neutrophil oxidase system in host defense against bacteria is clearly 
illustrated in patients with chronic granulomatous disease. With respect to oxidative 
activity, neutrophils may exist in quiescent, primed or activated states. In the primed 
state there is no increase in oxidative activity yet subsequent stimulation provokes a 
response that is larger than in non-primed cells. Inflammatory mediators such as formyl 
peptides and C5a prime at low concentrations but initiate a respiratory burst at high 
concentrations. Other mediators including TNFa and GM-CSF may be described as 
‘dedicated primers’ and as such do not activate respiratory burst but prime for 
subsequent activation. IL-18 alone did not induce respiratory burst in human neutrophils 
(n = 5, data not shown). However, prior incubation of neutrophils with IL-18 led to
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significant enliancement of the response to fMLP that was evident in normal and in RA- 
derived PB neutrophils (Fig. 3.15). SF neutrophils did not exhibit an enhanced response 
to fMLP following preincubation with IL-18. This observation that may be related to 
the previously described phenomenon of neutrophil “exhaustion” relating to respiratory 
burst (186). Synovial fluid neutrophils are highly activated in vivo and a greater 
proportion of this population is likely to have been exposed to priming stimuli or 
stimulation of respiratory burst. Thus, the SF derived neutrophils are less susceptible to 
priming effects of IL-18 than PB derived neutrophils.
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Figure 3.14 IL-18 induced granule release by neutrophils
(a) Neutrophils from normal PB, RA PB, or RA SF (n = 4) were cultured as 
described in Fig. 3.6 with increasing concentrations of IL-18, and granule 
release was estimated using lactoferrin release as a surrogate, (b) These data 
were extended using 100 ng/ml IL-18 (n = 8). Data are mean ± SEM of each 
group. */? < 0.05 vs. medium control, **p < 0.01 SF vs. normal and RA PB 
neutrophils, by Student’s t test.
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Figure 3.15 IL-18 enhanced neutrophil respiratory burst
Neutrophils from normal PB (n = 5), RA PB (n = 5), or RA SF (n = 7) were 
incubated with 100 ng/ml IL-18 or medium alone for 1 h before stimulation 
with 1 pM fMLP. Reactive oxygen intermediate release was assessed 
immediately as in methods. Vmax is the rate of increase in emitted light to the 
maximum level recorded (see Fig. 2.1). Data are mean ± SEM of each group. 
< 0.01 vs. medium control by Student’s t test.
3.11 Effects of IL-18 on leukotriene release by neutrophils
There are limited studies of the relationship of IL-18 to fatty acid metabolism. Unlike its 
relative IL-1, IL-18 has no effect on cyclooxygenase activity. IL-18 exerts inhibition of 
prostaglandin E% synthesis by PBMC, mediated via IFNy (217). However, the role of 
IL-18 in metabolism o f arachidonic acid ( AA) b y neutrophils, which do not produce 
IFNy in response to IL-18, has not been investigated. Cytokines are known to activate 
neutrophil phospholipase A], releasing AA. Neutrophils contain AA, which they are 
capable of metabolising to produce LTB4. LTB4 is a potent proinflammatory mediator.
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promoting neutrophil cheraotaxis, adhesion, superoxide production and degranulation. 
IL-18 treatment for 30 minutes promoted significant LTB4 release from human 
neutrophils (Fig. 3.16a and b). LTB4 activates neutrophils, for example by enhancing 
CD llb expression. To investigate if this rapid production of LTB4 mediated IL-18 
induced neutrophil cytokine production, parallel cultures were set up for 18 h and IL-8 
release into the supernatant was assessed by ELISA. MK-886 (3-[l-(p~Chlorobenzyl)-5- 
(isopropyl)-3-r-butylthionindol-2-yl]-2,2-dimethylpropanoic acid, Sodium) is a 
leukotriene synthesis inhibitor that binds the 5-lipoxygenase-activating protein, 
preventing activation of 5-lipoxygenase. Addition of this inhibitor demonstrated that IL- 
8 release in  response to IL-18 was independent o f  LTB4 synthesis (Fig. 3 .16c). This 
does not however conclusively demonstrate that other neutrophil functions induced by 
IL-18 are independent of LTB4. However, IL-18 promoting release of LTB4, provides 
an amplification loop for whereby IL-18 may peipetuate neutrophil activation.
3.12 Effects of IL-18 on neutrophil apoptosis
Anti-apoptotic effects of innate cytokines including IL-15 and GM-CSF have been 
previously observed for neutrophils. Therefore, we investigated whether IL-18 can 
promote neutrophil survival at sites of inflammation. After up to 24 h of incubation with 
IL-18 (100 ng/ml), apoptosis was determined by propidium iodide and annexin V 
staining. No difference was observed in IL-18-treated cells compared with medium 
controls at any time point (B. Leung, personal communication).
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Figure 3.16 IL-18 induced LTB4 from neutrophils
Purified neutrophils were cultured for 30 minutes in the presence of 100 ng/ml 
IL-18 or 1 pM fMLP. Release of LTB4 was inhibited by 1 pM MK-866. 
Supernatants were harvested and assessed for LTB4 by ELISA, (a) Normal PB 
neutrophils (n = 2) and (b) RA PB neutrophils (n = 2). (c) Normal PB 
neutrophils cultured for a further 18 h and IL-8 release assessed by ELISA. IL- 
18 induced IL-8 was not LTB4 dependent. Data are mean ± SEM. *p < 0.05 vs. 
medium, < 0.05, significant inhibition of LTB4 synthesis in response to IL- 
18 or fMLP.
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Discussion
The present report clearly demonstrates that IL-18 can play an important role in 
neutrophil activation. Data described define a novel pathway whereby IL-18 can 
amplify acute inflammation thiough promoting neutrophil adhesion, cytokine and 
chemokine production, granule release, respiratory burst and arachidonic acid 
metabolism. This strongly indicates that the biological effects of IL-18 extend beyond 
promoting Th/cl type responses, to include a role in developing innate immune 
responses. By implication, regulation of IL-18 may be an important determinant in the 
evolution of immune responses from acute to acquired or clironic phases. 
Polymorphonuclear cell activation by IL-18 may also be important in host pathogen 
interactions, especially during gram-positive bacterial infection, in which neutrophil 
function is paramount.
Constitutive IL-18Ra chain expression indicated that IL-18 dependent responses might 
be rapidly instigated. Higher levels of IL-18R expression were detected in neutrophils 
derived from RA synovial fluids than from blood. Wide variability was observed in the 
magnitude of neutrophil IL-18R expression between individuals and in cells from 
different tissue compartments. Since samples were collected and treated in a similar 
manner, it is unlikely that processing artefacts can explain all of the observed variation. 
This presumably therefore reflects altered neutrophil activation status in vivo. The 
relative importance of IL-18 in regulating acquired and innate responses implies that IL- 
18Ra and (3 chain expression will be tightly regulated. Factors regulating IL-18R 
expression on neutrophils are as yet unknown. IL-18R is a member of the Toll/IL-IR 
family, suggesting that the IL-18/IL-18R system has evolved as a component of the 
innate response (39). Pathways that modulate IL-18R will likely modulate neutrophil
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function and may in due course have implications for Toll/IL-IR family regulation on 
neutrophils and other cell types.
Commensurate with a role in early immune responses, IL-18 induced GDI lb expression 
by peripheral blood neutrophils. Subsequent work by Koch et al demonstrates that IL- 
18 upregulates ICAM-1 on endothelial cells and promotes migration of endothelial cells 
tlirough a gel (123) Further work in our laboratory has shown that IL-18 also induces 
lymphocyte migration (Komai et al, submitted, J. Immunol.), Direct evidence for IL-18 
promoting neutrophil migration has been discussed in chapter 4. Moreover, the effects 
of IL-18 on GDI lb expression by neutrophils have recently been confîimed by Silliman 
and colleagues, who showed upregulation of GDI lb within 15 minutes of exposure to 
IL-18 (218).
IL-18 induced IL-8, granule r elease, enhanced r espiratory burst and LTB4 r elease b y 
peripheral blood neutrophils. Additionally, recent work has shown that IL-18 also 
induces IL-1(3, and soluble IL-IRII by neutrophils (219). The observed IL-18 induced 
neutrophil degianulation has been confinned in an independent study, which assessed 
elastase release, instead of lactoferrin, as a surrogate marker for granule release (218). 
Whether IL-18 stimulates neutrophil production of auto-regulatory inhibitors such as 
IL-18BP or IL-IH awaits investigation. Although these data suggest that neutrophils 
could contribute directly to the cytokine milieu, the extent to which neutrophils augment 
overall inflammatory mediator production in vivo is difficult to evaluate. On a per cell 
basis, neutrophil cytokine production is less than a macrophage, but the relative 
abundance of neutrophils at sites of inflammation may readdress this balance. This has
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important implications in considering critical cell targets in chronic diseases such as RA 
or Crohn’s disease, in which cytokine production is crucial
The pathways involved in the observed responses to IL-18 were only superficially 
investigated. IL-8 release in response to IL-18 required de novo protein synthesis, was 
sensitive to steroids, but did not require LTB4 production. Signalling inliibition studies 
demonstrated that p38 MAP kinase activation was necessary for IL-18 stimulated IL-8 
release. Pathways involved in other neutrophil responses to IL-18 (e.g. respiratory burst 
and granule release) were not delineated to the same extent. However, recent work 
demonstrated p38 dependence of IL-18 induced upregulation of CD 11b and enlianced 
respiratory burst in response to fMLP (218), suggesting that this may be a predominant 
signalling pathway activated by exposure of neutrophils to IL-18.
The pathophysiological importance of IL-18 induced neutrophil activation is intriguing. 
Sustained IL-18 expression has been reported in a number of chronic inflammatory 
disease states including RA, inflammatory bowel disease and sarcoidosis (78, 132, 220). 
The mechanisms whereby IL-18 could contribute to disease pathogenesis remain poorly 
defined. In RA, proposed mechanisms whereby IL-18 can drive synovitis include 
regulation of local Thl responses, effects on proinflammatory cytokine production, 
enhanced nitric oxide production, and direct effects on chondrocytes and matrix 
degradation (67, 78). Commensurate with high levels of IL-18R expression, synovial 
neutrophils retained a high degree of responsiveness to IL-18, leading to significant 
cytokine and chemokine production. The quantitative contribution of neutrophils to 
cytokine expression in RA is unclear but could be considerable given their abundance 
within the synovial compartment. That IL-18 also induced degranulation is of
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importance since neutrophil gianule contents include collagenase, cathepsin G, 
gelatinase, elastase and phospholipase Ai, all of which may be of functional 
significance in promoting articular destruction. Although neutrophils are detected in low 
numbers at the cartilage pannus junction, the majority are trafficked to synovial fluid. 
Thus, IL-18 activated neutrophils could contribute to altered cartilage turnover, since 
synovial fluid directly bathes the caitilage matrix, or could modulate synovial lining 
layer cells through adjacent release of cytokines or chemokines. Work presented in this 
chapter aie relevant to other disease states in which IL-18 is over expressed and in 
which neutrophils are present in high numbers, such as psoriasis and Crohn’s disease.
Taken together, the data suggest a role for IL-18 in innate neutrophil led responses in 
addition to its clearly defined role in T cell maturation. These data have two-edged 
consequences for therapeutic targeting of IL-18. IL-18 blockade may simultaneously 
abrogate host toxic effects of neutrophils, but could potentiate infections in which 
neutrophils are essential in host responses. I therefore sought to explore in more detail 
the in vivo effects of IL-18 in inflammatory (Chapter 4) and infectious (Chapter 5) 
models of acute inflammation.
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Chapter 4 In vivo effects of IL-18 on neutrophil function
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Introduction
IL-18 effectively activates neutrophils in vitro (Chapter 3). Such in vitro observations 
have significant limitations, which may be addressed by manipulation of IL-18 in vivo, 
for example with IL-18-deficient mice or neutralising antibodies. Effects of IL-18 
modulation have been extensively studied in vivo demonstrating important effects 
during host responses to infection. Thus, protective responses during murine 
Cryptococcus neoformans. Yersinia and Streptococcus pneumoniae infections may be 
abrogated or enhanced by manipulation of IL-18 expression (13, 14), clearly indicating 
a role in microbial host defense. Neutralisation of IL-18 before LPS challenge reduces 
tissue myeloperoxidase (MPO) levels, suggesting that IL-18 is implicated at some stage 
in neutrophil activation (16). Moreover, we recently demonstrated that IL-18-deficient 
mice exhibit reduced capacity to kill Staphylococcus aureus in vivo associated with 
increased severity of septic arthritis (15). These studies imply a role for IL-18 in 
neutrophil activation in vivo although none specifically address direct effects on 
neutrophil function. Evaluation of human neutrophil activation in vivo is limited to 
studies of exudated neutrophils using a skin blister/chamber technique. This model of 
aseptic inflammation allows study of in vivo activated neutrophils and factors that may 
influence their migration. However, this system was not ethically appropriate for 
studying the effects of modulating IL-18 expression. Therefore murine models were 
investigated. Murine neutrophil migration into the peritoneal cavity, and a model of 
acute footpad inflammation were studied to assess the role of IL-18 in neutrophil 
activation in vivo.
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Results
4.1 IL-18 promoted migration of neutrophils to the peritoneal cavity
Constitutive expression of IL-18R, together with the observation that IL-18 up- 
regulated GDI lb expression by human neutrophils implied that IL-18 exerts early 
effects on neutrophil migiation. In vivo evidence of this was sought by injecting rmlL- 
18 into the peritoneal cavity of BALB/c mice. Doses of both 20 ng and 60 ng of rmlL- 
18 effectively induced neutrophil recruitment to the peritoneal cavity after 4 h (Fig. 
4.1a). This response was maximal at 4 h and reduced by 48 h (Fig. 4.1b), commensurate 
with IL-18 exerting early, rapid effects.
4.2 Effects of contaminating LPS present in rmIL-18
RmIL-18 was commercially preduced i nE.  co li{Peprotech), and certified toeontain 
<0.1 ng endotoxin per 1 pg IL-18. To confirm that significant LPS was not introduced 
by the handling procedure, reconstituted IL-18 was subjected to an E-toxate assay, 
which demonstrated that the rmIL-18 used in these experiments contained < 25 ng LPS 
per 1 pg IL-18 (the limit of sensitivity of the assay). To ensure this dose of LPS did not 
contribute to the neutrophil recruitment obsei'ved in Fig. 4.1, identical experiments were 
carried out in which up to 60 ng of LPS were injected i.p., and shown to induce minimal 
cell recruitment (personal communication, Dr. Fernando Cunha, Department of 
Pharmacology, School of Medicine Ribeirao Preto, University ofSao Paulo, Sao Paulo, 
Brazil). C3H/HeJ mice have a spontaneous mutation at the LPS response locus
which renders the animals endotoxin resistant. IL-18 effectively induced neutrophil
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migration into the peritoneal cavity C3H/HeJ mice, confirming that LPS contamination 
is unlikely to explain our observations (Fig. 4.2).
4.3 Mechanisms of IL-18 induced cell recruitment
To investigate the mechanism of IL-18 induced cell recmitment I next sought to identify 
downstream pathways. TNFa is involved in leukocyte migration, and IL-18 induces 
TNFa from a variety of cells. This led us to examine whether IL-18 operated via a 
TNFa dependent pathway to promote cell migration. The majority of biologic responses 
classically attributed to TNFa are mediated by the p55 receptor subunit (209). IL-18 
was administered i.p. to TNFR p55-deficient or wild-type control C57B1/6 mice. 
Compared to PBS control, IL-18 induced significant migration of leukocytes into the 
peritoneal cavity of wild type C57B1/6 mice. However, IL-18 administration had no 
effect in TNFR p55-deficient mice, demonstrating that TNFa signalling was critical for 
the response to IL-18 (Fig. 4.3). A ‘background’ response to PBS was observed in each 
of the neutrophil migration studies, presumably caused by physical stimulation and 
stretch responses following the i.p. injection. Interestingly, TNFR p55 -/- mice exhibited 
a reduced background response to PBS alone, implying that TNFa is required for all 
cell migration, independent of stimuli, and that administration of IL-18 did not 
compensate for this defect.
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Figure 4.1 IL-18 promoted migration of PMN to the peritoneal cavity
IL-18 administration induced accumulation of neutrophils in the peritoneal 
cavity of 4 to 5 week old BALB/c mice, (a) Mice received 0, 20, or 6 0 n g 
rmIL-18 in a total volume of 0.5 ml PBS. Cell counts and cytospins of 
peritoneal lavage were performed after 4 h, and neutrophil accumulation was 
assessed by histology, (b) Thereafter, to establish a time course, 20 ng IL-18 
was injected, and neutrophil accumulation was estimated at the time points 
shown. Data are mean ± SEM, representative of five separate experiments with 
five mice per group. */? < 0.05 vs. PBS control group by Student’s t test. These 
experiments were performed in collaboration with Dr. Fernando Cunha.
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Figure 4.2 LPS contamination did not contribute to IL-18 induced neutrophil 
migration
LPS resistant C3H/HeJ mice received 0, 20 or 60 ng of IL-18 (derived from 
same batch as the rmIL-18 administered in Fig. 4.1) in PBS in a total volume 
of 0.5 ml. Cell counts and cytospins of peritoneal lavage were performed after 
4 h , and neutrophil accumulation was assessed by flow cytometry o f  1 avage 
cells and confirmed by histology. Data are mean ± SEM of 5 mice per group. 
*/7 < 0.05 vs. PBS by Student’s t test.
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Figure 4.3 IL-18 induced neutrophil recruitment is TNFa dependent
C57B1/6 wild type (+/+) and TNFR p55 knock out (-/-) mice received an i.p. 
injection of 60 ng rmIL-18 or carrier alone. 4 h post injection, cell counts and 
cytospins of peritoneal lavage were performed, neutrophil accumulation was 
assessed by flow cytometry of lavage cells, and confirmed by histology. Data 
are mean ± SEM of 5 mice per group, representative of 2 similar experiments.
< 0.05 vs. PBS by Student’s t test; ns, not significantly different to PBS 
group.
4.4 Role of IL-18 in acute inflammation
The murine model of carrageenan induced footpad inflammation is associated with 
rapid neutrophil recruitment, and was therefore appropriate for further investigating the 
role of IL-18 in acute, neutrophil led inflammation. IL-18 mRNA was upregulated in 
the lymph node draining the carrageenan injected footpad compared to contralateral 
control (Fig. 4.4). To investigate the role of extracellular IL-18 in this system, a
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neutralising antibody was administered i.p. 1 h prior to injection of caiTageenan. The 
antibody manufacturer (R&D Systems) demonstrated neutralising activity of this 
antibody (0.3-1 pg of the anti-IL-18 antibody neutralised 50% IFNy from activated T 
cells stimulated with 15 ng/ml rmIL-18). Prior data indicate cytokine inhibitory 
antibodies operate in the range of 1-10 mg/kg (221). Given antibody availability, a dose 
of 1.5 mg/kg was selected empirically. Following carrageenan administration, footpad 
swelling was assessed by caliper measurement and the difference between injected and 
contralateral control paws was calculated (A footpad thickness). Administration of anti- 
IL-18 significantly reduced early (6 h post injection) signs of inflammation and this 
effect was consistently observed up to 48 h (Fig 4.5 and Table 4.1).
4.5 Mechanisms of anti-IL-18 action
To investigate the molecular and cellular effects of anti-IL-18 antibody treatment, 
changes in cytokine mRNA expression, locally at the site of inflammation (the footpad) 
and in the draining lymph node, were assessed 24 h after footpad challenge. RNA was 
extracted and cytokine mRNA expression was assessed by real time PCR. IL-18 drives 
TNFa and IFNy production at sites of inflammation; therefore changes in TNFa and 
IFNy mRNA expression were sought. In addition, to investigate autocrine mechanisms 
of IL-18 regulation, changes in IL-18 mRNA expression was investigated. 
Neutralisation of IL-18 in vivo reduced TNFa mRNA expression in the footpad (Fig. 
4.6a). No difference was observed in TNFa mRNA expression in the draining lymph 
nodes when mice receiving anti-IL-18 were compared with those receiving isotype 
control (Fig 4.6b). Similarly, IFNy mRNA expression was reduced in footpads from 
anti-IL-18 treated animals (Fig. 4.6c), although there was some elevation of IFNy
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mRNA in the draining lymph node (Fig.4.6d). Neutralisation of IL-18 had no consistent 
effect on IL-18 mRNA expression in either footpads or lymph nodes. These results 
suggested the effects of IL-18 neutralisation were predominantly manifest locally.
To confiim that the effects of neutralising extracellular IL-18 operated locally at the site 
of inflammation rather than influencing responses in the draining lymph nodes, single 
cell suspensions of lymph nodes, pooled from 10 mice per group, were stimulated with 
immobilised anti-CD3 for 48 h. [^H] Thymidine was added for the final 6 h of culture 
and proliferation assessed. Lymph node cultures exhibited a strong proliferative 
response to anti-CD3, which was not modulated by prior in vivo treatment with anti-IL- 
18 antibody (Fig. 4.7). Un-stimulated cells showed no significant backgi'ound 
proliferation. Cytokine release into the supernatant of anti-CD3 stimulated cultures was 
assessed by ELISA. Anti~CD3 stimulated significant monokine (IL-6 and TNFa) 
release into the supematant which was unaffected b y prior treatment with anti-IL-18 
antibody in vivo (Fig 4.8a). Cytokine production (IL-5 and IFNy) by lymph nodes 
cultures derived from anti-IL-18 or sham treated mice was similar (Fig. 4.8b).
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Figure 4.4 Elevation of IL-18 mRNA in draining lymph node following 
carrageenan administration
BALB/c mice received 300 pg carrageenan in 50 pi PBS s.c. into one footpad. 
Lymph nodes draining the carrageenan injected footpad or contralateral control 
footpad were removed, RNA extracted and IL-18 mRNA expression assessed 
by real time PCR. Data are mean ± percentage error, lymph nodes were pooled 
from 5 mice per group.
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Figure 4.5 Effect of neutralising IL-18 on acute inflammation
BALB/c mice received 1.5 mg/kg rat anti-mouse IL-18 mAb or isotype control 
by i.p. injection 1 h before injection of 300 pg carrageenan in 50 pi PBS into 
the right hind footpad. Footpad thickness was assessed in injected and 
contralateral control paw by caliper measurement and the difference expressed 
in millimeters. Data are mean ± SEM of at least 20 mice/group pooled from 4 
independent experiments (See Table 4.1). */? < 0.01 by Mann-Whitney U test.
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Table 4.1 Effect of neutralising IL-18 on carrageenan induced inflammation
Time (h) No.
mice/group
A Footpad thickness (mm) 
mean ± SEM
p  (PBS vs. Anti-IL-18, 
Mann Whitney)
PBS Anti-IL-18
6 40 0.86 ± 0.022 0.56 ± 0.028 0.0001
24 40 1.02 ±0.025 0,67 ± 0.027 0.0001
48 20 1.38 + 0.07 1.03 ±0.067 0.0027
72 17 1.3 ±0.065 1.12 ±0.07 ns
96 17 0.92 ± 0.064 0.72 ± 0.044 0.0138
Experimental conditions are as in Fig. 4.4, The reduction in number of mice 
over time is due to sacrifice of animals for in vitro analysis.
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Figure 4.6 Cytokine mRNA expression
Pretreatment with anti-IL-18 reduced TNFa (a) in footpad but had no effect on 
TNFa expression in (b) lymph nodes. Similarly, neutralisation of IL-18 
reduced IFNy mRNA expression in (c) footpads; however, expression was 
elevated in (d) lymph nodes of treated mice. IL-18 mRNA expression in 
footpads (e) was unaffected by treatment with neutralising antibody. The 
observed reduction in IL-18 mRNA expression in draining lymph (f) nodes 
was not consistent in the 2"^  experiment. TNFa and IL-18 footpad data are 
mean ± SEM of 5 individual footpads per group; lymph node data are
139
representative of 2 similar experiments in which lymph nodes were pooled 
from 5 mice per group per experiment. The IFNy data are derived from 2 
footpads per group and lymph nodes from one experiment only. */? < 0.05 vs. 
IgG control by Mann Whitney U test.
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Figure 4.7 Effect of neutralising IL-18 on draining lymph node cell 
proliferation
24 h after injection of carrageenan, draining lymph nodes were removed from 
10 animals per group, single cell suspensions prepared, and stimulated with 5 
pg/ml immobilised anti-CD3 for 48 h. Proliferation was assessed by addition 
of [^H] thymidine for the final 6 h of culture. No significant differences were 
found in proliferation when lymph nodes from anti-IL-18 or sham treated mice 
were compared. Data shown are mean ± SEM of triplicate cultures and are 
representative of two similar experiments.
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Figure 4.8 Effect of neutralising IL-18 on draining lymph node cell cytokine 
production
Single cell suspensions were prepared as described in Fig. 4.7. (a) TNFa and 
IL-6 and (b) IFNy and IL-5 release into culture supernatants was assessed by 
ELISA. No significant differences were found in cytokine production when 
lymph node cultures from anti-IL-18 or sham treated mice were compared. 
Data are mean ± SEM of triplicate cultures, representative of 2 similar
experiments.
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4.6 Local effects of auti-IL-18 treatment
The observed changes in footpad mRNA expression and absence of measurable changes 
in draining lymph node responses suggested that anti-IL-18 antibody administration 
mediated local effects. To investigate neutrophil infiltration in the footpad, 
myeloperoxidase (MPO) content was assessed as a marker of neutrophil accumulation. 
MPO is stored in neutrophil primary granules and catalyses the production of 
bactericidal hypochlorite. This enzyme activity may be quantified colorimetrically by 
oxidation of o-dianisidine in the presence of hydrogen peroxide. Footpads were 
removed 24 h after carrageenan challenge, weighed and MPO activity assayed and 
expressed as units of MPO activity per gram of tissue. Treatment with anti-IL-18 
antibody compared to IgG control significantly reduced MPO content in footpads in 2 
independent experiments (Fig. 4.9). This suggested that neutraliation of IL-18 reduced 
neutrophil accumulation in the inflamed tissue. To confirm this observation, sections of 
footpads were examined histologically. Normal, unchallenged footpad (Fig. 4.10a) 
demonstrated a defined tissue architecture, which was clearly disrupted by the 
inflammatory infiltrate induced 24 h following carrageenan challenge (Fig. 4.10b). 
Under high power, this infiltrate was identifiable as predominantly polymorphonuclear 
cells (Fig. 4.10c). Prior treatment with anti-IL-18 markedly reduced inflammatory 
infiltrate and (Fig, 4.10d), examination under high power demonstrates that fewer 
neutrophils were present in the tissue (Fig. 4.10e).
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Figure 4.9 Myeloperoxidase activity in footpads
24 h following carrageenan injection, footpads were removed from 5 mice per 
group. Footpads were weighed, homogenised and MPO activity estimated. 
Data are measurements from individual paws. < 0.05 vs. control IgG by 
Student’s t test, representative of 2 similar experiments.
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Figure 4.10 Histology of carrageenan induced inflammation
Footpads were removed 24 h after administration of carrageenan, fixed in 
formaldehyde, decalcified, then cut and stained with H&E. (a) Normal footpad, 
low power magnification, (b) carrageenan injected footpad from sham treated 
animal, low power and (c) high power, (d) Carrageenan injected footpad from 
anti-IL-18 treated animal, low power and (e) high power magnification.
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Discussion
These data are the first to explore a role for IL-18 in neutrophil function in vivo. 
Injection o f  rm IL-18 into the peritoneal cavity induced a rapid influx o f  neutrophils, 
which was dependent on intact TNFa signalling. Furthermore, in a model of 
can'ageenan induced acute inflammation, prior neutralisation of IL-18 reduced 
inflammation and neutrophil accumulation, demonstrated histologically and by tissue 
MPO accumulation. There was also evidence of a TNFa-IL-18 axis in this model, as 
local TNFa mRNA expression was reduced by anti-IL-18 treatment. Although changes 
were observed in the footpad, systemic neutralisation of IL-18 had no measurable 
effects on draining lymph node responses. Together these data suggest that the in vitro 
observations reported in chapter 3 have in vivo relevance.
Administration of anti-IL-18 antibody reduced carrageenan induced footpad MPO 
content, histological evidence of neutrophil infiltration, and local TNFa mRNA 
expression, suggesting effects on the local inflammatory processes. The relationship and 
functional hierarchy between TNFa and IL-18 in the early phases of inflammation is 
intriguing. Evidence from these models suggests that IL-18 activities may lie upstream 
of TNFa. Neutralization of IL-18 reduced local TNFa mRNA expression in 
carrageenan induced inflammation. Furthennore, IL-18 induced neutrophil migration 
required intact TNFa signaling, demonstrated by the absence of IL-18 induced 
neutrophil migration in TNFR p55-deficient mice. Further investigation of the reduced 
‘background’ neutrophil recruitment (i.e. PBS control) in the TNFR p55-deficient mice 
could be addressed, for example, by administration of thioglycolate. It is of interest that 
IL-18 did not compensate for this defect. Blocking free TNFa with soluble receptors or
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neutralising antibody would also be appropriate to further investigate the IL-18-TNFa 
axis in these models, however reagents were not available to perfoim this study.
The use of LPS controls in this study was important, as BALB/c mice are particularly 
sensitive to LPS. Titration of low doses of LPS demonstrated that the maximum 
contaminating dose of LPS in the nnIL-18 could not induce significant neutrophil 
infiltration. Combined with the studies in endotoxin resistant mice, this provided sound 
evidence that contaminating LPS was not masquerading the effects of rmIL-18. The 
analysis of draining lymph node function could be further investigated using an antigen 
specific system and phenotypic analysis of cell populations. Furthermore, the cytokine 
mRNA expression data in footpad and lymph node were obtained from a limited 
number of animals. These studies were not extended due to limited antibody availability 
and in accordance with the refinement and reduction of animal experiments. It would, 
however, be of interest to determine if subtle effects were exerted within draining lymph 
nodes, and to extend the molecular approach of investigating the effects of 
administering a neutralising antibody. Detailed information could be provided by gene 
array technology, and protein analysis would also be desirable. Moreover, the 
expression of other mediators could be explored in detail, perhaps providing insights 
into networks of cytokine function. Delineating whether these in vivo observations were 
the consequence o f  direct effects on neutrophil responses, or secondary to effects on 
other cells would also be of interest. These experiments were beyond the scope of this 
project, but are worthy of consideration given the therapeutic potential of neutralising 
IL-18 in human disease.
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Other approaches to neutralising IL-18 include targeting the IL-18R. Administration of 
anti-IL-18R antibody in this carrageenan model reduced footpad swelling but inhibited 
the Thl response in the draining lymph, presumably by targeting IL-18R expressing T 
cells (54). The natural IL-18 antagonist, 1L-18BP, has been administered in models of 
CIA and IBD with promising results (131, 138). This protein mediates disparate effects 
dependent on the dose given. Furthermore, IL-18BP is elevated along with IL-18 in 
several pathologies including sepsis and adult Still’s disease (ASD) (99), indicating that 
relative levels of agonist and antagonist activity are determining overall effect. 
Application of IL-18BP to the carrageenan model awaits availability of reagents. 
Several studies have demonstrated that soluble IL-18Ra or p chains are of insufficient 
binding affinity to mediate useful neutralising effects. Recombinant herterodimers also 
failed to bind as effectively as a binding protein (25, 27).
Neutralising IL-18 is an attractive therapeutic strategy, and whilst targeting pathological 
inflammatory effects, may also lead to immune compromise. These effects are 
especially difficult to evaluate in short term, murine experiments performed in carefully 
controlled environments with inbred animals. To partially address this issue, it would be 
of interest to neutralise IL-18 in the carrageenan and other models, in different strains of 
mice. Reagent limitations precluded this approach from the cunent study.
These data provide further evidence that IL-18 is involved in neutrophil migration, and 
recruitment to inflammatory lesions. As such, neutralising IL-18 may be beneficial, 
alone and in combination with targeting other cytokines. However, the full implications 
of neutralising IL-18, and the ideal vehicle for this purpose are not clear. Clearly, 
manipulation of cytokines in inflammation may have dramatic effects. To explore the
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consequences of such manipulation in host defense and inflammation initiated by a 
pathogen, S. aureus infection was investigated.
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Chapter 5 The role of enhanced IL-18 expression in gram-positive infection
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Introduction
Data in previous chapters show that IL-18 activates neutrophils in vitro (Chapter 3) and 
in vivo (Chapter 4). Bacterial killing is a key function of neutrophils. To extend the 
physiological relevance of the previously described effects of IL-18 on neutrophil 
activation a model of gram-positive infection was investigated. IL-18 is a critical 
regulatory cytokine linking innate and acquired responses. Manipulation of IL-18 
expression in vivo in models of parasitic (112), viral (107), fungal (222), and 
mycobacterial (52) infection indicates protective roles for IL-18. In murine models of 
gram-negative infection, IL-18 contributes to host resistance (94), but also promotes 
shock associated with administration of LPS (97). This role in endotoxic shock is 
critically dependent on initiating factors. Thus, Propionibacterium acnes primed IL-18- 
deficient mice show a defect in negative regulation of TNFa resulting in increased 
mortality following challenge with endotoxin (98).
Emerging evidence implicates IL-18 in gram-positive infections in vivo. Treatment with 
anti IL-18 receptor p chain antibody in a murine model of Listeria monocytogenes 
infection demonstrated protective effects of IL-18 through modulation of early innate 
immune responses, Thl development and memory responses (93). Furthermore, IL-18- 
deficient mice fail to clear Streptococcus pneumoniae as effectively as wild type 
controls (95). Finally, septic patients have elevated levels of both IL-18 and its natural 
antagonist IL-18BP (41, 99). Interestingly, septic patients with gram-positive infections 
have significantly higher IL-18 plasma levels than patients with gram-negative infection 
(100). Following staphylococcal infection, IL-18-deficient mice exhibit reduced
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septicaemia but increased end organ infection, namely inflammatory arthritis (96). This 
increased bacterial load may be indicative of a deficiency in neutrophil function.
Septic arthritis is a common complication of RA, affecting up to 3% of RA patients. 
Infection is associated with high mortality (20%), joint destruction and irreversible loss 
of joint function. In 30-60% of cases, the causative organism is Staphylococcus aureus. 
Furthermore, 1-5% of prosthetic joints become infected with S. aureus. Patients with 
RA, who are known to exhibit elevated IL-18 levels in tissues and serum, are more 
susceptible to gram-positive infection, particularly S. aureus, which is often 
complicated by septicaemia with significant associated mortality (223). That patients 
with a priori elevated IL-18 expression show a poor prognosis following gram-positive 
infection led us to investigate the protective versus pathogenic effects of IL-18 in a 
murine model of gram-positive sepsis. Cytokine modulation is an attractive therapeutic 
strategy for many diseases; therefore detemiining whether IL-18 plays a predominantly 
protective or pathogenic role in the pathogenesis of S. aureus infection is crucial.
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Results 
5.1 Human neutrophil expression of IL-18
Neutrophils are capable of synthesising abroad array o f  c ytokines. N eutrophil IL-18 
expression was investigated by intracellular FACS analysis. This facilitated 
identification of neutrophils by size and granularity, reducing the potential for false 
positive results. Contaminating cells within purified neutrophil populations (Fig. 3.2), 
which express IL-18, could give false positives in sensitive assays such as PCR or 
Western blot. Neutrophils were cultured with an inhibitor of golgi function, Brefeldin 
A, to promote accumulation of intracellular protein. A modest increase in the 
fluorescence intensity of staining with anti-IL-18 antibody was observed compared to 
isotype control (Fig. 5.1a and b). This suggested that either neutrophils express low 
levels of IL-18 on a per cell basis or that only a subpopulation of neutrophils are IL-18 
positive. The latter was implied by dot plot analysis (Fig. 5.1c and d). The anti-IL-18 
antibody used in this study does not differentiate pro and mature forms of IL-18. 
However, control of neutrophil production, processing and release of IL-18 is currently 
under investigation (Dr. S. Roberstons, Centre for Rheumatic Diseases, Glasgow Royal 
Infirmary). Nevertheless, these data suggest that endogenous IL-18 may potentially 
auto-activate neutrophils, which may contribute to their bactericidal role.
5,2 IL-18 promoted bacterial killing
To determine if IL-18 may promote bacterial killing by human neutrophils in vitro, 
neutrophils were incubated with 100 ng/ml IL-18 for 1 h before exposure to opsonised 
S. aureus. This period of incubation with IL-18 was previously detennined as optimal
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for enhancing subsequent respiratory burst in response to fMLP (Section 3.9). Prior 
incubation of human neutrophils with IL-18 modestly enhanced bacterial killing (Fig. 
5.2). Such a modest effect was unsurprising given that neutrophils were derived from 
normal healthy donors, and bactericidal activity of such neuti'ophils should be highly 
efficient in any case.
To further investigate if the IL-18 identified in neutrophils may play a role in bacterial 
killing, leukocytes were obtained from IL-18-deficient DBAl mice, or wild type 
controls. Thioglycolate induced peritoneal neutrophils are highly activated in vivo 
(CDllb^\ CD62L’°), and thus less susceptible to priming than human blood derived 
neutrophils. Therefore murine huffy coat leukocytes were assayed. Accordingly, whole 
blood was collected via cardiac puncture under terminal anaesthetic and huffy coats 
containing peripheral leukocytes separated by dextran sedimentation. Neutrophils were 
not purified from murine peripheral blood due to the limited blood volume available and 
the relatively low frequency o f  neutrophils (Chapter 6, Fig. 6.1). Leukocytes derived 
fi'om IL-18-defîcient mice exhibited significantly reduced ability to kill bacteria in vitro, 
compared to wild type controls. This deficiency in bactericidal activity was partially 
restored by addition of exogenous IL-18 (Fig. 5.3). Addition of exogenous IL-18 to 
leukocytes derived from wild type mice did not enhance bacterial killing, as was evident 
in human samples. This may reflect prior in vivo activation caused by the traumatic 
route of blood collection, or the different constitution of blood cell subsets in mice 
compared with humans. The compromised bactericidal capacity observed in IL-18- 
deficient mice in vitro may contribute to their increased susceptibility to bacterial 
infections.
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Figure 5.1 Human neutrophils from healthy donors expressed IL-18 protein
Neutrophils were purified from normal donors (n = 4), cultured with 10 pg/ml 
brefeldin A for 2 h, stained for intracellular cytokine expression, and analysed 
by flow cytometry, (a) Representative histogram analysis of neutrophils stained 
with anti-human IL-18 (solid line) or isotype control (dotted line), (b) Pooled 
data of mean fluorescent intensity of 4 donors. Data are mean ± SEM. *p < 
0.01 vs. control, (c) Representative dot plot of isotype control and (d) dot plot 
of IL-18 staining.
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Figure 5.2 IL-18 promoted bacterial killing by human neutrophils
Peripheral blood neutrophils were purified from normal human volunteers (n =
10) and incubated at 10^/ml for 1 h with medium alone or 100 ng/ml IL-18. 
Neutrophils were added to an equal volume of opsonised S. aureus (10^ 
CFU/ml, assessed spectrophotometrically, confirmed by plating serial dilutions 
on blood agar). After 20 minutes, remaining viable bacteria were counted by 
plating serial dilutions on blood agar. Mean bacterial killing of neutrophils 
pretreated with IL-18 was 63.7% compared with 49.6% bacterial killing by 
neutrophils incubated in medium alone. *p < 0.05 vs. medium by 1 sample t 
test.
155
Medium
Medium
0  IL -18+/+
1 1 I L - 1 8  - / -
0 10 20 30 40 50
% S. aureus killed
Figure 5.3 Endogenous IL-18 promoted bacterial killing
IL-18 wild type (+/+) or deficient (-/-) DBA-1 mice were terminally 
anaesthetised by i.p. administration of 12.5 mg avertin, blood was collected via 
cardiac puncture into heparinised syringes and leukocytes separated by dextran 
sedimentation. Murine cells were incubated with 100 ng/ml rmIL-18 or 
medium alone for 1 hour prior to addition of bacteria as in Fig. 5.2. Data are 
mean ± SEM of 4 experiments with 3 mice per group in each experiment. *p <  
0.05 vs. wild type medium by Student’s t test.
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Figure 5.4 Outline of experimental design to investigate the role of elevation 
of IL-18 in bacterial infection
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5.3 Incidence and severity of septicaemia following IL-18 administration
Previous investigation determined that IL-18 deficiency modified S. aureus infection in 
mice (96). A more common scenario is a priori elevated IL-18 levels, such as observed 
in autoimmune diseases. The incidence and severity of sepsis following rmIL-18 
administration was therefore investigated as shown in Fig. 5.4. Swiss mice were 
infected with 5x10^ CFU/animal S. aureus by intravenous inoculation. Tarkowski et al 
previously established that low dose infection (=10^ CFU per animal) promotes 
predominantly arthritis whereas high dose infection (slO^ CFU per animal) induces 
predominantly septicaemia (211). An intermediate dose was selected in the following 
experiments that caused severe arthritis and evidence of sepsis in a small-scale pilot 
experiment. The dose of IL-18 employed in these studies was estimated on the basis of 
studies in CIA models, in which a similar bolus effectively modulated immune 
responses (129). In compliance with Home Office recommendations, which stipulate a 
reduction and refinement in the use of animals, further dose response experiments were 
not perfonned to minimise animal usage.
In 2 experiments, mice received 200 ng of rmIL-18, 2 h prior to infection, (n = 30, 
‘pretreaf ), 18 h post infection (n = 30, ‘posttreat’), or received carrier alone (n = 30 
‘PBS’). Significantly increased mortality was observed in  pre-treated mice compared 
with controls. Survival at day 5 in the pre-treated group was 58%, compared with 93% 
in the PBS group (Fig. 5.5). Post infection administration of IL-18 had no effect on 
mortality. Onset of clinical evidence of septicaemia was accelerated in IL-18 pre-treated 
mice compared with the control group (Fig. 5.6a). The severity of systemic disease, 
quantified by determining septic index (only in involved mice), was greater at early time
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points (day 2 and 4) in pre-treated mice compared to controls (Fig. 5.6b). From day 4 
through day 10 there was no significant difference in clinical signs of sepsis between 
groups suggesting that the predominant effects of prior IL-18 elevation were manifest at 
an early stage. Post infection administration of IL-18 had no effect on incidence or 
severity of sepsis. Weight loss was monitored daily, revealing significant weight loss in 
all groups, which was not affected by administration of IL-18 at any time point (Fig. 
5.6c).
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Figure 5.5 Administration of IL-18 modulated mortality following S. aureus 
infection
Mice received 200 ng rmIL-18, 2 h prior to (‘pretreat’) or 18 h post 
(‘posttreat’) infection. The ‘PBS’ group received carrier alone either prior to or 
post infection (Fig. 5.4). Mortality was assessed by Kaplan Mayer analysis, 
which accounts for animals sacrificed for in vitro analysis, n = 3 0 mice per 
group, from 2 independent experiments. *p < 0.05 vs. PBS by Chi-squared test.
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Figure 5.6 Clinical assessment of sepsis following S. aureus infection
Mice were treated as in Fig. 5.4. (a) Incidence of septicaemia, representing the 
proportion of animals exhibiting signs of sepsis, (b) Severity of sepsis, judged 
by septic index (Section 2.11.3), data are from involved animals only, (c) 
Weight loss, recorded as % starting weight. Data are mean ± SEM, n = 30 mice
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per group, representative of 2 similar experiments, < 0.01 vs. PBS by Mann 
Whitney U test; **p < 0.005 vs. PBS by Chi-squared test.
5.4 Incidence and severity of septic arthritis
Within 2 days of infection with S. aureus, clinical signs of arthritis were observed in the 
majority of mice. 100% of the animals exhibited involved joints from day 4 through day 
10. Incidence of artliritis was similar in all groups (Fig. 5.7a). Control mice developed 
severe arthiitis, detennined by articular index, and pre-treatment with IL-18 did not 
further increase the magnitude of such already severe articular disease. However, post 
infection administration of IL-18 significantly reduced the severity of arthritis (Fig. 
5.7b). To further investigate this observation, hind paws were subjected to histological 
analysis at day 5. Footpads were formalin fixed, then decalcified and 4 pm sections 
stained with heamatoxylin and eosin. Sections were examined for signs of synovial 
hyperplasia, joint space invasion and cartilage and bone destruction. There was 
evidence of all these features of joint destruction (Fig. 5.8). Surprisingly, no differences 
were o bserved b etween the g roups, s uggesting e ither t hat the r educed a rticular i ndex 
was due to altered oedema in the footpads, or that the animals obtained were not 
representative. It is likely that larger studies would be required to accurately detemiine 
mechanisms of altered pathogenesis.
5.5 Distribution of bacteria
Distribution of bacteria was assessed by sequentially diluting cultures of blood and 
homogenised tissues at 6 h, 24 h, and a t days 2 ,5  and 1 0, post infection. 24 h post
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infection, IL-18 pretreated mice showed elevated levels of bacteria in peripheral blood 
and kidney compared to controls (Table 5.1). This suggested some inefficiency in 
killing at early time points in pretreated mice. Similar numbers of viable S. aureus were 
detected in the blood, kidneys, spleens and footpads of mice at later time points, in all 
groups.
In post infection IL-18 treated mice, there was no evidence of consistently reduced 
bacterial load in the footpads. Thus increased bacterial clearance did not account for the 
observed reduction in articular- index, or the footpads obtained were not representative.
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Figure 5.7 Pathogenesis of septic arthritis following infection with S. aureus
Experimental protocol is described in Fig. 5.4. (a) Incidence of arthritis 
representing the proportion of animals exhibiting signs of arthritis, (b) Severity 
of arthritis was judged by arthritic index (Section 2.11.3), data are mean ± 
SEM, of involved animals only. From day 4 through day 10, all animals 
exhibited clinical signs of arthritis, n = 30 mice per group, from 2 independent 
experiments. *p < 0.01 vs. PBS by Mann Whitney U test.
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Figure 5.8 Articular histology subsequent to S. aureus infection
Left and right hind paws were removed at day 5 post S. aureus infection, fixed 
in formaldehyde then decalcified. 4 pm Sections were prepared from 5 mice 
per group, and stained with H&E. Degree of erosion, infiltration and synovial 
hyperplasia were assessed as previously described (224). No histological 
differences were observed at this time point between the 3 groups, (a) 
Representative section, low power magnification, and (b) same section, high 
power magnification.
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Table 5.1 Peripheral distribution of bacteria following infection with S. 
aureus^.
Time Group nper Blood Kidney Spleen Paws
Post group CFU/ml CFU/kidney CFU/g CFU/paw
infection xlO^ xlO^ xlO^ xlO^
6h PBS 5 21701+4365 0.19+0.05 21701436 not
Pretreat 5 18063+6054 0.58±0.39 18061605 done
PBS 5 0.27±0.20 0.08+0.03 167158 22.418.0
24h Pretreat 5 2.15+0.69* 1.54+0.59* 151149 128198.2
Posttreat 5 0.41+0.20 0.07±0.03 186137 25.818.3
PBS 5 0.28+0.19 9.90+8.08 4.3610.82 94.0129.0
48h Pretreat 5 0.21+0.08 263±181 2.8511.20 183.0168.5
Posttreat 5 0.32+0.13 0.25+0.16 2.0111.15 196.0193.6
PBS 3 226.33+188.06 440.04+302.63 0.4610.40 622.01190.0
d5 Pretreat 3 466.68+466.66 770.65+367.85 0.0210.01 659.81275.9
Posttreat 3 o.ooto.oo 818.20±437.92 0.0610.04 335.11166.1
PBS 3 0.00 910.69 0 131.1
dlO Pretreat 3 0.00 1124.67 0 55.6
Posttreat 3 0.00 799.33 0.05 82.0
^Experimental design outlined in Fig. 5.4. Values are mean ± SEM of number 
of mice per group as indicated in the table. The data obtained at 24 h are 
representative of 2 similar experiments. < 0.05 vs. PBS control by Mann 
Whitney U test.
165
5.6 Pharmo-kiiietics of IL-18 administration
As a surrogate for pharmokinetics of IL-18 administration, IL-18 levels in the sera were 
assessed by ELISA. IL-18 was detected in the serum 2 and 6 h following i.p. 
administration. IL-18 levels declined rapidly over the next 48 h (Fig. 5.9). Comparison 
of IL-18 levels 6 to 8 h post administration (i.e. 6 h post infection for pretreated mice, 
and 24 h post infection for post-treated mice) indicated similar levels of circulating IL- 
18. This suggests that any up regulation of IL-18 binding proteins or other negative 
regulators by S. aureus was not sufficient to interfere with detection of circulating IL-18 
levels at this time point. Measurement of such inhibitors was hampered by absence of 
reagents. Tissue IL-18 protein levels could not be easily measured. Of particular 
importance, the 1-3 ng/ml of IL-18 detected in these murine sera are comparable to IL- 
18 c oncentrations delected in  s era o f  p atients with severe disease such as s epsis and 
Adult Still’s Disease. Septic patients exhibit elevated serum IL-18 at various stages of 
disease. It was therefore surprising that only very low levels of IL-18 were detected in 
infected mice which been treated with PBS instead of IL-18.
5.7 Altered cytokine mRNA and protein expression 2 h after administration of 
IL-18
To investigate changes induced by IL-18 prior to infection, mice were sacrificed 2 h 
after IL-18 administration and cytokine mRNA expression in peripheral blood 
leukocytes (PBL) was determined. Significant increase in expression of IFNy mRNA in 
IL-18 treated mice was observed compared to PBS controls (Fig. 5.10a). Since 
monokine over-expression can be induced by IL-18 in vitro and is associated with 
septicaemia (225) TNFamRNA expression was also analysed, and found to be
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significantly elevated in PBL following IL-18 administration (Fig. 5.10b). In parallel, 
we investigated whether exogenous IL-18 administration altered the cytokine mRNA 
profile in spleen. IL-18 enhanced IFNy mRNA (Fig. 5.10c), but did not alter TNFa 
(Fig. 5.10d). To provide an indication of modulation of Thl response induction, IL- 
12p40 mRNA expression was assessed, and to assess whether IL-18 exerted auto- 
regulatory effects at the mRNA level, expression of IL-18 mRNA was also investigated. 
No effect on IL-12p40 or IL-18 mRNA expression in PBL or spleen was observed 2 h 
post IL-18 administration.
Serum IFNy protein was detected 2 h post IL-18 administration in 80% of recipients at 
low levels up to 300 pg/ml (Fig. 5.11). TNFa protein was not detected in the semm of 
any group.
5.8 IL-18 modulated TLR expression
To determine if in addition to altering cytokine expression, IL-18 administration 
affected otherpathways o f  immuneresponse tobacterial infection, Toll-likereceptor 
(TLR) expression was investigated. TLRs are a large family of pattern recognition 
molecules that mediate responses to valions pathogen components. In this study, 
modulation of TLR2 and TLR9 were investigated, TLR2 binds bacterial peptidoglycan 
and is involved in immunity to gram-positive bacteria; TLR9 mediates host responses to 
bacterial CpG motifs. To determine whether IL-18 could affect TLR mRNA expression, 
experiments were performed as in section 5.5. Two hours post IL-18 administration, 
TLR2 mRNA expression in PBL was significantly elevated in IL-18 treated mice 
compared to PBS controls ( Fig. 5 .12a). TLR9 mRNA expression in  p eripheral b lood
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followed a similar trend of elevation, although the difference between the groups was 
not statistically significant (Fig. 5.12b). Administration of IL-18 had no effect on TLR2 
or TLR9 mRNA expression in the spleen (Fig. 5.12c and d). Protein detection reagents 
for murine TLR2 and TLR9 were not available at the time of these studies.
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Figure 5.9 Serum IL-18 following i.p. administration of IL-18
Blood was obtained a t times indicated following inoculation with 5'. a ureus. 
Blood was allowed to clot overnight at 4°C and centrifuged to obtain serum, 
which was assayed for cytokines by ELISA. Data are mean ± SEM of 5 mice 
per group per time point. *p < 0.05 vs. PBS group by Student’s t test. Serum 
IL-18 levels at days 5 and 10 were similar to those observed at 48 h.
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Figure 5.10 Cytokine mRNA expression 2 h post IL-18 administration
To investigate the immediate effects of IL-18 administration, mRNA was 
extracted from peripheral blood leukocytes (PBL) or sections of spleen. 
Changes in cytokine mRNA expression were assessed by real time PCR. (a) 
IFNy and (b) TNFa mRNA expression in PBL was elevated 2 h post i.p. 
administration of IL-18. (c) Splenic expression of IFNy mRNA was similarly 
elevated but administration of IL-18 had no effect on TNFa mRNA expression 
in spleen (d). Data are mean ± SEM of 5 mice per group. * p < 0.05 vs. PBS by 
Mann Whitney U test. These data are also described in Tables 5.2 and 5.3.
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Figure 5.11 Serum IFNy 2 h post i.p. administration of IL-18
Whole blood was obtained via cardiac puncture 2 h post i.p. administration of 
200 ng of IL-18. Serum cytokine concentration was assayed by ELISA. Data 
are mean ± SEM of 5 mice per group. *p < 0.05 vs. PBS by Mann Whitney U 
test.
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Figure 5.12 Changes in TLR mRNA expression following IL-18 
administration
Experiments were performed as in Fig. 5.10. (a) TLR2 and (b) TLR9 mRNA 
expression in PBL was elevated 2 h post i.p. injection of IL-18. Splenic 
expression of (c) TLR2 mRNA or (d) TLR9 mRNA was unaffected by 
administration of IL-18. Data are mean ± SEM of 5 mice per group. *p < 0.05
vs. PBS by Mann Whitney U test.
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5.9 Effects of IL-18 administration on ex vivo immune responses
To investigate whether this rapid induction of cytokine mRNA (Section 5.5) indicated 
‘priming’ of the immune response to subsequent stimulus, spleen and heparinised blood 
were obtained 2 h after i.p. injection of IL-18. Single cell suspensions were cultured for 
48 h with Con A or formalin fixed bacteria.
i) Ex vivo response to Con A
Proliferative responses to Con A in peripheral blood or spleen cultures were similar 
irrespective of prior IL-18 administration (Fig. 5.13a and b). However, in leukocyte 
cultures, Con A induced production of IFNy was significantly increased by prior 
treatment with IL-18 in vivo (Fig. 5.13c). IFNy production to Con A in spleen cultures 
was similar in both groups (Fig. 5.13d), suggesting that the primary early effects of IL- 
18 administration had been in the periphery. Con A stimulated IL-6 production by both 
leukocyte and spleen cultures. IL-6 production by PBL in response to Con A was 
moderately depressed by prior in vivo administration of IL-18. (Fig. 5.13e and f) 
suggesting some selectivity in the modulation of cytokine release. Residual free 
recombinant IL-18 was unlikely to influence subsequent leukocyte cultures since 
erythrocytes were lysed and remaining leukocytes thoroughly washed prior to addition 
of stimulus.
ii) Ex vivo response to S, aureus
In vitro stimulation with formalin-fixed S. aureus did not induce significant 
proliferation (Fig. 5.14a and b) or IFNy release in leukocyte cultures (Fig. 5.14c). 
Spleen cell cultures produced only modest levels of IFNy in response to fixed S. aureus, 
regardless of prior exposure to IL-18 (Fig. 5.14d). S. aureus stimulated significant IL-6 
production by both PBL and splenocyte cultures. Furtheimore, the PBL response was
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enhanced by prior in vivo  exposure to IL-18 (Fig. 5.14e and f). Together these data 
suggest that IL-18 administration alters subsequent immune responsiveness, primarily 
in the periphery, and this in turn could alter early responses upon subsequent S. aureus 
infection.
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Figure 5.13 Administration of IL-18 altered ex vivo immune responses to Con 
A.
Mice were sacrificed 2 h after receiving 200 ng rmIL-18 or PBS i.p. Single cell 
suspensions of spleen and peripheral blood leukocytes were stimulated with 
Con A. Proliferation of (a) PEL and (b) spleen cell cultures, was assessed by 
[^H] thymidine incorporation. Data are expressed as a proliferative index which 
normalises the response to medium control. Con A induced IFNy release in (c) 
PEL and (d) spleen cultures. IL-6 release in response to Con A was detected in 
PEL (e) and spleen (f) cultures. Data are mean ± SEM of 5 mice per group. */? 
< 0.05 vs. PES by Student’s t test.
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Figure 5.14 Administration of IL-18 altered ex vivo immune responses to S. 
aureus
Experiments were performed as in Fig. 5.14, except cell cultures were 
stimulated with lO^CFU/ml formalin fixed S. aureus. Proliferation in response 
to fixed S. aureus was minimal in both (a) PEL cultures and (b) spleen cell 
cultures. S. aureus failed to induce IFNy release in (c) peripheral blood 
cultures, but (d) stimulated IFNy release by spleen cultures. Prior in vivo 
administration of IL-18 enhanced PEL IL-6 release in response to S. aureus 
(e), although IL-6 production by spleen cultures (f) was unaffected. Data are 
mean ± SEM of 5 mice per group. *p <  0.05 vs. PES, by Student’s t test, ns, 
not significantly different to PES control.
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5.10 Immunomodulatory effects of prior IL-18 administration on subsequent S,
aureus infection
Potential immune mechanisms whereby prior IL-18 administration modified subsequent 
responses to 6'. aureus were investigatedby measuring serum cytokine concentration 
and cytokine inRNA expression in tissue compartments 6 h and 24 h after infection.
i) Peripheral responses
Cytokine mRNA expression in peripheral blood leukocytes was assessed prior to 
infection and 6 h and 24 h post infection. In PBS treated, control mice, S. aureus 
infection resulted in increased TNFa, IFNy, and IL-12p40 mRNA expression, but no 
change in expression of IL-18 mRNA. Changes in mRNA expression were maximal 6 h 
post infection and largely returned to prior infection levels 24 h post infection (‘PBS’ 
group, Table 5.2). Administration of IL-18 prior to infection with S. aureus resulted in 
exaggerated IFNy mRNA expression at 6 h and 24 h post infection. Pretreated mice also 
exhibited elevated IL-18 mRNA expression 6 h post infection (‘Pretreat’ group, Table 
5.2 and Fig. 5.15). Prior treatment with IL-18 had no effect on TNFa or IL-12p40 
mRNA expression.
Changes in protein expression in the periphery were assessed by ELISA of serum. 
Infection with S. aureus resulted in little measurable change in serum IL-4, IL-5, IFNy 
or TNFa at any time point. However, semm IL-6 was modestly elevated 24 h and 48 h 
post infection. Significant changes in serum cytokine expression were observed in mice 
receiving IL-18 prior to infection. Pretreated animals exhibited elevated serum IL-6 and 
IFNy 6 h post infection. Serum IFNy remained modestly elevated at 24 h post infection 
in pretreated mice, but was undetectable in any group after that time (Fig. 5.16).
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ii) Spleen responses
Changes in splenic cytokine mRNA expression were assessed in parallel with peripheral 
blood leukocytes (Section (i), above). Similar to PBL, infection with S. aureus resulted 
in elevated TNFa, IFNy, and IL-12p40 mRNA expression; changes were also maximal 
6 h post infection. Like PBL, no change in splenic IL-18 mRNA expression was 
observed following infection ( ‘PBS’ group, T able 5.3). Prior administration o f  IL-18 
predominantly enhanced expression of IFNy mRNA (illustrated in Fig. 5.15). 
Interestingly, in contrast to PBL mRNA expression, prior IL-18 administration also 
resulted in elevated IL-12p40 mRNA expression, 6 h post infection (‘Pretreat’ group. 
Table 5.3).
Together these data clearly indicate that exposure to IL-18 predisposed to accelerated 
and exaggerated IFNy transcription and protein expression upon subsequent S. aureus 
infection.
5.11 Immunomodulatory effects of post infection administration of IL-18
Post infection treatment with IL-18 resulted in increased IFNy mRNA expression in 
both PBL (‘Posttreat’ group, Table 5.2) and spleen (‘Posttreat’ group. Table 5.3), 
although this effect was less pronounced than that caused by prior infection 
administration of IL-18. Similarly, post infection treated mice exhibited elevated 
circulating IFNy (Fig. 5.18).
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Table 5.2 Cytokine mRNA expression in peripheral blood leukocytes 
following IL-18 administration and infection with S. aureus^.
Time
(Post
infection)
Treatment
Group
IFNy TNFa IL-12 p40 IL-18
Oh PBS 0.03+0.02 28.1+11.9 0.08+0.07 15.61+3.69
Pretreat 1.88±0.53* 311+111* 0.00+0.00 16.7+0.65
6h PBS 22.8+6.20 362+96.0 0.40+0.20 36.9+9.80
Pretreat 149+40.1* 380+200 0.30+0.10 124+27.5*
PBS 1.36+0.44 6.12+6.79 0.02±0.01 33.4+6.90
24 h Pretreat 16.9±5.21* 20.8±1.16 0.08+0.04 27.414.70
Posttreat 15.2+4.40* 6.30+1.00 0.01+0.00 30.0+3+6
Values are mean ± SEM of 5 mice per group. < 0.05 vs. PBS by Maim 
Whitney C/ test. See also Fig. 5.15.
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Figure 5.15 Effects of administering IL-18 on early S. aureus infection, in 
peripheral blood leukocytes
Mice received either PBS or IL-18 (Pretreat) 2 h prior to infection with S. 
aureus, and were sacrificed 6 or 24 h post infection. RNA was extracted from 
peripheral blood leukocytes, reverse transcribed and mRNA levels quantified 
by real time PCR. IFNy mRNA expression was assessed in PBL. Data are 
mean ± SEM of 5 mice per group. */? < 0.05 vs. PBS by Mann Whitney U test.
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Figure 5.16 Effects of prior treatment with IL-18 on serum cytokines 
following S, aureus infection
Bloods were obtained at the time points indicated after inoculation with S. 
aureus. Serum was separated from clotted blood and assayed for cytokines by 
ELISA. Data are mean ± SEM of 5 mice per group per time point, 
representative of 2 similar experiments. */? < 0.05 vs. PBS group by Student’s t 
test. Serum cytokines were also measured at days 5 and 10; no cytokines were 
consistently detected in any group.
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Table 5.3 Changes in cytokine mRNA expression in spleen following IL-18 
administration and infection with S. aureus^.
Time
(Post
infection)
Treatment
Group IFNy TNFa 1L-I2p40 IL-18
Oh PBS 1.24+0.08 38.9+4.39 0.142±0.005 48.4+1.3
Pretreat 5.94+1.54* 62.1±10.5 0.09+0.009 40.2+2.01
6h PBS 18.1±6.45 426+90.6 1.79+0.47 50.7+7.94
Pretreat 177+28.2* 604+102 8.79+0.73* 52.1+11.6
PBS 4.89+0.96 40.4+7.30 0.87+0.18 26.1+3.36
24 h Pretreat 20.9+4.49* 69.1+28.7 1.79+0.61 24.6+3.57
Posttreat 10.74+2.87 22.2+1.63 0.36+0.06* 11.2+1.37*
Values are mean ± SEM of 5 mice per group. < 0.05 vs. PBS by Mann 
Whitney U test.
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Figure 5.17 Effects of administering IL-18 on early S. aureus infection in 
spleen
Mice received either PBS or IL-18 (Pretreat) 2 h prior to infection with S. 
aureus, and were sacrificed 6 or 24 h post infection. RNA was extracted from 
whole spleen, reverse transcribed and IFNy mRNA expression quantified by 
real time PCR. Data are mean ± SEM of 5 mice per group. < 0.05 vs. PBS 
by Mann Whitney U test.
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Figure 5.18 Effects of post infection administration of IL-18 on serum 
cytokines following S. aureus infection
Bloods were obtained at the time points indicated after inoculation with S. 
aureus. Serum was separated from clotted blood and assayed for cytokines by 
ELISA. Data are mean ± SEM of 5 mice per group per time point, 
representative of 2 similar experiments. *p < 0.05 vs. PBS group by Student’s t 
test. Serum cytokines were also measured at days 5 and 10 and no cytokine 
expression was consistently detected in any group.
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5.12 Low dose LPS does not prime for enhanced IFNy release
To determine if LPS contamination of the IL-18 contributed to the exaggerated 
responses observed, mice received either the maximum contaminating dose of LPS (5 
pg, determined by E-Toxate assay), 200 ng rmIL-18, or PBS carrier, 2 h prior to 
infection with 5 x 10^  CFU/animal S. aureus. Animals were sacrificed 6 h post 
infection, and mRNA extracted from peripheral blood leukocytes and spleen, and serum 
cytokines analysed by  ELISA. Prior treatment with IL-18, but not LPS, significantly 
enhanced IFNy mRNA expression in the PBL (Fig. 5,19a) and spleen (Fig. 5.19b), and 
serum IFNy (Fig. 5 .19c) and IL-6 (Fig. 5 .19d), confirming the previous observations 
and indicating that low dose contaminating LPS did not account for these changes.
5.13 Longevity of altered responsiveness
Finally, to determine the duration of the foregoing effects, serum was obtained at days 
2, 5 and 10 following infection (Fig. 5.4). No cytokine protein levels (TNFa, IFNy, IL-4 
and IL-5) were consistently detected in serum at these time points. Variable levels of 
serum IL-6 were measured at each time point, with no difference between the groups. 
Accordingly, spleens were obtained at days 2, 5 and 10, and single cell suspensions 
stimulated with formalin-fixed S. aureus, to which the mice were now likely to be 
responsive. At day 2, proliferation of spleen cell cultures in response to fixed S. aureus 
was modest but equivalent in all gioups (Fig. 5.20a), however, production of IFNy in 
response to fixed S. aureus remained higher in IL-18 pre-treated mice than in PBS or 
post treated groups (Fig. 5.20b), whereas IL-6 (Fig. 5.20c) and TNFa (Fig. 5.20d) 
production and proliferation were similar between groups. Only low levels of IL-4 and
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IL-5 were detected in all cultures commensurate with a dominant Thl response. Similar 
cultures on day 5 and day 10 yielded IL-6, TNF and IFNy production that was similar 
between groups (data not shown), suggesting that the early effects of IL-18 
administration had been lost.
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Figure 5.19 Low dose LPS did not prime for subsequent enhanced IFNy 
expression
Mice received 5 ng LPS, 200ng IL-18, or PBS alone 2 h prior to infection with 
S. aureus. 6 h post infection animals were sacrificed, tissues harvested and 
IFNy mRNA expression assessed in (a) peripheral blood leukocytes and (b) 
spleen. ELISA of serum demonstrated changes in circulating (c) IFNy and (d) 
IL-6. Data are mean ± SEM of 5 mice per group. < 0.05 vs. PBS by Mann 
Whitney U test.
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Figure 5.20 Spleen cell responses following staphyloccal infection
Spleens were removed 2 days post infection and cultured for 48 h in the 
presence of 10^  formalin fixed S. aureus per ml. A dose response of between 
10^  and 10  ^ CFU/ml demonstrated that 10^  CFU/ml elicited maximum 
response, (a) Proliferation was assessed by [^H] thymidine incorporation. 
Cytokine and monokine release into the supernatant was assessed by ELISA, 
(b) IFNy release was enhanced by prior in vivo exposure to IL-18. Cultures 
produced significant IL-6 (c) and TNFa (d) in response to formalin fixed S. 
aureus which was not affected by exposure to IL-18 in vivo. Data are mean ± 
SEM of 3 mice per group per time point. */? < 0.05 vs. PBS group by Student’s 
11 est. S imilar e xperiments w ere p erformed o n days 5 a nd 1 0 p ost i nfection, 
although no differences were observed between the groups.
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5.14 Cytokine detection in serum of patients with septic arthritis
Patients attending the Glasgow Royal Infiimary were diagnosed with septic arthritis on 
the basis of isolation of bacteria in synovial fluids, blood cultures or both. Mean patient 
age and underlying arthropathies, where known, are indicated in table 5.4. Serum 
samples were obtained from sample stores retained at -70°C, at the Royal Infirmary.
Serum IFNy has not been previously measured in patients with septic arthritis. Such 
patients may have a priori elevated IL-18 levels related to an underlying autoimmune 
disease, such as RA. In light of the exaggerated IFNy response seen in animals receiving 
IL-18 prior to infection, it was of interest to deteimine the presence of IFNy in patient 
sera. IL-6 levels in semm were assessed as a measure of acute phase response. Normal 
control sera were obtained from 1 aboratory colleagues, thus the average age is 1 ower 
than in the patient cohort (average age of normal cohort was 36.1 years, patient cohort 
72.25 years). However, neither IFNy nor IL-6 were detected in any normal sera. IL-6 
was detected at variable levels in 21 of 33 patients (Fig. 5.19a). 7 of 33 septic patients 
had measurable IFNy present in the sera (5.19b). Interestingly, within the IFNy positive 
cohort of septic patients, there was a strong correlation between IL-6 levels and IFNy 
levels in the sera (Fig. 5.19c). No correlation between serum cytokine levels and 
underlying disease was observed. However, these are at best preliminary observations 
given the insufficient power of this study. A larger, prospective patient cohort and age 
matched normal donors would be appropriate to further investigate these observations.
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Figure 5.21 Serum from patients with septic arthritis
Serum was obtained from 33 septic patients and 11 normals. IFNy and IL-6 
were assayed by ELISA. Neither IFNy nor IL-6 was detected in normal sera, 
(a) IL-6 was delected in the majority o f  septic patients, (b)7 o f  3 3 patients 
exhibited detectable IFNy in the sera, (c) Within the IFNy positive patient
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population there was a strong correlation of IFNy with levels of IL-6. Pearson 
correlation = 0.916,/? = 0.004.
Table 5.4 Details of patients diagnosed with septic arthritis.
Disease n
n
(known
age)
Average 
Age (years) Min Max
n positive for 
cytokine
IL-6 IFNy
RA 11 5 68 43 86 7 1
OA 11 10 74 74 74 6 3
NonRA 3 1 80 67 92 2 2
ND 8 4 75 67 88 6 1
TOTAL 33 20 72.25 43 92 21 7
RA -  rheumatoid arthritis, OA -  osteoarthritis, ND -  no diagnosis
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Discussion
The pieiotropic effects of IL-18 render it a candidate for promoting not only host 
defence but also deleterious auto-toxicity during gram-positive infection. In vitro, IL-18 
promoted bacterial killing; exogenous rhIL-18 enhanced normal human neutrophil 
bactericidal activity, and IL-18-deficient cells failed to kill bacteria as effectively as 
wild type controls. Discrepancies were manifest in vivo; in the presence of a priori 
elevation of IL-18, infection with S. aureus led to increased mortality, however, 
administration of IL-18 post infection reduced the severity of arthritis. This pattern 
reflects previous work in which IL-18-deficient animals exhibited reduced systemic 
sepsis but more severe arthritis following S, aureus infection.
Alterations in bacterial distribution following IL-18 administration either pre or post 
infection may have predisposed to the clinical changes observed. Administration of IL- 
18 induced IFNy, which is associated with increased phagocytosis and bacterial killing, 
thus the early elevation of bacteria in kidney and blood were surprising. The cause of 
these changes in early bacterial distribution is not clear but may reflect impaired 
neutrophil function associated with sepsis or early haemodynamic change. A priori 
elevation of IL-18 caused immune deregulation, which may have resulted in ‘immune 
paralysis,’ and this in turn led to inefficient bacterial clearance. No changes were 
obseiTed in bacterial loads of the footpads, however, the use of labeled bacteria would 
be appropriate to further investigate this obsei*vation.
To further investigate mechanisms underlying the clinical obseiTations, the effects of 
IL-18 administration alone were examined. Given the haematogenous route of infection,
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in addition to obtaining spleens, peripheral blood leukocyte responses were 
investigated. Furthermore, these are routinely studied in humans, but seldom explored 
in mice. Enlianced IFNy, at both mRNA and protein level, was evident in PBL and 
spleen 2 h post IL-18 administration. Elevated TNFa mRNA was observed in PEL 
only. Identification of the IFNy producing cells, hypothesised to be NK cells, by 
intracellular FACS analysis was unsuccessful; the reagents available detected IFNy only 
in cells producing the cytokine in high concentrations, such as driven Thl cells. Ex vivo 
responses to mitogen and superantigen were also enhanced by prior exposure to IL-18, 
but only in the peripheral compartment. An alternative explanation for the modified 
response to S. aureus following administration of IL-18 was speculated to lie in 
modification of Toll-like receptors. In peripheral blood leukocytes, IL-18 administration 
enhanced TLR2, and to a lesser extent TLR9, mRNA expression. This is consistent with 
studies in a model of murine fungal induced astlimatic disease, in which neutralisation 
of IL-18 was associated with reduced TLR2 expression (104). These changes in TLR 
expression await verification at protein level, but may contribute to subsequently altered 
immune responses. That the peripheral blood leukocytes showed several discrepant 
responses, compared to whole spleen, following administration of IL-18 may have 
important implications for studying S. aureus and other infections.
Analysis of cytokine profiles post infection demonstrated that IL-18 predominantly 
exaggerated IFNy production following infection. It was assumed that TNFa 
deregulation may account for some of our observations. Administration of IL-18 alone 
induced elevated TNFa mRNA expression in PBL. However, although TNFa mRNA 
expression was elevated following infection, this was not further modulated by a priori 
addition of IL-18. This is surprising given the potential ability of IL-18 to drive TNFa
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release directly from NK cells and macrophages (77). However, our methodology did 
not allow detection of membrane bound TNFa, or soluble TNFa receptors. To 
determine if this enhanced IFNy was directly responsible for the increased mortality of 
pretreated mice, IFNy neutralising antibodies could be administered. Previous studies 
have shown that administration of IFNy before or after infection reduces mortality and 
increases septic arthritis. Neutralising anti-IFNy antibody has no effect on survival but 
reduces arthritis (226). IFNy receptor deficient mice exhibit greater arthritis and display 
altered mortality dependant on stage of disease (227). The discrepant results of these 
studies highlight the complex role of IFNy thioughout the disease. As an upstream 
modulator of IFNy, IL-18 is likely to be important in understanding these observations. 
Remarkably, post infection IL-18 treatment had no apparent effect on Thl responses, as 
assessed by recall responses of spleen cells. Prior administration of IL-18 enhanced Thl 
responses at 2 days post infection. No significant effects on Thl responses were 
measured from day 5 onwards arising from early enhanced IL-18 expression. This is 
unsurprising since IL-12 and IL-18 signalling were intact in the present model and we 
did not anticipate that a single IL-18 bolus would significantly alter these processes.
These studies were extended to include a preliminary investigation of septic patients. 
Some of the patient cohort expressed IFNy protein in the sera. It is tempting to speculate 
that, as this correlated with IL-6 1 evel, the appearance o f  IFNy in  the serum maybe  
linked to a severe, systemic inflammatory response. However, the cohorts are too small 
for conclusions to be drawn and preexisting and current levels of IL-18 in these patients 
are unknown.
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Incidence of staphylococcal infection is likely to increase further with wider therapeutic 
use of immunosuppressive drugs and invasive investigative techniques. Moreover, new 
treatment strategies are essential in the face o f emerging antibiotic r esistant bacterial 
strains. Therefore, whether IL-18 plays a primarily protective or aggressive pathogenic 
role in gram-positive sepsis is important to elucidate. Elevated IL-18 prior to infection 
may be found in individuals with autoimmune disease. Furthermore, IL-18 has been 
employed as a vaccine adjuvant (228, 229), shows a protective role in tumour immunity 
(230), and therapeutically reverses established murine allergic astlima (144, 231). 
Conversely, neutralising IL-18 is an attractive therapeutic option for patients with IBD 
(138) and RA (78, 131). Our data suggest that redressing immune system imbalances, 
for example by targeting IL-18, may reduce pathogenic immunity to gram-positive 
infection. Moreover, these data caution the use of IL-18 as a vaccine adjuvant or to 
augment anti-tumour immunity.
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Chapter 6 Neutrophil interactions with the adaptive immune response
194
Introduction
Neutrophils c learly r espond t o IL-18 in v  itro and v ivo. M oreover, IL-18 p romotes 
neutrophil bactericidal activity, and may alter complex immune responses to pathogens. 
IL-18 was originally defined with a role in the adaptive immune response, promoting 
Thl development. A role for IL-18 in innate immunity has only subsequently emerged. 
Intricate links between innate and adaptive responses are becoming apparent. 
Neutrophils were traditionally described as terminally differentiated, short-lived 
phagocytes that mediate only innate immune responses, however, these cells are 
increasingly believed to influence the ultimate outcome of adaptive immunity. 
Emerging evidence suggests that neutrophils and T cells communicate. This could occur 
via direct mechanisms, for example antigen processing and co-stimulation; or via 
cytokine release, which may for example influence the polarisation of the immune 
response.
In vivo depletion of neutrophils potently alters adaptive immune responses. Depletion of 
neutrophils prior to Leishmania infection of BALB/c mice results in a switch to a 
protective Thl response. This effect was IL-12 dependent, perhaps indicating that 
neutrophil 1 ysis r eleased p re-stored IL-12, s ufficient to m  ediate a p redominantly T hi 
response (171). The role of neutrophil derived cytokines has been documented in rodent 
models of Legionella pneumophilia (232), Toxoplasma gondii (233), Mycobacterium 
tuberculosis (234) and Candida albicans (235). Human neutrophils are also reported to 
express IL-12 (236).
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There are limited studies of cross talk between neutrophils and T cells. Fixed 
PHA/PMA stimulated T cells stimulate neutrophils to release IL-lp and TNFa, and 
prime for enhanced respiratory burst in response to fMLP. This cell contact is 
speculated to  1 ocalise n eutrophil a ctivation to s ites o f  a ctivated T c ells, t hus 1 imiting 
neutrophil mediated tissue damage (237). The hypothesis that neutrophils may actively 
modulate T cells has recently received further attention. Murine neutrophils process 
phagocytosed bacteria via an alternate MHC Class I antigen-processing pathway, which 
allows MHC Class I presentation of peptides derived from the bacteria. Such 
neutrophils may release processed peptide into the extracellular space and this peptide 
may then bind MHC-1 on neighbouring cells (e.g. macrophages) for presentation to 
CDS cells (175).
MHC class II expression can be induced on a number of cells including eosinophils, 
kératinocytes, synovial fibroblasts, tubular epithelial cells and others, by culturing in the 
presence of cytokines, notably IFNy, GM-CSF, and IL-3. These cytokines also induce in 
vitro synthesis of MHC Class II by PMN derived from healthy donor. Of note is the 
variable response when cells of different donors are compared (176). Class II expression 
is observed on PMN of patients with active Wegener’s Granulomatosis, and correlates 
with disease activity (238). Class II is upregulated in patients receiving GM-CSF (239), 
and entranced expression has been reported on RA synovial fluid derived neutrophils 
(240). Interestingly, no elevation of Class II expression is found in patients with acute 
bacterial infections. In addition to MHC Class II expression, culturing nonnal human 
PMN with IFNy induces B7.1 and B 7.2 expression (179). As such, these neutrophils 
may present tetanus toxoid peptide antigen on MHC Class II to T cell clones and induce 
proliferation and cytokine production (241).
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To estimate the relative contribution of neutrophil antigen presentation and cytokine 
production to an adaptive response, preliminary studies were undertaken, using both 
novel and more established experimental systems. These studies first addressed whether 
murine neutrophils present or process a Class II restricted antigen. Secondly, 
experiments were designed to determine whether soluble mediator release by 
neutrophils could influence their interactions with T cells. In particular, I was interested 
to explore a role for IL-18 in this process, given previous data implicating IL-18 in the 
progression from innate to adaptive immunity.
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Results
6.1 Purification of murine neutrophils
Neutrophils were purified from thioglycollate induced peritoneal exudate cells (PEC), 
as there is a relative paucity of neutrophils in murine peripheral blood. To confirm the 
latter, whole blood obtained via cardiac puncture was stained with anti-GRl antibody, 
lysed, and analysed by flow cytometry. Less than 20% of circulating leukocytes in the 
mouse were GRl positive neutrophils (Fig. 6.1a and b). Published data suggest that 
neutrophils constitute 17.9% (range 6.7-37.2%) of circulating leukocytes. 
Intraperitoneal injection of 1.5 ml thioglycollate induced a rapid influx of cells into the 
peritoneal cavity. PEC were harvested 4 h post thioglycollate administration as it was 
previously shown that the number of neutrophils present peaks at this time, after which 
an increasing proportion of macrophages are recruited (242). Approximately 65% of 
thioglycollate induced PEC were identified as neutrophils on the basis of GRl staining 
(Fig. 6.1c and d). PEC were further enhanced for neutrophils with a Ficoll gi*adient 
purification as previously described (242). Following purification, samples were 
routinely 85% GRl positive (Fig. 6.2a and b). Importantly, samples contained few 
macrophages (<4%) as determined by F4/80 staining (Fig. 6.2c). Cytospins of 
neutrophil preparations were also prepared and stained (Section 2.8.2), allowing 
identification of neutrophils by their characteristic multilobed nuclei (Fig. 6.3). Percol 
giadient purifications are reported to yield up to 97% pure neutrophil populations, 
however this method provided less consistent samples than the Ficoll purifications.
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Figure 6.1 Neutrophil populations in murine peripheral blood and 
thiogylcollate induced peritoneal exudate cells
Heparinised peripheral blood (PB) was collected from untreated BALB/c mice 
via cardiac puncture, and analysed by flow cytometry demonstrating (a) cell 
size and granularity and (b) proportion of GR-1 positive neutrophils as % total 
cells. Peritoneal exudate cells were obtained from BALB/c mice 4 h after 
receiving 1.5 ml thioglycollate i.p. (c) Cells size and granularity was assessed 
by flow cytometry, cells outside the gate stained positive for propidium iodide, 
and (d) cells within the PI negative gate, labelled with FITC anti-GR-1 
antibody or an isotype control to identify neutrophils. Data are representative 
of 2 similar experiments, with 3 mice per group in each.
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Figure 6.2 Purification of murine neutrophils
BALB/c mice received 1.5 ml i.p. 4 h prior to harvest of PEC by lavage. PEC 
from 2 mice were washed, resuspended in 8 ml PBS and separated by density 
centrifugation over Ficoll. Cell pellets were resuspended and analysed by flow 
cytometry, (a) Forward/side scatter indicating cells size and granularity; cells 
out with the gate were propidium idodide positive, (b) Neutrophils stained by 
GR-1 and (c) staining of macrophages by F4/80. Sample purity was routinely 
assessed and data are representative of > 6 similar experiments.
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Figure 6.3 Cytospin preparations of murine neutrophils
Neutrophils were purified as in Fig. 6.2 and cytospins prepared. Cytospins 
were stained with DiffQuick™ and examined microscopically, (a) low power 
magnification, (b) high power magnification.
6.2 Murine neutrophils presented peptide antigen
To investigate whether murine PEC derived neutrophils were capable of antigen 
presentation on MHC Class II, a system for detecting antigen presentation was sought. 
The murine T cell hybridoma, DO 11.10, expresses a T cell receptor (TcR) that 
recognises the ovalbumin peptide, OVA323-339 in the context of the MHC class II, I-A^ .
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The DO 11.10 hybridoma was transfected with a plasmid allowing expression of green 
fluorescent protein (GFP) under the NT AT promoter. When the transfected hybridoma, 
DOll.lO-GFP, recognises OVA323-339 presented by I-A^, GFP expression is induced 
within 4-5 h, and declines after 18 h. Expression of GFP is co-stimulation independent, 
providing a quantitative measure of antigen presentation via Class II. The DOll.lO- 
GFP cells were a kind gift of David Underhill, Dept, of Immunology, University of 
Washington, Seattle, Washington. This system is schematically outlined in Fig.6.4.
DOll.lO-GFP cells were grown in medium containing a 0.5 mg/ml geneticin. This 
enhanced the proportion of plasmid containing cells prior to the start of the experiments. 
12 h prior to use, DOll.lO-GFP cells were washed and grown in complete medium 
without antibiotic, reducing cany-over toxicity to other cells. Initially, antigen 
presentation to the DOll.lO-GFP cells was investigated by flow cytometry. Co-cultures 
were established in which neutrophils or macrophages were incubated with 10 pg/ml 
OVA323-339 peptide and DOll.lO-GFP hybridoma cells, in the ratio indicated in the 
figures. Cells were cultured for 14 h, washed, and then analysed by flow cytometry. The 
hybridoma does not respond to peptide alone (Fig. 6.5, ‘background’), and plate bound 
anti-CD3 provided a positive control in these experiments. Neutrophils or macrophages 
alone had no effect on GFP expression by DOll.lO-GFP. However, neutrophils or 
macrophages in the presence of OVA peptide stimulated significant GFP expression 
when cells were cultured at a 1:1 ratio. A dilution of macrophages was performed to 
provide some indication of the contribution of contaminating macrophages to the results 
observed with neutrophil populations. This demonstrated that at a ratio of 1 macrophage 
to 10 DOll.lO-GFP cells, there was significantly less expression of GFP protein 
compared to that induced by neutrophils at a 1:1 ratio (Fig. 6.5). At a ratio of 1:100,
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there was no consistent GFP expression detected (data not shown). As there were <5% 
F4/80 positive macrophages contaminating the neutrophil samples (Fig. 6.2c), these 
titration experiments indicated that only a small proportion of the T cell hybridoma 
activation observed in the ‘neutrophil presentation’ assays could be attributable to 
macrophage contamination.
To visualise the cell-cell interactions, similar co-cultures were established for 4-6 h and 
then viewed microscopically. As the microscopy was less sensitive to the green 
fluorescent protein than flow cytometry, dendritic cells were used as a positive control 
to provide optimum in vitro antigen presentation. Co-culture of DOll.lO-GFP with 
DC+OVA323-339 resulted in a distinct clustering of GFP positive cells, presumably 
around the APC (Fig. 6.6a). Of interest, discrete GFP positive cells were also observed 
when purified neutrophils were co-cultured with DOll.lO-GFP (Fig. 6.6b), Cells in co­
cultures were identified as neutrophils by biotinylated anti-GRl antibodies and detected 
with streptavidin Texas red. Control cells were stained with biotin labelled isotype 
control antibody and secondary detection reagents. These experiments demonstrated 
that neutrophils could be specifically stained for GR-1 and, in some fields, were seen in 
contact with individual green cells (Fig. 6.6b). In further control experiments, no GFP 
positive cells were observed in co-cultures in the absence of peptide (data not shown).
Preliminary studies were undertaken to follow these neutrophil-DO 11.10-GFP cell 
interactions in real time, which showed promising results but time constraints prohibited 
fully exploring this avenue. Nevertheless, these experiments, using a novel cellular 
technology, strongly support the notion that neutrophils can indeed present peptide to T 
cells in a Class II restricted manner.
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Figure 6.4 T cell hybridoma, DOl 1.10, transfected with pNFATeGFP
A T cell hybidoma, DOll.lO, was stably transfected with a construct in which 
green fluorescent protein (GFP) expression is controlled by a NFAT responsive 
promoter. Thus, upon productive interaction with an APC the T cell becomes 
fluorescent. This stably transfected cells line was a kind gift of David 
Underhill, Dept, of Immunology, University of Washington, Seattle.
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Figure 6.5 GFP expression by the DOl 1.10-GFP hybridoma following co­
culture with APCs
Purified murine neutrophils (PMN) or macrophages (Mac) were cultured in the 
presence of 10 pg/ml OVA323-339 peptide with DOll.lO-GFP cells for 14 h. 
Cells were washed and GFP expression was assessed by flow cytometry. 
Background is a measure of GFP expression of DOl 1.10-GFP cells cultured 
with ova peptide alone; anti-CD3 is a positive control. Data are mean ± SEM 
of 3 experiments. In each experiment, neutrophils were purified from 
thioglycollate induced PEC pooled from 5 BALB/c mice. Macrophages were 
obtained from 2 similarly treated BALB/c mice. *p < 0.05 vs. background by 
Mann Whitney U test.
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Figure 6.6 Analysis of DO 11.10-GFP by fluorescence microscopy
DOll.lO-GFP cells were co-cultured with (a) dendritic cells and (b) purified 
neutrophils in the presence of OVA323-339 for 12 h then examined 
microscopically, (c) Neutrophils were stained, in the presence of OVA, with 
GR-1—Texas red, and co-cultured with DOll.lO-GFP for 6 h. No GFP 
expression was observed in the absence of peptide. The GR-1 isotype control 
antibody staining of neutrophils provided no red signal (data not shown), (a) 
Representative of a single experiment, (b) of 3 and (c) of 2 similar 
experiments.
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6.3 Neutrophil interactions with lymph node derived T cells
To investigate a more physiological system than T cell hybridomas, neutrophils were 
co-cultured with primary T cells. Lymph nodes were obtained from DOll.lO transgenic 
BALB/c mice. These mice express the OVA specific TcR on a proportion of their T 
cells, which is recognised by a clonotypic antibody, KJ 1.26. Fig. 6.7a shows a 
representative plot of KJ 1.26 positive cells derived from lymph nodes of DOll.lO 
mice. Single cell suspensions of lymph nodes were adhered to plastic for 3 h to remove 
the majority of adherent antigen presenting cells, after which the population was 
routinely 70% CD3 positive (data not shown). The presence of endogenous APCs in the 
lymph node facilitated a strong response to OVA peptide alone (Fig. 6.8a). Therefore, 
neutrophils and macrophages were pulsed with peptide for 2 h then washed 3 times to 
remove unbound peptide. In these experiments, Con A was used as a positive control 
mediating antigen independent stimulation. Cells were co-cultured for 72 h at the ratios 
indicated in the figures. Proliferation was assessed by [^H] thymidine incorporation for 
the final 18 h of culture. Cytokine release into the supernatants was assessed by ELISA.
Neutrophils pulsed with OVA induced proliferation (Fig. 6.8a), IL-2 (Fig, 6.8b) and 
IFNy (Fig. 6.8c) production. Low levels of IL-5 were detected in some experiments 
(data not shown). The neutrophil induced responses were less than those evoked by 
macrophages at the same cell ratio. A titration of macrophages was performed to give a 
more physiologically relevant cell ratio and an estimate of the contribution of 
contaminating cells. This result suggested that not all the observed neutrophil induced 
activity could be attributable to contaminating macrophages.
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Figure 6.7 Lymph node derived DO 11.10 transgenic T cells
Single cell suspensions were prepared from lymph nodes of DOll.lO BALB/c 
mice and stained for analysis by flow cytometry. The lymphocyte population 
was gated according to forward/side scatter (a) and this was analysed on the 
basis of CD4-PE expression and KJ 1.26-FITC staining (b), identifying the 
OVA-specific TcR on CD4 cells. Data shown are representative of > 5 similar 
experiments.
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Figure 6.8 In vitro proliferation of DO 11.10 lymph node cells
Single cell suspensions of lymph nodes were obtained from a DOll.lO 
transgenic mouse and cultured for 72 h and proliferation was assessed by [^ H] 
thymidine incorporation over the final 18 h of culture, (a) Control experiments 
in which DOll.lO lymph node cells alone were cultured with the stimuli 
indicated, (b) DOll.lO lymph nodes were cultured with either macrophages or 
neutrophils derived from thioglycollate induced PEC. The ratio of APC to T 
cell in the culture, and whether the APC was pulsed with OVA prior to 
addition to the co-culture, is indicated on the x- axis. Data are mean ± SEM of 
triplicate cultures. <0.05 vs. medium by Student’s / test, representative of 3 
similar experiments.
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Figure 6.9 In vitro cytokine production by DOl 1.10 lymph node cells
Single cell suspensions of lymph nodes were obtained from a DOll.lO 
transgenic mouse and cultured for 72 h, after which IL-2 and IFNy levels in the 
supernatant were assessed by ELISA, (a) and (c) Control experiments in which 
DOll.lO lymph node cells alone were cultured with the stimuli indicated, (b) 
and (d) DOll.lO  lymph nodes were cultured with either macrophages or 
neutrophils derived from thioglycollate induced PEC. The ratio of APC to T 
cell in the culture, and whether the APC was pulsed with OVA prior to 
addition to the co-culture, is indicated on the x- axis. Data are mean ± SEM of 
triplicate cultures. */? <0.05 vs. medium by Student’s t test, representative of 3 
similar experiments.
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6.4 Effect of IL-18 on neutrophil T cell interactions
Neutrophil enzymes process IL-18. Furthermore, APCs (e.g. macrophages and DCs) 
produce IL-18; hence I next investigated whether soluble factors, such as IL-18, had any 
impact on the responses observed in the previous experiments (Fig. 6.8 and 6.9). 
Neutrophils were obtained from XL-18-deficient BALB/c mice. Co-cultures of APCs 
and DOll.lO lymph node cells were performed as in section 6.3. Again, neutrophils 
pulsed with OVA stimulated proliferation (Fig. 6.9a) and IFNy production (Fig. 6.9b) 
by DOll.lO derived lymph node cultures. Neutrophils derived from IL-18 wild type or 
IL-18-deficient mice behaved similarly.
6.5 Cell contact dependence of neutrophil T cell interactions
To determine the relative contribution of cell contact dependent mechanisms and 
soluble factors in neutrophii-T cell interactions, ti'answells were placed between the cell 
populations. These consist of 0.2 pm membranes, allowing movement of soluble 
proteins but not cells. The responding OVA specific T cells were not a 100% pure T cell 
population and contained some APCs, demonstrated by the lymph node response to 
OVA alone. Thus, the transwells permitted preliminary investigation of whether lymph 
node derived APCs were presenting soluble proteins derived from dead or degraded 
neutrophils. Bone marrow derived dendritic cells (DC) were used as a positive control. 
Free OVA peptide or Con A crossed the transwell membrane and stimulated cell 
proliferation and cytokine production (Fig. 6.11). When separated from the lymph node 
cells by the transwell, pulsed cells, either neutrophils or DCs did not release sufficient 
OVA to cross the membrane and stimulate a response from the OVA specific T cells
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below (Fig. 6.11). These experiments demonstrated that cell contact was primarily 
responsible for the proliferation and cytokine production observed in the previous 
experiments (Fig. 6.8 and 6.9).
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Figure 6.10 APCs from IL-18-deficient mice
Experiments were performed as in F ig. 6.8, except neutrophils were derived 
from IL-18-deficient mice (-/-) or wild type littermate controls (+/+). (a) 
Proliferation was assessed by [^H] thymidine incorporation and (b) IFNy 
release was assessed by ELISA. Thioglycollate induced PEC were pooled from 
4 mice per group per experiment. Data are mean ± SEM of triplicate cultures.
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Figure 6.11 Antigen specific proliferation and cytokine production was cell 
contact dependent
Single cell suspensions derived from lymph nodes of DOll.lO mice, were 
stimulated with Con A, OVA peptide, or APCs (DCs or neutrophils), which 
had been pulsed with OVA peptide. In parallel cultures, the stimulus was 
separated from the responding T cells by a transwell membrane. The stimulus 
was placed in the upper compartment, and proliferation (a) and IFNy 
production (b) of the OVA specific T cells in the lower chamber was assessed. 
T cells did not respond when cultured with APCs alone (data not shown). 
Similarly, culturing T cells in the upper chambers resulted in no measurable 
response in the lower chambers. Data are mean ± SEM of triplicate cultures 
and representative of 2 similar experiments.
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Discussion
Data presented here demonstrate a novel system for investigating whether neutrophils 
present antigen. The use of the DOl 1.10-GFP hybridoma cells allowed both preliminary 
quantitative analysis of antigen presentation and visual evaluation of cell/cell 
interactions. These data suggest that neutrophils are indeed capable of presenting 
antigen on Class II MHC.
The DOll.lO-GFP hybridoma cells respond in a Class II restricted manner, and the data 
presented demonstrate that it is highly likely that neutrophils, rather than contaminating 
cells, w ere m ediating t his r esponse. F urtherraore, t he i nteractions o f  n eutrophils w ith 
lymph node derived cells were clearly cell contact dependent. Future use of MHC class 
II neutralising antibodies should confirm the specificity of these interactions. 
Additionally, the C4H3 antibody identifies hen egg lysosyme peptide complexed to I- 
A ,^ and as such could be used to further address the question of neutrophil Class II 
expression and peptide presentation. The expression of Class II by neutrophils seems 
critically dependent on activation status. For example, SF derived neutrophils require ex 
vivo culture, but not stimulation, before MHC Class II can be detected on their surface 
(240). Preliminary investigations of MHC-II expression on murine neutrophils were 
inconclusive.
The impact of neutrophil derived cytokines on adaptive immune responses was of 
interest. Neutrophils both secrete and process cytokines, including IL-18. Neutrophil 
elastase, cathepsin G, and proteinase 3 process IL-18; both from pro to mature fomis 
and also to generate other IL-18 fragments, the functions of which remain unknown. 
The relative importance of IL-18 on T cell mediated responses suggested that this
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neutrophil processing was worthy of further investigation. However, studies using IL- 
18-deficient mice demonstrated no role for endogenous IL-18 in neutrophil interactions 
with T cells in this system. Murine neutrophils express IL-12, which may additionally 
influence Thl type responses. This awaits further investigation and availability of IL- 
12/18 double knock out mice. Use of the transwell system confirmed the lack of 
involvement of soluble factors in this system, although the proliferation and cytokine 
production assays may not be sufficiently sensitive to detect fine-tuning of T cell 
responses. Analysis of cell surface markers or intracellular signalling events may better 
characterise subtle changes.
Data described here demonstrate neutrophil presentation of a peptide antigen. Using the 
DOll.lO-GFP technology, preliminary investigations into antigen processing capacity 
of neutrophils were perfoimed, using whole ovalbumin compared to OVA peptide. 
These studies were inconclusive although the neutrophils did not appear to process the 
ovalbumin effectively, demonstrated by a lack of response by DOll.lO-GFP T cells 
(data not shown). An MHC Class I processing pathway within neutrophils was elegantly 
defined with E. coli transfected to express a fusion protein containing a MHC Class I 
restricted epitope of OVA. This demonstrated that neutrophils are capable of non- 
classical antigen processing for presentation on MHC Class I (175). However, there is 
no current evidence of any Class II processing pathway. These studies could be 
addressed by use of bacteria transfected with the MHC Class II restricted epitope, 
OVA323-339. In addition to Class II, there is an array of molecules, associated with T cell 
activation, reportedly expressed on neutrophils (e.g. CD80 and CD86). It will be 
important to elucidate if this reflects variable responsiveness of different sub-
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populations of neutrophils, or different susceptibility of neutrophils to activation 
dependent on maturation status.
I investigated neutrophil interactions with primary, naïve T cells, from a population 
containing an artificially high proportion of antigen specific cells. Physiologically, the 
location of such neutrophil-T cell interactions is likely to be restricted to sites of chronic 
or established inflammation. Therefore, investigation of the interaction of neutrophils 
with memory type T cells may be more relevant. However, these antigen experienced 
cells aie likely have acquired a cytokine producing phenotype, which neutrophil derived 
factors are less likely to influence. The abenant expression of MHC on neutrophils may 
be of particular significance in chronic inflammatory diseases such as RA. Due to the 
neutrophils’ unique proteolytic activities, this may represent a mechanism of 
presentation of novel or cryptic antigens.
There are discrepancies between human and murine neutrophils especially in terms of 
documented MHC Class II expression. Given that only 20% of circulating leukocytes in 
the mouse are neutrophils, compared to 70% in humans, this also raises questions as to 
whether murine and human neutrophils perform parallel functions as is assumed.
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Chapter 7 General Discussion
I l l
Cytokine networks operating in host defence and a variety of disease states provide a 
highly evolved, complex communication system for the immune system. The character 
of these messages critically influences the outcome of insults to host integrity. 
Understanding the role played by each messenger, both individually and in context of a 
cytokine network, provides vital insight into protective and pathogenic immune 
responses, in turn providing opportunities for therapeutic intervention.
The most important observation in this study is that documenting IL-18 induced 
neutrophil activation. IL-18 enhanced neutrophil adhesion molecule expression, 
cytokine release, degranulation, respiratory burst and arachidonic acid metabolism. 
These observations support a proinflammatory role for IL-18 in the context of 
neutrophil activation. This work has been extended and confiimed by other 
investigators (218, 219). Interestingly, the latter studies have shown that IL-18 
stimulates IL-lp and sIL-lRII. Thus, like LPS, IL-18 initiates both pro- and anti­
inflammatory activities, the b alance o f  which may detemiine the n et e ffect o f  IL-18. 
This could alter in distinct tissues, or as immune response kinetics change. Dinarello et 
al have shown that the effects of IL-18 on neutrophils are mediated largely through p38 
MAP kinase activation (218), which is of interest given the reported predominance of 
IRAJC/NFkB signalling pathways in other cell types. Clarifying whether IL-18 
stimulates a secondary wave of cytokines, and how important these are for each 
neutrophil response, would allow more accurate charting of the position of IL-18 within 
the cytokine network.
In vivo relevance of IL-18 neutrophil activation was demonstrated by neutralising IL-18 
in a model of acute inflammation. The subsequent reduction in tissue myeloperoxidase,
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and histological evidence of reduced neutrophil accumulation implicates IL-18 as a 
modulator of in vivo neutrophil function. Moreover, addition of exogenous IL-18 prior 
to infection, promoted an exaggerated early immune response to S. aureus, with 
devastating consequences in this model. A system of investigating neutrophil -  T cell 
interactions was established. However, in preliminary studies, no role for neutrophil 
derived IL-18 was observed in mediating neutrophil interactions with T cells. 
Nevertheless, IL-18 effects in DC function have been clearly documented and likely 
constitute the primary mode of action of IL-18 in T cell activation (74, 76).
IL-18 represents part of a complex intracellular communication network. Previously, 
IL-18 was described as a T cell differentiation factor, working primarily in synergy with 
IL-12, to regulate the phenotype of subsequent adaptive responses. However, data in the 
present studies advocate an independent inflammatory role for IL-18 early in the innate 
response. Figure 7.1 schematically outlines how the role of hypothetical cytokine may 
be considered, emphasising that this may alter throughout an immune response.
219
/  \‘ole o f  theoretical cytokine;/
hierarchy i
within cytokine network
kinetic
s ta g e ^f immune response
inflammatory
potential of cytokine
Figure 7.1 A hypothetical cytokine may mediate discrete functions as an 
immune response develops (adapted from (243))
The above figure illustrates, in 3 dimensions, how the qualitative and 
quantitative contribution of a cytokine may vary during different stages of an 
immune response.
The hierarchical relationship between IL-18 and TNFa remains intriguing. In the acute 
inflammatory model described in Chapter 4, neutralising IL-18 abrogated TNFa mRNA 
expression. Furthermore, addition of IL-18BP in a murine model of colitis reduces 
expression of numerous inflammatory genes, including TNFa (138). However, RA 
patients receiving anti-TNFa therapy exhibit persistent decrease in serum IL-18 levels 
(244). Thus, either in chronic disease, such as arthritis, TNFa regulates IL-18, or these 
two cytokines cooperatively promote inflammation. Such observations may be 
interpreted as rational for combined cytokine targeting therapy, or are an indication of 
deficiencies in evidence provided by animal models.
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Further evidence suggesting that IL-18 operates very early in the immune response, and 
may form part of the first response to insult, is documented below,
• Widespread expression o f IL-18 mRNA and pro-IL-IS protein
IL-18 has been identified in a diverse array of cells and tissues, from kidney mesangial 
cells to platelets (JA Grade, personal communication). Thus this cytokine seems ideally 
positioned for rapid mobilisation.
• Constitutively high levels IL-18 mRNA expression
Very few, if any, investigators demonstrate up regulation of IL-18 mRNA in response to 
proinflammatory stimulation. In the S. aureus infection model (Chapter 5), IL-18 
mRNA expression was unaltered, in any group, 6 h post infection; which contrasted 
sharply with TNFa, IFNy or IL-12 p40 mRNA expression, all of which were markedly 
increased following infection. Thus, IL-18 mRNA appears constitutively, highly 
expressed, a further provision for rapid deployment.
• IL-18 homologues
Structurally, IL-18 is a member of the IL-1 family. Matzinger classifies IL-ip as “an 
endogenous, non-foreign alarm signal” to which APCs respond by upregulating co­
stimulatory molecules and initiating immune response. Furtheimore, the IL-18 receptor 
chains contain Toll/IL-1 Receptor domains (TIRS), which links IL-18 to the Toll-like 
receptor (TLR) family, which are conserved through evolution from Drosophila. 
Similarly, IL-18R and TLRs share common molecules, such as MyD88 and IRAK, 
within their signalling pathways.
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The TLR family comprises 10 currently define receptors (TLRl-10), which recognise 
conserved pathogen motifs, and host molecules, such as heat shock proteins (reviewed 
(245, 246)). These receptors are fundamental to immune response initiation and may be 
considered either as conveyors of ‘danger signals,’ or for recognition of ‘infectious, 
non-self’ According to either hypothesis, the TLR family constitute essential first line 
host defence. However, whether the host evolved to recognise and respond to pathogens 
via TLRs, or pathogens evolved to bind TLRs, remains controversial. Accordingly, the 
homology b etween the IL-1 receptor family and TLRs raises the possibility that this 
cytokine receptor family is an evolutionary progression from the TLR family. In this 
context, IL-1 family members, such as IL-18, may be considered to function at one level 
more like heat shock proteins, i.e. as endogenous alarm signals. Perhaps, pathogens are 
currently evolving to further ‘hijack’ this cytokine receptor system, which may already 
occur, unbeknown to investigators.
The precise role of neutrophils in early immune system activation is as yet poorly 
understood. Although the first cells to migrate to sites of insult, neutrophils respond to 
insults; sounding the ‘alarm bell’ is the task of the tissues and cells within them, such as 
resident dendritic cells. As the earliest cells to enter tissues, neutrophil responses are 
likely to be crucial to the subsequent immune response. Various data describe a role for 
TLRs in neutrophil function (247, 248). Interplay between IL-18 and TLRs is alluded to 
in this and other studies; IL-18 modulates TLR2 expression (104). The extent to which 
IL-18 may regulate other TLRs awaits examination. Similarly, whether IL-18 primes for 
enhanced neutrophil responses to TLR ligands awaits investigation.
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The addition of exogenous IL-18 prior to onset of S. aureus infection resulted in 
increased mortality. This scenario mirrors human disease, such as RA, in which IL-18 is 
elevated a priori, which is similarly associated with increased mortality. Thus 
supplementing with IL-18 to promote protective immunity, as has been proposed for 
vaccine adjuvants, should be undertaken with caution. The corollary of these 
observations is that neutralising IL-18 in inflammatory disease may rebalance the 
immune system and under certain circumstances actually promote protective rather than 
pathogenic reactions. These studies, performed on genetically similar animals in a 
constant environment, should be cautiously interpreted. In general, targeting IL-18 is an 
attractive therapeutic goal for the assorted diseases in which elevated expression of IL- 
18 has been documented. Indeed, neutralising IL-18 in animal models of arthritis and 
IBD provide promising results. Predicting the long-term outcome of disturbing the 
cytokine networks in human populations is difficult. Dose, timing, route of 
administration, and choice of inliibitor (e.g. recombinant soluble receptors or humanised 
antibodies) will likely prove important.
Whether strong disease association polymorphisms exist in IL-18, IL-18R, or IL-18BP 
loci, as described for IL-1 family, has not been determined. Allelic differences in IL-18 
mediate enhanced IL-18 expression, only apparent following mitogenic stimulation. No 
differences in allele frequency were observed when a cohort of MS patients was 
compared with a normal population (13). Preliminary data (Mclnnes, Gracie, 
unpublished) suggest the Tow production’ phenotype predominates in RA patients. 
Such apparent contradiction may be resolved by hypothesising that a deficiency in ÏL- 
18 production may predispose to infection, which in turn could promote autoimmunity 
in a genetically otherwise predisposed individual. Once inflammation associated with
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autoimmune disease is established, there is an aberrant over expression of IL-18. 
However, further studies of IL-18 polymorphisms and their functional implications are 
awaited.
Conclusions
Work carried out in this project provided the following novel infonnation which 
advanced our understanding of the biology and potential therapeutic role of IL-18.
1. IL-18 promoted human neutrophil activation in vitro.
2. IL-18 induced in vivo neutrophil recruitment and neutralising IL-18 
abrogated acute, neutrophil led, inflammation.
3. Addition of exogenous IL-18 promoted in vitro bactericidal activity of
neutrophils. However, in vivo, IL-18 promoted lethal sepsis rather than 
bacterial clearance. Thus, IL-18 is a two edged sword in the immune system.
4. Murine neutrophils were capable of Class II restricted presentation of
peptide to specific T cells. This was cell contact dependent.
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Future Work
Reference has been made in the text to further investigations at specific points of 
interest. Key areas include the following:
• IL-18 expression is confirmed in human neutrophils. Neutrophils are 
capable of protein processing and generate discrete fragments of IL-18. 
The functional implications of this are under investigation.
• The hierarchy of IL-18 with respect to IFNy and TNFa is interesting. For 
example, neutralising IL-18 abrogated TNFa mRNA expression in a 
model of acute inflammation. However, in a model of S. aureus 
infection, the predominant response was IFNy mediated. Studies 
including neutralising antibodies would adequately address these issues.
• Further exploration of IL-18, IL-18R, or IL-18BP polymorphisms and 
their functional consequences.
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